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ABSTRACT 
KYLE DAVID KONZE: Chemical Probes for the Lysine Methyltransferases EZH2 
and G9a: Design, Development, and Application 
(Under the direction of Jian Jin) 
 
In eukaryotic genomes, DNA is wrapped around histone proteins to form 
repeating units known as nucleosomes, which are further condensed into 
chromosomes. This high level of structure creates a barrier to transcription, 
which is maintained or reversed via modifications to the N-terminal tails of 
histone proteins. Histone lysine methyltransferases catalyze the mono-, di-, 
and/or trimethylation of lysine residues within histone tails; the methylation state 
of histone tails has profound effects on transcription. For example, polycomb 
repressive complex 2 (PRC2) is responsible for regulating the methylation status 
of histone 3 lysine 27 (H3K27) via the catalytic subunit EZH1 or EZH2, and the 
lysine methyltransferase G9a catalyzes mono- and dimethylation of histone 3 
lysine 9 (H3K9). These methyltransferases are of great interest, because 
trimethylation of H3K27 and dimethylation of H3K9 are transcriptionally 
repressive marks that play a key role in the progression of many diseases.  
Chemical probes that selectively inhibit the methyltransferase of interest 
are valuable tools to drive further understanding of the biological function of 
these proteins and assess their potential as therapeutic targets. Here we 
describe the design, development, and application of chemical probes and tools
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for both EZH1 and EZH2 (UNC1999), and G9a (UNC0965). UNC1999 was the 
first orally bioavailable chemical probe of EZH1 and EZH2. This discovery led to 
the design of a biotinylated tool (UNC2399), which allows for selective 
chemiprecipitation of EZH1 and EZH2 from cellular lysates. UNC1999 is also the 
most panactive EZH1 and EZH2 chemical probe to date. We exploited this 
feature to demonstrate the potential therapeutic application of small molecule 
inhibition of both EZH1 and EZH2 in MLL-rearranged leukemia. Lastly, we detail 
the in vitro and ex vivo use of a biotinylated G9a inhibitor (UNC0965) in a 
chemical-based chromatin immunoprecipitation (chem-ChIP) assay for studying 
G9a chromatin occupancy.
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CHAPTER I: INTRODUCTION 
 
Histone Lysine Methyltransferases 
 
The eukaryotic genome is organized into 23 pairs of chromosomes, which 
are dense structures consisting of DNA and proteins. In order to package the 
entirety of the eukaryotic genome into an average 10 µm diameter cell, DNA and 
proteins are wrapped around histones for compaction. This DNA-protein 
amalgam is referred to as chromatin. The basic units of chromatin, nucleosomes, 
are comprised of DNA wrapped around 4 sets of dimeric histone proteins (H2A, 
H2B, H3, and H4), which have long tails protruding from their core (figure 1.1). 
Histone H1 is also involved in this compaction and serves as a sort of “cap” to 
keep the DNA wrapped around the nucleosome. DNA is wound around these 
proteins in ~147 bp segments, which limits the accessibility of genes contained 
within. As such, the dense environment of chromatin is a natural barrier to 
transcription, yet the genetic information encoded by DNA needs to be readily 
accessible for cells to respond to external and internal stimuli. Modifications to 
the globular domain, and tail, of histone proteins affect the state of chromatin by 
either promoting or deterring compaction, which makes the DNA more or less 
accessible to transcriptional machinery, and leads to a cascade of downstream
2 
events [1]. Regions of high density, termed heterochromatin, are less accessible 
to transcriptional machinery, whereas regions that are not as compact, termed 
euchromatin, are more accessible, and correlate with more actively transcribed 
regions. Alterations in gene activity, which are not due to changes in the DNA 
sequence, are referred to as epigenetics (“above genetics”). 
Modifications to histones are maintained via three main families of 
epigenetic proteins: “writers” (the enzymes responsible for producing post-
translational modifications (PTMs)), “readers” (the proteins responsible for 
binding PTMs), and “erasers” (the enzymes responsible for removing PTMs).  
These proteins work in concert to dynamically regulate the chromatin landscape, 
controlling the temporal expression of genes in the process. One class of 
“writers” is protein lysine methyltransferases, which are capable of catalyzing 
mono-, di-, and/or trimethylation of lysine residues on histone and non-histone 
substrates. Most lysine methyltransferases (excluding DOT1L) catalyze the 
methylation of a given lysine residue by utilizing their Su(var)3-9 and enhancer of 
zeste (SET) domain, and the endogenous methyl donor S-Adenosyl methionine 
(SAM). The products of a methyl transfer from the sulfonium ion of SAM are S-
Adenosyl homocysteine (SAH) and methylated lysine (Figure 1.1). Even a small 
chemical modification like the methylation of a lysine residue has a profound 
effect on transcriptional activity. For example, trimethylation of lysine 4 on histone 
H3 (H3K4me3) corresponds to regions of active transcription, whereas 
dimethylation of histone 3 lysine 9 (H3K9me2) or trimethylation of histone 3 
lysine 27 (H3K27me3) correspond to regions of silenced, less transcriptionally 
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active chromatin. Dysregulation of these processes often occurs in many 
developmental diseases and maladies. Hypertrimethylation of H3K27 is present 
in many cancers, and usually correlates with a late-stage metastatic disease with 
poor prognosis. Although, lysine residues within each histone are structurally 
similar, specific enzymes are responsible for their maintenance.  
 
Polycomb Repressive Complex 2 
 
The methylation state of lysine residues on histone proteins is modulated 
by two classes of proteins: trithorax and polycomb proteins. Trithorax group 
proteins serve to maintain expression via methylation of specific lysines. For 
example, the Mixed Lineage Leukemia (MLL) (Figure 1.2, MLL-MLL4) proteins 
catalyze the mono-, di-, and/or trimethylation of H3K4. And H3K4me3 is 
associated with the 5’ regions of nearly all actively transcribed genes. Further, 
H3K4me3 is highly correlated with histone acetylation, high rates of transcription, 
and polymerase II occupancy [2, 3].  In contrast to trithorax group proteins, 
polycomb group proteins function to repress gene expression. For example, 
Polycomb Repressive Complex 2 (PRC2) catalyzes the di- and trimethylation of 
H3K27, which leads to a repressive chromatin state, shutting down expression of 
genes upstream of H3K27me3 containing promoters. 
As the name implies, PRC2 is a multi-component complex that contains 
four essential core components for catalytic activity: enhancer of zeste homolog 
1 or 2 (EZH1 or EZH2) (Figure 1.2), embryonic ectoderm development (EED), 
suppressor of zeste 12 (Suz12), and retinoblastoma protein-associated protein 
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48 and 46 (RbAp48/46). EZH1 or EZH2 are the catalytically active subunits, 
which utilize their evolutionarily conserved SET domain to methylate H3K27me1 
or H3K27me2 to produce H3K27me2 or H3K27me3, respectively [4]. EED and 
RbAP46/48 contain repeats of the WD40 domain, which facilitates binding to 
H3K27me3 via the tryptophan (W) and aspartic acid (D) rich domains [5, 6]. 
Suz12 contains a zinc-finger domain necessary for DNA binding, and a VEFS 
domain necessary for interaction with EZH1 or EZH2; Suz12 is believed to 
function as a facilitator of DNA-binding for PRC2 [7, 8].  
While the afore mentioned four core components of PRC2 are absolutely 
necessary for PRC2 function, and exhibit embryonic lethality when deleted or 
silenced in mouse embryos, there are several other proteins that are known to 
interact with PRC2 in a cell- and tissue-specific manner. These include, but are 
not limited to: AEBP2, which enhances PRC2 enzymatic activity at certain genes 
[9], PCL1, PCL2 and PCL3, which are tudor domain containing proteins that co-
localize with PRC2 at specific promoters [10], and JARID2A a Jumonji family 
demethylase capable of demethylating H3K27 [11]. PRC2 has also been shown 
to interact with various other epigenetic machineries like histone deacetlyases, 
and other histone methyltransferases, but their effect on PRC2 function is less 
understood [5]. Altogether, PRC2 plays an essential role in development and 
stem cell fate in normal healthy organisms, but dysregulation of H3K27me3 via 
overexpression or gain-of-function EZH2 mutations is a major occurrence in the 
progression of many cancers, ranging from solid tumors like breast [12, 13] and 
prostate [14], to blood tumors including lymphoma [15], leukemia [16], and 
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myeloma [17]. To further complicate matters, EZH2 has been described as both 
a tumor suppressor [18] and tumor promoter [16]. This paradox highlights the 
need for the development of chemical probes to study the mechanisms of EZH1 
and EZH2 (EZH1/EZH2) catalytic activity. 
 
Role of EZH2 and EZH1 in Disease Progression 
 
As mentioned earlier, the catalytically active subunit of PRC2 is either 
EZH1 or EZH2. EZH1/EZH2 are highly homologous, mutually exclusive members 
of PRC2 that share 76% overall sequence identity, and 96% sequence identity in 
the catalytic SET domain [19]. Despite being highly homologous, EZH1/EZH2 are 
differentially expressed; EZH2 is present in poorly differentiated and actively 
dividing cells, whereas EZH1 is expressed in all cells [5]. In adult hematopoietic 
stem cells EZH1 deletion leads to defects in self-renewal and quiescence that is 
not seen upon EZH2 deletion, demonstrating that these two proteins differ 
functionally as well [20]. PRC2-EZH1 complexes are less catalytically active than 
PRC2-EZH2 complexes [21], but this lack of catalytic activity may be 
supplemented by the cooperative effect of PRC2 complexes containing EZH1 
(PRC2-EZH1) and those containing EZH2 (PRC2-EZH2). For example, the 
nucleosome binding ability of PRC2-EZH1 leads to increased activity of PRC2-
EZH2 complexes [22]. However, PRC2-EZH1 complexes still retain catalytic 
activity, so their sole purpose is not simply a scaffolding function. These 
observations are just the “tip of the iceberg” in terms of what we have to learn 
about EZH1/EZH2 biology. 
6 
Overexpression of EZH2 was first linked to the progression of prostate 
cancer merely twelve years ago [14]. Since that time, aberrations in both EZH2 
expression and catalytic activity have been attributed to highly invasive cancers 
with poor prognosis. In solid tumors, overexpression of EZH2 leads to 
hypertrimethylation of H3K27 and subsequent repression of genes encoding 
proteins important for cell cycle regulation, cell-cell contacts, and cell-matrix 
adhesions [23, 24]. In blood tumors, like MLL-rearranged leukemia, both EZH1 
and EZH2 have been shown to contribute to disease progression. MLL-
rearranged leukemia result in aberrantly active proteins produced from 
chromosomal translocations of MLL and a host of transcription factors (e.g., AF4, 
AF9, ENL, PTD) [25]. These translocations lead to unnecessary recruitment of 
machinery responsible for transcriptional elongation and increased expression of 
key leukemic genes Hoxa and Meis1 [26]. The MLL-AF9 fusion complex 
contributes to the initiation of acute myeloid leukemia (AML), but cancer is not a 
one step process [27, 28], and MLL-AF9 is not the sole contributor to the AML 
phenotype. Recently, a MLL-AF9 AML mouse model demonstrated that EZH2-/- 
mice retain H3K27me3 at distinct loci [16]. This finding suggests a role for both 
EZH1/EZH2 in the progression of MLL-AF9 leukemia. Indeed, EZH1 has been 
shown to compensate for the function of EZH2 [29, 30] and plays a role as a 
regulator of hematopoietic neoplasms [16, 31]. 
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Current Chemical Probes for EZH2 
 
The identification of EZH2 overexpression in various human cancers has 
led the community to propose EZH2 as an attractive drug target for therapeutic 
intervention [25], and has inspired several pharmaceutical companies to 
endeavor on high-throughput screening campaigns for inhibitors of EZH2. 
Independent efforts by Epizyme, GlaxoSmithKline (GSK), and Novartis revealed 
a structurally similar, cofactor-competitive, small molecule, which potently 
suppresses EZH2-catalyzed H3K27me3 [32-38]. These independent hits were 
then optimized via traditional medicinal chemistry to enhance the drug-likeness of 
these compounds.  
The first two published EZH2 inhibitors are EPZ005687 [33] and GSK126 
[32] (Table 1.1), which potently inhibit wild type and lymphoma-associated gain-
of-function EZH2 mutants. Additionally, both of these compounds are highly 
selective for EZH2 over a range of methyltransferases, kinases, and GPCRs. 
EPZ005687, from Epizyme, was not suitable for in vivo studies, but it was an 
essential tool compound for target validation and overall study of EZH2 biology. 
GSK126, from GSK, demonstrated in vivo potency via IP administration [32]. 
These compounds share very similar pharmacophoric features, and are fairly 
selective for EZH2 versus EZH1 (50-150 fold selectivity, Table 1.1), 
demonstrating the high specificity of these compounds. Soon after the disclosure 
of GSK126, GSK343 was published with similar potency against EZH2, but 
differs from GSK126 in that it contains an indazole core and several different 
substitutions such as the piperazine-substituted pyridine (Table 1.1). El1 (Table 
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1.1) is a compound that was optimized from a high-throughput screening 
campaign hit at Novartis [34]. El1 has similar structural features and selectivity as 
EPZ005687 and GSK126, but did not display any in vivo activity. UNC1999 
(Table 1.1) represents the first orally bioavailable inhibitor of EZH2, and is the 
most panactive EZH1/EZH2 inhibitor to date [35]. UNC1999 shares similarity in 
structure to GSK343, differing only in the substitution of the pyridine, and the 
capping group of the piperazine. However, this small modification has a large 
effect on the pharmacokinetic properties of the compound, and the EZH1/EZH2 
selectivity. This EZH1/EZH2 panactivity poses a potential advantage for 
UNC1999 in cancer cells that rely on both EZH isoforms, such as MLL-
rearranged leukemia [16, 39]. Shortly after the disclosure of UNC1999, Epizyme 
released an orally bioavailable derivative of EPZ005687: EPZ-6438 [36] (Table 
1.1). Unlike previously published compounds that contain a bicyclic core, EPZ-
6438 has a monocyclic phenyl core. The only non-pyridone containing inhibitor of 
EZH2 is Constellation Pharmaceuticals compound 3 (Table 1) [37]. This 
compound is not suitable for in vivo studies, and shows about 10-fold selectivity 
for EZH2 versus EZH1. All of these inhibitors demonstrate high potency and high 
selectivity towards wild-type EZH2 and its lymphoma-associated mutant forms 
[32-38] (Table 1.1).  
 
Summary and Significance 
 
As detailed above, the pharmaceutical industry has already begun to 
target EZH2 inhibition as a potential treatment for blood tumors like lymphomas 
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and leukemia. However, as a relatively nascent target in the field of drug 
discovery, there is a lack of complete knowledge of PRC2 function, and this may 
present a barrier to success in the clinic. For example, it is well-received that 
EZH2 plays a role in the progression of prostate cancer, and that overexpression 
of EZH2 in this context correlates with late-stage, metastatic disease [14, 40]. 
Contrarily, EZH2 also appears to have a tumor suppressor role, because EZH2 
deletion has been observed in the development of myelodysplastic syndrome 
(MDS) [18, 41]. This observation is compounded by the fact that both EZH2 and 
EZH1 are regulators of hematopoietic stem cell function [20, 42]. Even within the 
realm of what is known about PRC2, the effects of complexes containing either 
EZH2 or EZH1 are still confounding. Suffice to say; much more research is to be 
conducted on PRC2 biology before it can be certain that it is a viable therapeutic 
target. 
Until recently, the main methods used to study the role of PRC2 were 
genetic knockouts (KOs) or RNA interference (RNAi) of PRC2 components. 
These methods have many disadvantages: embryonic lethality, loss of complex 
integrity, residual expression, and lack of translation to animal studies. Complete 
removal of a protein from a biological system often results in a different 
physiological response than inhibition of catalytic activity with a small molecule, 
because many proteins have scaffolding functions apart from their catalytic 
activity, which are required for other biological processes. Small molecule 
chemical probes [43], that solely target the catalytic function of an enzyme are 
superior to KO and RNAi, because the protein is still produced at physiological 
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levels. However, early chemical probes of EZH2 were not orally bioavailable [32, 
44], complicating clinical translation, and current probes do not display as potent 
EZH1 inhibition, which can be beneficial in certain diseases [39]. The lack of a 
panactive EZH1/EZH2 inhibitor further highlights the need for the development of 
more advanced chemical probes.  
In solid tumors like ovarian and prostate cancer, it is known that EZH2, 
rather than both EZH1/EZH2, is the main contributor to disease progression. 
Therefore, a selective inhibitor of EZH2 in these cases would be more beneficial 
than a panactive EZH1/EZH2 compound. To establish selective EZH2 inhibition 
we plan to create an irreversible inhibitor of EZH2 by targeting a cysteine residue 
near our hypothesized binding site. Importantly, this cysteine residue is a serine 
residue in EZH1 which will allow for selective covalent engagement of EZH2. 
This finding will have profound impact on the field, as it may provide: 1) the most 
selective EZH2 inhibitor to date, 2) further evidence for our previously proposed 
binding hypothesis, and 3) the first EZH2-inhibitor co-crystal structure. 
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Tables 
 
 
Table 1.1. Summary of current EZH2 inhibitors. 
ND = no data; nM = nanomolar  
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Figures 
 
Figure 1.1: Graphical representation of histones. 
DNA (black) is coiled around histone proteins (large circles) for compaction. The 
histone proteins are composed of 4 sets of homodimeric subunits (H2A (green), 
H2B (yellow), H3 (red) and H4 (blue)) and an additional monomeric H1 subunit 
(not pictured). Lysines on histone tails (pictured on H3 tail only for simplicity) are 
modified by lysine methyltransferases via donation of a methyl group from SAM; 
trimethylated H3K27 is pictured.  
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Figure 1.2: Phylogenetic tree of lysine methyltransferases. 
There are approximately 60 protein methyltransferases in the human genome. 
These are composed of both lysine and arginine methyltransferases, which have 
histone and non-histone substrates. The lysine methyltransferases of interest in 
the research presented herein are EZH1 and EZH2 (red box), G9a and GLP 
(blue box) and MLL1-4 (green box).
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CHAPTER II: UNC1999 IS AN ORALLY BIOAVAILABLE INHIBITOR OF THE 
LYSINE METHYLTRANSFERASE EZH2 
 
Introduction 
 
Due to the impact of chromatin modifications on genetic expression, 
epigenetic “writers” (the enzymes responsible for producing post-translational 
modifications (PTMs)), “readers” (the proteins responsible for binding PTMs), and 
“erasers” (the enzymes responsible for removing PTMs) have gained increasing 
interest as an important class of drug targets [45, 46]. One “writer” of specific 
interest is the lysine methlytransferase EZH2, which is the catalytic component of 
PRC2. PRC2 is responsible for the methylation status of H3K27; H3K27me3 
correlates with regions of repressed expression, and the process of monitoring 
this methylation state often goes awry in many cancers. As such, EZH2 is an 
attractive target for potential therapeutic intervention.  
Recent advances in EZH2 inhibitor development have been spearheaded 
by Epizyme, GSK and Novartis. Specifically, independent high-throughput 
screening campaigns at all three of these companies identified small molecules 
capable of potent EZH2 inhibition. These hits were optimized via traditional 
medicinal chemistry methods to enhance the drug-likeness of the identified 
compounds, which resulted in the discovery of EPZ005687, GSK126, and El1 
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(Table 1.1).  These inhibitors were very potent in in vitro and cellular assays, but 
only GSK126 displayed any in vivo activity, and none were orally bioavailable. 
 Herein, we report the design and development of UNC1999, the first orally 
bioavailable inhibitor of EZH2. In addition to optimizing the physicochemical 
properties of this class of EZH2 inhibitors, we also designed several compounds 
that serve as additional tools for studying EZH2 biology. UNC2400 is a 
structurally similar, yet inactive, analog of UNC1999 that serves as a negative 
control. UNC2399 is a biotinylated derivative of UNC1999 that is capable of 
chemiprecipitating EZH2 from cell lysates. UNC2239 is a UNC1999 derivative 
that contains a cell penetrant dye capable of engaging EZH2 in cells. These four 
compounds together, help to validate our proposed binding hypothesis for 
UNC1999, and also provide a useful chemical toolbox for the research 
community to accelerate further study of EZH2 biology. 
 
Methods 
 
Chemistry General Procedures 
HPLC spectra for all compounds were acquired using an Agilent 6110 
Series system with UV detector set to 254 nm. Samples were injected (5 µL) onto 
an Agilent Eclipse Plus 4.6 x 50 mm, 1.8 µM, C18 column at room temperature. 
Method 1: A linear gradient from 10% to 100% B (MeOH + 0.1% acetic acid) in 
5.0 min was followed by pumping 100% B for another 2 minutes with A being 
H2O + 0.1% acetic acid. Method 2: A linear gradient from 50% to 100% B (MeOH 
+ 0.1% acetic acid) in 5.0 min was followed by pumping 100% B for another 2 
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minutes with A being H2O + 0.1% acetic acid. The flow rate was 1.0 mL/min. 
Mass spectra (MS) data were acquired in positive ion mode using an Agilent 
6110 single quadrupole mass spectrometer with an electrospray ionization (ESI) 
source. Nuclear Magnetic Resonance (NMR) spectra were recorded using a 
Varian Mercury spectrometer with 400 MHz for proton (1H NMR) and 100 MHz 
for carbon (13C NMR); chemical shifts are reported in ppm (δ). Preparative HPLC 
was performed on Agilent Prep 1200 series with UV detector set to 254 nm. 
Samples were injected onto a Phenomenex Luna 75 x 30 mm, 5 µM, C18 column 
at room temperature. The flow rate was 30 mL/min. A linear gradient was used 
with 10% (or 50%) of MeOH (A) and 0.1 % TFA in H2O (B) to 100% of MeOH (A). 
HPLC was used to establish the purity of target compounds, all compounds had 
> 95% purity using the HPLC methods described above unless noted otherwise. 
High-resolution (positive ion) mass spectrum (HRMS) for compound UNC1999 
was acquired using a Thermo LTqFT mass spectrometer under FT control at 
100000 resolution. 
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Compound Synthesis 
 
Scheme 2.1. Reagents and conditions: (a) K2CO3, NMP (1-methyl-2-
pyrrolidinone), 120°C, 50%; (b) 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-
dioxaborolane), KOAc, 1,4-dioxane, Pd(dppf)Cl2 · CH2Cl2, 80°C, 55%; (c) KOAc, 
1,4-dioxane, H2O, Pd(dppf)Cl2 · CH2Cl2, reflux, 78%; (d) HCl (aq), rt, 95%; (e) 
formaldehyde solution (37 wt.% in H2O) / acetaldehyde / acetone, NaBH3CN, 
AcOH, MeOH, 0°C - rt, 48-86%; (f) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl2 · 
CH2Cl2, 1,4-dioxane, 80°C, Ar; (g) 2-bromo-5-fluoropyridine, Pd(PPh3)4, K2CO3, 
1,4-dioxane, H2O, 90°C, 61% (two steps); (h) K2CO3, (4-fluorophenyl)boronic 
acid, Pd(PPh3)4, 1,4-dioxane, H2O, microwave, 150°C, 73%. 
 
tert-Butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-
yl)piperazine-1-carboxylate. 5-Bromo-2-chloropyridine (10 g, 52.0 mmol), tert-
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butyl piperazine-1-carboxylate (29 g, 156 mmol), and potassium carbonate (22 g, 
156 mmol) were mixed in NMP (50 mL) and heated to 120°C overnight.  The 
mixture was then cooled to room temperature and diluted with water until 
precipitate was observed.  The solid was collected by filtration, washed with 
water and dried under vacuum to give tert-butyl 4-(5-bromopyridin-2-
yl)piperazine-1-carboxylate  as a white solid (9 g, 50% yield). tert-Butyl 4-(5-
bromopyridin-2-yl)piperazine-1-carboxylate (5 g, 14.6 mmol), 4,4,4',4',5,5,5',5'-
octamethyl-2,2'-bi(1,3,2-dioxaborolane) (4.46 g, 17.6 mmol), and potassium 
acetate (2.15 g, 22.0 mmol) were mixed with 1,4-dioxane (120 mL) in a flask. To 
this mixture, 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride 
dichloromethane complex (600 mg, 0.73 mmol) was added under argon 
atmosphere at room temperature.  The mixture was heated to 80°C for 5 h and 
cooled to room temperature. The resulting mixture was then diluted with EA and 
washed with water. The combined organic layers were dried over sodium sulfate.  
After concentration in vacuo, the crude product was purified by silica 
chromatography (Hex/EA = 5/1) to afford the title compound as a white solid (3.2 
g, 55% yield). 1H NMR (300 MHz, CDCl3), δ: 8.56 – 8.51 (m, 1H), 7.83 (dd, J = 
8.6, 1.9 Hz, 1H), 6.59 (d, J = 8.5 Hz, 1H), 3.60 (dd, J = 6.6, 3.2 Hz, 4H), 3.52 (dd, 
J = 6.7, 3.2 Hz, 4H), 1.48 (s, 9H), 1.31 (s, 12H).  
 
6-Bromo-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)-1H-indazole-4-carboxamide. This compound was synthesized 
according to the procedures reported previously. [47] 
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1-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-
(6-(piperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide (2.1). 6-Bromo-1-
isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-
indazole-4-carboxamide (1 g, 2.3 mmol), tert-butyl 4-(5-(4,4,5,5-tetramethyl-
1,3,2- dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-carboxylate (965 mg, 2.48 
mmol), and potassium acetate (680 mg, 6.90 mmol) were mixed with 1,4-dioxane 
(20 mL) and water (5 mL). 1,1'-bis(diphenylphosphino) ferrocene-
palladium(II)dichloride dichloromethane complex (190 mg, 0.23 mmol) was 
added to the mixture under argon atmosphere at room temperature.  The 
resulting mixture was heated to reflux for 5 h, then cooled and diluted with EA.  
The mixture was washed with water, dried over sodium sulfate and concentrated 
in vacuo.  The crude product was purified by silica chromatography (DCM/MeOH 
= 40/1) to give tert-butyl 4-(5-(1-isopropyl-4-(((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)carbamoyl)-1H-indazol-6-yl)pyridin-2-yl)piperazine-1-
carboxylate as a white solid (1.1 g, 78% yield). This product was then dissolved 
in a saturated solution of HCl in EA. The mixture was stirred at room temperature 
overnight.  The solvent was removed in vacuo to give the title compound 2.1 as a 
yellow solid (1 g, 95% yield). 1H NMR (400 MHz, d4-MeOH), δ: 8.49 (d, J = 2.3 
Hz, 1H), 8.35 (s, 1H), 7.93 (dd, J = 8.9, 2.6 Hz, 1H), 7.88 (s, 1H), 7.75 (d, J = 1.2 
Hz, 1H), 6.84 (d, J = 8.9 Hz, 1H), 6.10 (d, J = 0.6 Hz, 1H), 5.06 (dt, J = 13.3, 6.6 
Hz, 1H), 4.58 (s, 2H), 3.52 (dd, J = 6.0, 4.3 Hz, 4H), 2.91 (dd, J = 5.9, 4.3 Hz, 
4H), 2.76 – 2.67 (m, 2H), 2.24 (s, 3H), 1.62 (td, J = 15.0, 7.5 Hz, 2H), 1.56 (t, J = 
5.7 Hz, 6H), 1.00 (t, J = 7.3 Hz, 3H).  
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1-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-
(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide (2.2). 
Compound 2.2 was prepared according to previously published procedures. [47] 
 
6-(6-(4-Ethylpiperazin-1-yl)pyridin-3-yl)-1-isopropyl-N-((6-methyl-2-oxo-4-
propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (2.3). 
Compound 2.1 (50 mg, 0.089 mmol),  acetaldehyde (50 µL, 0.89 mmol) and 
acetic acid (~0.5 µL, 0.009 mmol) were mixed with MeOH (1 mL) at 0°C and then 
sodium cyanoborohydride (17 mg, 0.267 mmol) was added. The reaction was 
stirred at room temperature overnight and then purified by preparative HPLC 
(10% – 100% methanol / 0.1% TFA in H2O) to afford compound 2.3 as a white 
solid (24 mg, 48% yield). 1H NMR (400 MHz, CDCl3), δ: 12.66 (s, 1H), 8.48 (d, J 
= 2.5 Hz, 1H), 8.39 (s, 1H), 8.00 (t, J = 5.7 Hz, 1H), 7.76 (dd, J = 8.8, 2.6 Hz, 
1H), 7.71 (d, J = 1.2 Hz, 1H), 7.58 (s, 1H), 6.67 (d, J = 8.8 Hz, 1H), 5.93 (s, 1H), 
4.87 (dp, J = 13.1, 6.6 Hz, 1H), 4.67 (d, J = 5.8 Hz, 2H), 3.75 – 3.58 (m, 4H), 
2.75 – 2.67 (m, 2H), 2.65 (s, 4H), 2.56 (dd, J = 14.2, 7.1 Hz, 2H), 2.16 (s, 3H), 
1.65 (dd, J = 15.2, 7.5 Hz, 2H), 1.58 (d, J = 6.7 Hz, 6H), 1.18 (t, J = 7.2 Hz, 3H), 
1.01 (t, J = 7.3 Hz, 3H). 
 
1-Isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-
4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(UNC1999 (2.4)). The procedure used for preparation of compound 2.3 was 
followed for synthesis of the title compound (UNC1999); acetone was used 
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instead of acetaldehyde. This compound was obtained as a white solid (21 mg, 
78%). 1H NMR (400 MHz, d4-MeOH), δ: 8.48 (d, J = 2.4 Hz, 1H), 8.36 (s, 1H), 
7.91 (dd, J = 8.9, 2.6 Hz, 1H), 7.87 (s, 1H), 7.75 (d, J = 1.2 Hz, 1H), 6.81 (d, J = 
8.9 Hz, 1H), 6.09 (s, 1H), 5.06 (dt, J = 13.3, 6.6 Hz, 1H), 4.58 (s, 2H), 3.61 – 3.46 
(m, 4H), 2.70 (ddd, J = 13.1, 8.6, 6.3 Hz, 3H), 2.63 (dd, J = 11.2, 6.0 Hz, 4H), 
2.23 (s, 3H), 1.63 (dt, J = 15.3, 7.5 Hz, 2H), 1.55 (d, J = 6.6 Hz, 6H), 1.09 (d, J = 
6.5 Hz, 6H), 1.00 (t, J = 7.3 Hz, 3H). 
 
6-(5-Fluoropyridin-2-yl)-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (2.5). 6-Bromo-1-
isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-
indazole-4-carboxamide (50 mg, 0.112 mmol), bis(pinacolato)diboron (34 mg, 
0.135 mmol), and potassium acetate (16.5 mg, 0.168 mmol) were mixed with 1,4-
dioxane (1.25 mL) under argon atmosphere at room temperature. The mixture 
was added a catalytic amount of [1,1-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) complex with dichloromethane (9.1 mg, 0.011 
mmol), and heated to 80°C. After being stirred overnight, the resulting mixture 
was concentrated in vacuo, and used for the next step without further purification. 
To the solution of crude 1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
indazole-4-carboxamide and 2-bromo-5-fluoropyridine (158 mg, 0.896 mmol) in 
1,4-dioxane and water (1.25 mL/0.25 mL) was added 
tetrakis(triphenylphosphine)palladium (26 mg, 0.022 mmol), and potassium 
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carbonate (46 mg, 0.336 mmol). After being stirred overnight at 90°C, the 
resulting mixture was purified by preparative HPLC (10% – 100% methanol / 
0.1% TFA in H2O) to afford the title compound 2.5 as a white solid (32 mg, 61% 
yield). 1H NMR (400 MHz, CDCl3), δ: 12.69 (s, 1H), 8.52 (d, J = 2.2 Hz, 1H), 8.44 
(s, 1H), 8.22 (s, 1H), 8.07 (s, 1H), 7.94 (s, 1H), 7.85 (dd, J = 8.6, 4.1 Hz, 1H), 
7.47 (td, J = 8.4, 2.3 Hz, 1H), 6.02 (s, 1H), 4.97 (dt, J = 13.2, 6.6 Hz, 1H), 4.69 
(d, J = 3.8 Hz, 2H), 2.82 – 2.68 (m, 2H), 2.21 (s, 3H), 1.70 – 1.62 (m, 2H), 1.60 
(d, J = 6.6 Hz, 6H), 1.02 (t, J = 7.3 Hz, 3H).  
 
6-(4-Fluorophenyl)-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (2.6). To a 
microwave vessel containing 6-bromo-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-
1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (50.6 mg, 0.112 
mmol) was added potassium carbonate (46.4 mg, 0.336 mmol), (4-fluorophenyl) 
boronic acid (23.5 mg, 0.168 mmol), and tetrakis(triphenylphosphine)palladium 
(1.16 mg, 0.001 mmol). After adding 1 mL of dioxane:H2O (5:1), the vessel was 
placed in a microwave reactor for 20 minutes at 150°C. The contents were 
separated using EA and brine, extracting 3 times with EA then dried using 
Na2SO4. The crude product was purified using HPLC and then concentrated in 
vacuo to yield compound 2.6 (37.7 mg, 73%). 1H NMR (400 MHz, CDCl3), δ: 8.41 
(s, 1H), 7.88 (s, 2H), 7.72 (s, 1H), 7.61 (d, J = 9.5 Hz, 3H), 7.11 (s, 2H), 6.06 (s, 
1H), 4.89 (dt, J = 13.3, 6.7 Hz, 1H), 4.68 (d, J = 5.4 Hz, 2H), 2.82 – 2.71 (m, 2H), 
2.19 (s, 3H), 1.72 – 1.55 (m, 8H), 1.02 (t, J = 7.3 Hz, 3H).  
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Scheme 2.2. Reagents and conditions: (a) DMF, K2CO3, CH3I, rt, 68%; (b) 
DMF, NaH, CH3I, rt, 92%; (c) K2CO3, Pd(PPh3)4, 1-(5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)pyridin-2-yl)piperazine, 1,4-dioxane, H2O, microwave, 150°C; 
(d) TFA, DCM, 88%; (e) acetone, MeOH, AcOH, NaBH3CN, 0°C - rt, 83%. 
 
6-Bromo-N-((1,6-dimethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-
isopropyl-N-methyl-1H-indazole-4-carboxamide (2.7). 6-Bromo-1-isopropyl-N-
((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (50.8 mg, 0.112 mmol), and potassium carbonate (102.4 mg, 0.741 
mmol) were added to a 4 mL scintillation vial, and dissolved in DMF (0.5 mL). 
The resulting mixture was stirred at room temperature for 5 minutes before 
adding iodomethane (100 µL), and stirring at room temperature for 24 hours. The 
resulting mixture was purified by HPLC to yield 6-bromo-N-((1,6-dimethyl-2-oxo-
4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide 
(35.7 mg, 0.078 mmol, 68%). 6-Bromo-N-((1,6-dimethyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide (15 mg, 
0.033 mmol) and sodium hydride (2 mg, 0.050 mmol) were added to a 4 mL 
scintillation vial and were dissolved in DMF (0.15 mL). The mixture was stirred at 
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room temperature for 5 minutes before adding iodomethane (10 µL). The 
resulting mixture was stirred at rt for 24 hours and purified by HPLC to yield the 
title compound (14.4 mg, 0.030 mmol, 92%). 1H NMR (the major rotamer is 
reported here) (400 MHz, CDCl3),  δ: 7.93 (s, 1H), 7.64 (s, 1H), 7.25 (s, 1H), 6.12 
(s, 1H), 4.85 (s, 2H), 4.81 – 4.66 (m, 1H), 3.59 (s, 3H), 2.93 (s, 3H), 2.70 (t, J = 
Hz, 2H), 2.38 (s, 3H), 1.76 – 1.46 (m, 8H), 1.01 (t, J = 7.3 Hz, 3H). 
 
N-((1,6-Dimethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-
isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-methyl-1H-
indazole-4-carboxamide (UNC2400 (2.8)). 6-Bromo-N-((1,6-dimethyl-2-oxo-4-
propyl-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-N-methyl-1H-indazole-4-
carboxamide (22.6 mg, 0.034 mmol) was added to a microwave vessel with tert-
butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine-1-
carboxylate (27.9 mg, 0.112 mmol), potassium carbonate (23.2 mg, 0.168 mmol), 
and a catalytic amount of tetrakis(triphenylphosphine)palladium (1 mg, 0.001 
mmol). The resulting mixture was dissolved in 1 mL of dioxane:H2O (5:1) and 
placed in a microwave reactor at 150°C for 20 minutes. The resulting mixture 
was separated with EA and brine, extracted 3 times with EA, and purified by 
HPLC. The dried product was then dissolved in 1 mL TFA:EA (1:1), basified 
using NH3 (1 mL), and then concentrated in vacuo to yield N-((1,6-dimethyl-2-
oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-N-methyl-6-(6-
(piperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide (19.9 mg, 0.030 mmol, 
88%). N-((1,6-Dimethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-
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isopropyl-N-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide 
(19.9 mg, 0.030 mmol) was added to a vial containing sodium cyanoborohydride 
(15 mg, 0.239 mmol) on ice, and dissolved in methanol (0.2 mL). Acetone (30 µL) 
and acetic acid (25 µL) were then added to the mixture, the vial was removed 
from ice and the reaction was run at room temperature overnight. The mixture 
was then purified using HPLC to yield the title compound (UNC2400 (2.8)) (14.9 
mg, 0.025 mmol, 83%). 1H NMR (the major rotamer is reported here) (400 MHz, 
CDCl3), δ: 8.47 (s, 1H), 7.93 (s, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.50 (s, 1H), 7.32 
(s, 1H), 6.73 (d, J = 8.8 Hz, 1H), 6.00 (s, 1H), 4.98 – 4.79 (m, 3H), 3.63 (s, 3H), 
3.55 (s, 3H), 2.94 (s, 3H), 2.83 – 2.60 (m, 7H), 2.35 (s, 3H), 1.83 – 1.52 (m, 9H), 
1.10 (d, J = 6.5 Hz, 6H), 1.02 (t, J = 7.2 Hz, 3H).  
 
 
Scheme 2.3. Reagents and conditions: (a) hex-5-yn-1-yl 4-
bromobenzenesulfonate, K2CO3, DMF, rt, 74%; (b) azide-dye, Cat. 
Cu(CH3CN)4PF6, DCM, rt, 90%.  
 
6-(6-(4-(Hex-5-yn-1-yl)piperazin-1-yl)pyridin-3-yl)-1-isopropyl-N-((6-methyl-2-
oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(2.9). To a solution of hex-5-yn-1-ol (2.07 g, 21.09 mmol) in DCM (30 mL) was 
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added 4-bromobenzenesulfonyl chloride (5.93g, 23.20 mmol) and DABCO (2.84 
g, 25.30 mmol) at 0ºC. The resulting mixture was stirred for 2 hours at 0ºC. 15 
mL of distilled water was added. The organic phase was collected, dried with 
sodium sulfate, filtered, concentrated and purified by silica gel chromatography 
(hexanes to 15% EA in hexanes) to afford hex-5-yn-1-yl 4-
bromobenzenesulfonate (6.15 g, 92%). To a solution of compound 2.1 (56 mg, 
0.10 mmol) and hex-5-yn-1-yl 4-bromobenzenesulfonate (44 mg, 0.14 mmol) in 
1.0 mL of DMF was added potassium carbonate (41 mg, 0.30 mmol) at room 
temperature, and stirred overnight. After water (2 mL) was added, the mixture 
was extracted with EA (10 mL × 3). The combined organic phases were dried 
with sodium sulfate, filtered, concentrated and purified by preparative HPLC to 
give the title compound as a yellow solid (44 mg, 72%). 1H NMR (400 MHz, 
CDCl3), δ: 12.93 (s, 1H), 8.47 (dd, J = 2.5, 0.4 Hz, 1H), 8.39 (s, 1H), 8.01 (t, J = 
5.7 Hz, 1H), 7.75 (dd, J = 8.8, 2.6 Hz, 1H), 7.71 (d, J = 1.3 Hz, 1H), 7.57 (s, 1H), 
6.66 (d, J = 8.8 Hz, 1H), 5.92 (d, J = 0.6 Hz, 1H), 4.85 (dd, J = 13.3, 6.7 Hz, 1H), 
4.66 (d, J = 5.7 Hz, 2H), 3.65 – 3.56 (m, 4H), 2.70 (dd, J = 8.5, 7.0 Hz, 2H), 2.63 
– 2.51 (m, 4H), 2.48 – 2.38 (m, 2H), 2.23 (td, J = 6.9, 2.6 Hz, 2H), 2.15 (s, 3H), 
1.96 (t, J = 2.6 Hz, 1H), 1.73 – 1.52 (m, 12H), 1.00 (t, J = 7.3 Hz, 3H). 
 
(E)-Acetoxymethyl 1-(3-(acetoxymethoxy)-3-oxopropyl)-2-((2E,4E)-4-(1-
ethyl-3-(2-(4-(4-(4-(5-(1-isopropyl-4-(((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)carbamoyl)-1H-indazol-6-yl)pyridin-2-
yl)piperazin-1-yl)butyl)-1H-1,2,3-triazol-1-yl)ethyl)-2,4,6-
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trioxotetrahydropyrimidin-5(2H)-ylidene)but-2-en-1-ylidene)-3,3-
dimethylindoline-5-carboxylate (UNC2239 (2.10)). Cu(CH3CN)4PF6 (0.7 mg, 
0.0018 mmol) was added to a solution of 6-(6-(4-(hex-5-yn-1-yl)piperazin-1-
yl)pyridin-3-yl)-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)-1H-indazole-4-carboxamide (6.3 mg, 0.0104 mmol) and the azide-dye 
compound (5.9 mg, 0.0087 mmol) in DCM (1.0 mL); the mixture was stirred 
overnight at room temperature [48]. The resulting product was concentrated and 
purified by preparative HPLC to give the title compound (UNC2239 (2.10)) as a 
dark red solid (10.1 mg, 90%). 1H NMR (400 MHz, d4-MeOH), δ: 8.55 (s, 1H), 
8.33 (s, 1H), 8.11–8.04 (m, 1H), 8.04–7.93 (m, 3H), 7.91 (s, 1H), 7.83 (s, 1H), 
7.80–7.63 (m, 3H), 7.24–7.17 (m, 1H), 7.06 (d, J = 8.9 Hz, 1H), 6.23–6.07 (m, 
2H), 5.95 (d, J = 3.5 Hz, 2H), 5.68 (d, J = 8.6 Hz, 2H), 5.13–5.02 (m, 1H), 4.71–
4.63 (m, 2H), 4.62 (s, 2H), 4.43–4.21 (m, 5H), 3.88–3.77 (m, 2H), 3.75–3.32 (m, 
8H), 3.27–3.18 (m, 2H), 2.86 (dd, J = 14.5, 7.0 Hz, 2H), 2.82–2.73 (m, 3H), 2.27 
(s, 3H), 2.11 (s, 3H), 2.00 (d, J = 3.8 Hz, 3H), 1.89–1.71 (m, 4H), 1.74–1.61 (m, 
8H), 1.58 (d, J = 6.6 Hz, 6H), 1.11 (t, J = 7.0 Hz, 3H), 1.03 (t, J = 7.3 Hz, 3H). 
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Scheme 2.4. Reagents and conditions: (a) O-[2-(biotinylamino)ethyl]-O’-(2-
carboxyethyl)undecaethylene glycol, DMF, DIPEA, HATU, rt, 41%. (b) Biotin, 
DMF, DIPEA, HATU, rt, 78%. 
 
1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-
(6-(4-(41-oxo-45-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxa-40-
azapentatetracontanoyl)piperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxamide (UNC2399 (2.11)). Compound 2.1 (21.4 mg, 0.041 mmol) was 
added to a vial containing HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (18.5 mg, 0.049 mmol) and 
O-[2-(biotinylamino)ethyl]-O’-(2-carboxyethyl)undecaethylene glycol. The two 
components were dissolved in DMF (0.3 mL) and DIPEA (8.5 µL) was added to 
the resulting mixture. The reaction was run at room temperature for 24 hours, 
and purified by HPLC to yield UNC2399 (22.6 mg, 0.016 mmol, 41%). 1H NMR 
(400 MHz, d4-MeOH), δ: 8.51 (dd, J = 9.5, 2.4 Hz, 1H), 8.43 (d, J = 2.2 Hz, 1H), 
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8.40 (s, 1H), 8.10 (s, 1H), 7.80 (d, J = 1.3 Hz, 1H), 7.50 (d, J = 9.5 Hz, 1H), 6.18 
(d, J = 0.7 Hz, 1H), 5.13 (tt, J = 13.4, 6.6 Hz, 2H), 4.61 (s, 2H), 4.49 (dd, J = 7.9, 
4.2 Hz, 1H), 4.30 (dd, J = 7.9, 4.5 Hz, 1H), 3.97 – 3.78 (m, 9H), 3.67 – 3.55 (m, 
33H), 3.52 (t, J = 5.5 Hz, 2H), 3.34 (t, J = 5.5 Hz, 2H), 3.19 (ddd, J = 8.9, 5.8, 4.6 
Hz, 1H), 2.92 (dd, J = 12.8, 5.0 Hz, 1H), 2.79 – 2.67 (m, 5H), 2.28 (s, 3H), 2.20 (t, 
J = 7.4 Hz, 2H), 1.78 – 1.52 (m, 11H), 1.48 – 1.37 (m, 2H), 1.03 (t, J = 7.3 Hz, 
3H). 
 
1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-
(6-(4-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl)piperazin-
1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide (UNC2398 (2.12)). The 
procedure for UNC2398 is the same as UNC2399 except that biotin was used 
instead of O-[2-(biotinylamino)ethyl]-O’-(2-carboxyethyl)undecaethylene glycol to 
give UNC2398 in 78% yield. 
 
EZH2 Homology Modeling 
An EZH2 homology model was built using the X-ray crystal structure of the 
lysine methyltransferase GLP (PDB: 2RFI) as a template.  3D conformation of 
EPZ005687 or UNC1999 was constructed and docked into the EZH2 homology 
model. A subsequent induced-fit minimization was conducted to further optimize 
the complex. The ligand interaction diagram was drawn with Maestro 9.3 
(Schrodinger LLC, www.schrodinger.com). 
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Scintillation Proximity Assay 
Methyltransferase activity assays were performed by monitoring the 
incorporation of a tritium-labeled methyl group from S-adenosylmethionine (3H-
SAM) to biotinylated peptide substrates using Scintillation Proximity Assay (SPA) 
for PRC2 trimeric complex (EZH2:EED:SUZ12), SETD7, G9a, GLP, SETDB1, 
SETD8, SUV420H1, SUV420H2, SUV39H2, MLL1 tetrameric complex 
(MLL:WDR5:RbBP5:ASH2L), PRMT1, PRMT3, PRMT5-MEP50 complex and 
SMYD2. The reaction buffer for SMYD2 and SMYD3 was 50 mM Tris pH 9.0, 5 
mM DTT, 0.01% Triton X-100; for G9a, GLP and SUV39H2 was 25 mM 
potassium phosphate pH 8.0, 1 mM EDTA, 2 mM MgCl2 and 0.01% Triton X-
100; and for other HMTs 20 mM Tris pH 8.0, 5 mM DTT, 0.01% Triton X-100. To 
stop the enzymatic reactions, 10 µL of 7.5 M guanidine hydrochloride was added, 
followed by 180 µL of buffer, mixed and transferred to a 96-well FlashPlate (Cat. 
# SMP103; Perkin Elmer; www.perkinelmer.com). After mixing, the reaction 
mixtures were incubated and the CPM counts were measured using a Topcount 
plate reader (Perkin Elmer, www.perkinelmer.com). The CPM counts in the 
absence of compound for each data set were defined as 100% activity. In the 
absence of the enzyme, the CPM counts in each data set were defined as 
background (0%). IC50 values were determined using compound concentrations 
ranging from 100 nM to 100 µM. The IC50 values were determined using 
SigmaPlot software. For DNMT1, the assay was performed as described above 
using hemi-methylated dsDNA as a substrate. The dsDNA substrate was 
prepared by annealing two complementary strands (biotinylated (B) forward 
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strand: B-GAGCCCGTAAGCCCGTTCAGGTCG and reverse strand: 
CGACCTGAACGGGCTTACGGGCTC), synthesized by Eurofins MWG Operon. 
Reaction buffer was 20 mM Tris-HCl, pH 8.0, 5 mM DTT, 0.01% Triton X-100. 
Methyltransferase activity assays for DOT1L were performed using filter-plates 
(Millipore; cat.# MSFBN6B10; www.millipore.com). Reaction mixtures in 20 mM 
Tris-HCl, pH 8.0, 5 mM  DTT, 2 mM MgCl2, and 0.01% Triton X-100 were 
incubated at room temperature for 1h, 100 µL 10% TCA was added, mixed and 
transferred to filter-plate. Plates were centrifuged at 2000 rpm for 2 min followed 
by 2 additional 10% TCA wash and one ethanol wash (180 µL) followed by 
centrifugation. Plates were dried and 100 µL MicroO was added and centrifuged. 
70 µL MicroO was added and CPM were measured using Topcount plate reader. 
 
UNC1999 Mechanism of Action Studies 
To determine the mechanism of action of UNC1999, methyltransferase 
activity of PRC2-EZH2 was assessed in the presence of different concentrations 
of the compound (0, 1, 3 and 5 nM) at (1) fixed concentration of peptide (5 µM) 
and SAM concentrations from 0.625 to 10 µM and (2) fixed concentration of SAM 
(10 µM) and peptide concentrations from 0.3 to 5 µM. Assays were performed in 
triplicate, and kinetic values were obtained using Lineweaver-Burk plots 
(SigmaPlot, Enzyme Kinetics Module). 
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In-cell Western Assay  
MCF10A cells were grown in DMEM/F12 media 5% horse serum, EGF (20 
ng/mL), hydrocortisone (0.5 µg/mL), cholera toxin (100 ng/mL), and insulin (10 
µg/ml) in the presence of inhibitors as stated in the figures. MCF7 cells were 
cultured in DMEM supplemented with 10% FBS. Fixation in 96 well black wall 
clear bottom plates was performed by 2% formaldehyde in PBS for 10 min. After 
five washes with 0.1% Triton X-100 in PBS, cells were blocked for 1 h RT, or 
overnight at 4°C with 3% BSA, 5% goat serum in PBS. Three replicate wells from 
each experimental group were incubated in primary H3K27me3 antibody, 
Diagenode MAb-181-050 at 1/4000 dilution in 3% BSA, 5% goat serum PBS for 
18 h at 4°C. The wells were washed five times with 0.1% Tween-20 in PBS, then 
secondary IR800 conjugated antibody (Li-Cor) in Li-Cor blocking buffer (1:1000) 
and nucleic acid-intercalating dye, DRAQ5 (Cell Signaling Technologies) added 
for 1 h RT. After 5 washes with 0.1% Tween-20 PBS, the plates were read on an 
Odyssey (LiCor) scanner at 800 nm (H3K27me3 signal) and 700 nm (DRAQ5 
signal). Fluorescence intensity was quantified, normalized to the background, 
then to the DRAQ5 signal, and expressed as a percentage of control. 
 
Cell Viability Assay 
Cell viability assays were performed using 0.1 mg/mL of resazurin (Sigma) 
in the media. Resazurin reduction was monitored with 544 nm excitation, 
measuring fluorescence at 590 nm. 
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Kinase and GPCR studies 
Selectivity against a panel of 50 representative kinases and 46 
representative GPCRs was carried out by PDSP according to their standard 
protocols. 
 
Pharmacokinetic Studies 
These studies were conducted at Sai Life Sciences according to their 
standard protocols. 15, 50, and 150 mg/kg IP as well as 50 mg/kg PO PK studies 
were performed in male Swiss albino mice (9 per dosing regimen). Each study 
lasted 24 hours, plasma concentrations of UNC1999 were obtained at .08, .25, 
.5, 1, 2, 4, 8, and 24 hr post-dosing. 
 
EZH2 Y641N Biochemical Assay 
EZH2 Y641N mutants were generated and assayed by BPS Bioscience. A 
series of dilutions of UNC1999 were prepared with 10% DMSO in HMT assay 
buffer (BPS #52170) and 5 µL of the dilution was added to a 50 µL reaction so 
that the final concentration of DMSO is 1% in all of reactions. All of the enzymatic 
reactions were conducted in duplicate at room temperature for 60 minutes 
(EZH2; BPS #51004) and 180 minutes (EZH2 Y641N; BPS #51028) in a 50 µL 
mixture containing HMT assay buffer, S-adenoslymethionine (BPS #52120), 
enzyme, and UNC1999. These 50 µL reactions were carried out in wells of a 
HMT substrate pre-coated plate. After enzymatic reactions, the reaction mixtures 
were discarded and each of the wells was washed three times with TBST buffer, 
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and slowly shaken with Blocking Buffer (BPS #52100) for 10 minutes. Wells were 
emptied, and 100 µL of diluted 1° antibody (BPS #52140F) was added. The plate 
was then slowly shaken for 60 minutes at room temperature. As before, the plate 
was emptied and washed three times, and shaken with Blocking Buffer for 10 
minutes at room temperature. After discarding the Blocking Buffer, 100 µL of 
diluted 2° antibody (BPS #52131H) was added. The plate was then slowly 
shaken for 30 minutes at room temperature. As before, the plate was emptied 
and washed three times, and shaken with Blocking Buffer for 10 minutes at room 
temperature. Blocking Buffer was discarded and a mixture of the HRP 
chemiluminescent substrate was freshly prepared. 100 µL of this mixture was 
added to each empty well. Immediately, the luminescence of the samples was 
measured in a BioTek SynergyTM 2 microplate reader. 
 
DB Cell Proliferation Assay 
DB cells, a diffuse-large B-cell lymphoma cell line harboring the EZH2 
Y641N mutation [49, 50] were obtained from ATCC and cultured in RPMI 1640 
supplemented with 10% fetal bovine serum, antibiotics, and various 
concentration of compounds (either DMSO control, UNC1999 and UNC2400). 
The numbers of viable cells from at least three independent experiments were 
measured using the TC20 automated cell counter system (Biorad). Total histones 
were prepared from cell nuclei using an acidic extraction protocol as previously 
described. [51] About 1 microgram of total histones was separated using 15% of 
SDS-PAGE, transferred to PVDF membranes, and probed with histone 
35 
antibodies. Antibodies used in this study are those against EZH2 (BD bioscience 
612666), general H3 (Abcam ab1791), and H3K27me3 (Abcam ab6002). 
 
Results 
 
Discovery of UNC1999 
Homology modeling of EZH2 based on the X-ray crystal structure of GLP 
(PDB: 2RFI), an H3K9 methyltransferase, was performed in order to establish a 
binding hypothesis for pyridone-containing EZH2 inhibitors. Docking of 
EPZ005687 into the homology model identified a low energy conformation 
demonstrating that the terminal morpholine group was solvent exposed, and did 
not appear to make contacts with the EZH2 protein surface (figure 2.1 A & B). 
Other interesting interactions were observed; a hydrogen bonding network 
present between the central amide and pyridone of EPZ005687, and asparagine 
688 and histidine 689 of EZH2 (figure 2.1 A & B). On the basis of our binding 
hypothesis, and knowledge of key structural features of GSK126 and EPZ005687 
that lead to EZH2 inhibition, we designed several compounds with the aim of 
endowing oral bioavailability.  
 We focused on modifying the morpholinomethyl region of EPZ005687 to 
modulate the physicochemical properties of this series, which resulted in the 
design and synthesis of the compounds in Table 2.1. These changes were 
expected to have little to no effect on potency, because that region of the scaffold 
was hypothesized to be solvent exposed. We maintained the pyridone indazole 
core of EPZ005687 to retain key hydrogen bonds and hydrophobic interactions 
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with the protein. Among the compounds from Table 2.1, UNC1999 was docked 
into the homology model, and like EPZ005687, the docking model of UNC1999 
suggests that: (1) the secondary amide, and pyridone, maintain the respective 
key hydrogen bonds with N688 and H689, (2) the indazole core is buried in a 
hydrophobic pocket, and (3) the N-isopropyl piperazine does not interact with the 
protein (Figure 2.1 C & D). 
The compounds in Table 2.1 were evaluated in an EZH2 radioactive 
biochemical assay which measures the direct transfer of the tritiated methyl 
group from the cofactor 3H – SAM to a peptide substrate. IC50 values of these 
compounds in this assay, and their calculated partition coefficient (clogP) values, 
are summarized in Table 2.1. As expected, the unsubstituted and N-alkyl 
piperazines had high in vitro potency for EZH2 (IC50 < 10 nM), which indicated 
that modifications to the N-capping group are well tolerated. These in vitro results 
support our binding hypothesis: the N-alkyl piperazine does not interact with the 
protein. Among these four inhibitors, UNC1999 has the most desirable clogP 
(3.1), suggesting that this inhibitor may be well absorbed orally. In addition, 
UNC1999 has a more desirable clogP than either EPZ005687 (2.2) or GSK126 
(2.6). Interestingly, replacing the 2-piperazinyl pyridin-5-yl moiety with the 3-
fluoro pyridin-6-yl group retained high in vitro potency (IC50 = 10 ± 1 nM (n = 3)), 
but replacing the 3-fluoro pyridin-6-yl group with the 4-fluorophenyl group led to a 
6-fold loss in potency. Based on these results, we selected UNC1999 for 
subsequent mechanism of action (MOA), selectivity, cellular assays, and mouse 
PK studies. 
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Discovery of UNC2400 
To provide the research community with a set of useful tools, we aimed to 
create a structurally similar, but significantly less potent, EZH2 inhibitor as a 
negative control for in vitro and cell-based studies. The UNC1999 docking model 
suggests that the secondary amide and pyridone form key hydrogen bonds with 
N688 and H689 (Figure 2.1 C & D). So, we designed and synthesized UNC2400 
(Figure 2.2 A), which contains an N-methyl group at both the secondary amide 
and pyridone moieties of UNC1999. We hypothesized that the addition of these 
two N-methyl groups would abolish the hydrogen bonds between the secondary 
amide and pyridone of UNC1999 with N688 and H689 of EZH2, respectively. 
Indeed, UNC2400 displayed an IC50 = 13,000 ± 3,000 nM (n = 3) in the EZH2 
radioactive biochemical assay (Figure 2.2 B), which is more than 1000-fold less 
potent than UNC1999, thus supporting our in silico binding hypothesis for 
UNC1999. Importantly, UNC2400 was also inactive in a number of cell-based 
studies (see below). The high structural similarity and drastic potency difference 
between UNC1999 and UNC2400 suggest they will be excellent positive and 
negative control tool compounds. 
 
UNC1999 Is a SAM-competitive, Potent, and Selective Inhibitor of EZH2 and 
EZH1 
To determine the MOA of EZH2 inhibition by UNC1999, we generated 
classic Lineweaver-Burk plots [52] (Figure 2.2 C & D), which indicate that 
UNC1999 is competitive with cofactor SAM (Ki of 4.6 ± 0.8 nM; n = 2) and non-
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competitive with the H3 peptide substrate. We also determined that increasing 
the H3 peptide concentration had no effect on the IC50 values of UNC1999 
(Figure 2.2 E) while increasing SAM concentration dramatically affected the IC50 
values of UNC1999 (Figure 2.2 F), which further supports that UNC1999 is a 
SAM-competitive EZH2 inhibitor.  
We next determined the potency of UNC1999 against EZH2 Y641 
mutants. UNC1999 was highly potent for Y641N and Y641F mutants (Figure 2.3 
A, blue and green, respectively), displaying less than 5-fold more potent inhibition 
for the WT over the Y641N (IC50 = 24 nM) and Y641F (IC50 = 23 nM) mutant 
enzymes. This data is consistent with other pyridone containing EZH2 inhibitors 
to date [32, 34, 44]. To further determine the selectivity profile of UNC1999, we 
first tested UNC1999 against EZH1. Compared with EPZ005687, GSK126 and 
El1, which are at least 50-fold selective for EZH2 over EZH1, [32, 34, 44] 
UNC1999 had a higher in vitro potency for EZH1 (IC50 = 45 ± 3 nM; n = 3) 
(Figure 2.3 B); about 10-fold less potent for EZH1 than EZH2. UNC1999 is also 
very selective for EZH2 versus 15 other lysine, arginine or DNA 
methyltransferases (Figure 2.3 C) assayed; 10,000-fold selective for EZH2 (IC50 
< 10 nM) over these methyltransferases (IC50 > 100,000 nM).  
 We also evaluated the selectivity of UNC1999 over a broad range of non-
epigenetic targets. UNC1999 is competitive with SAM, an adenine nucleoside, so 
we tested it against a panel of 50 representative kinases (Table 2.2). UNC1999 
showed no appreciable inhibition (no more than 20% inhibition at 10,000 nM) 
against these kinases. Further, UNC1999 possesses an N-isopropyl piperazine 
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moiety, which is a potential pharmacophore for aminergic G protein-coupled 
receptor (GPCR) binding, so we tested it in the National Institute of Mental Health 
(NIMH) Psychoactive Drug Screen Program (PDSP) Selectivity Panel. This panel 
consists of 44 representative GPCRs, transporters, and ion channels (Table 2.3); 
UNC1999 was found to show no more than 50% inhibition at concentrations as 
high as 10,000 nM against 40 targets, and > 50% inhibition at 10,000 nM against 
4 targets in the panel. Ki determinations in the radioligand binding assay for each 
of the 4 interacting targets was subsequently performed (Table 2.4). UNC1999 
had Ki values of 4,700 nM, 65 nM, 300 nM, and 1,500 nM for sigma1, sigma2, 
histamine H3, and NET (norepinephrine transporter), respectively. Although we 
could not evaluate UNC1999 in sigma2 functional assays, because they do not 
exist, we tested UNC1999 in histamine H3 functional assays and found that it did 
not display any agonist or antagonist activities at concentrations up to 1,000 nM. 
Therefore, with the exception of sigma2, UNC1999 was more than 200-fold 
selective for EZH2 over a broad range of kinases, GPCRs, transporters, and ion 
channels. 
 
UNC1999 Potently Reduces H3K27me3 in Cells and Selectively Kills EZH2-
mutant DLBCL Cells 
To assess the cellular potency of UNC1999, we employed an H3K27me3 
antibody cell immunofluorescence In-Cell Western (ICW) assay. This assay 
allows for rapid processing of multiple samples for H3K27me3 
immunofluorescence signal and normalization to cell number via the use of the 
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nucleic acid dye, DRAQ5. We characterized UNC1999 and UNC2400 in 
MCF10A cells, which bear the WT EZH2 enzyme. UNC1999 (72 h exposure) 
exhibited concentration-dependent reductions in H3K27me3 with an IC50 of 124 
± 11 nM (n = 3) (Figure 2.4 A, blue dots). On the other hand, UNC2400 (negative 
control) showed little or no activity in this ICW assay (Figure 2.4 B, red dots), 
which is consistent with its poor in vitro potency. In addition, the treatment of 
MCF7 cells with UNC1999 at 5,000 nM for 72 h almost completely removed the 
H3K27me3 mark but did not have significant effects on cellular levels of EZH2 
(Figure 2.4 C).     
 One of the most desirable characteristics of a high quality chemical probe 
is low toxicity due to off-target effects. Both UNC1999 (EC50 = 19,200 ± 1,200 
nM; n = 3) and UNC2400 (EC50 = 27,500 ± 1,300; n = 3) had low cellular toxicity 
in a standard resazurin (Alamar Blue) reduction assay (Figure 2.4 A & B). Taken 
together, UNC1999 had an excellent separation of cellular potency and toxicity 
with a function/toxicity ratio of more than 150 (Figure 2.4 A, blue vs grey dots).  
 We next investigated whether DB cells, a DLBCL cell line harboring the 
EZH2 Y641N mutant [49, 50], are more sensitive to UNC1999 treatment. 
UNC1999 (8 day exposure) displayed robust, concentration-dependent inhibition 
of cell proliferation (EC50 = 633 ± 101 nM; n = 3) (Figure 2.5 A), which is slightly 
more potent than GSK126 [32]. At 5,000 nM, UNC1999 (8 day exposure) 
completely killed DB cells (Figure 2.5 A, blue line). Interestingly, we observed a 
delayed onset of activity for UNC1999; the 3 day treatment with this inhibitor did 
not have significant effects on cell proliferation at all tested concentrations 
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(Figure 2.5 A) as was also seen with EPZ005687 and GSK126 [32, 44]. We also 
compared the effects of the negative control UNC2400 on cell proliferation to 
UNC1999. UNC1999 (3,000 nM, 8 day treatment) significantly inhibited DB cell 
proliferation, while UNC2400 (3,000 nM, 8 day treatment) had negligible effects 
(Figure 2.5 B, blue bar vs red bar). Furthermore, UNC1999 (3,000 nM, 3 day 
treatment) significantly reduced the H3K27me3 mark but did not significantly 
change EZH2 levels in DB cells (Figure 2.5 C, well 2). On the other hand, 
treatment with UNC2400 at 3,000 nM for 3 days did not result in a significant 
reduction in the H3K27me3 mark, nor EZH2 levels in DB cells (Figure 2.5 C, well 
3). Combining the observed low toxicity in MCF10A cells and high sensitivity in 
DB cells, we provide evidence that UNC1999 selectively kills DLBCL cells 
heterozygous for Y641 point mutations. In addition, we showed that UNC1999 
has robust on-target activities in cells and UNC2400 is an excellent negative 
control for cell-based studies. 
 
Discovery of UNC2399 and UNC2239 
Our UNC1999 binding hypothesis predicts that the N-terminal nitrogen of 
the piperazine of UNC1999 is solvent exposed. To test this possibility, and create 
functionalized chemical tools, we appended both a PEG-biotin group (UNC2399) 
and a cell permeable dye (UNC2239) to the terminal piperazine nitrogen of 
UNC1999.  
To synthesize UNC2399, we used a simple amide coupling between the 
free piperazine of UNC1999 (compound 2.1) and O-[2-(biotinylamino)ethyl]-O’-(2-
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carboxyethyl)undecaethylene glycol (Scheme 2.4), which yielded a 12 PEG linker 
between the UNC1999 moiety, and biotin handle (Figure 2.6 A). We implemented 
a lengthy linker to ensure that the biotin handle would be sufficiently solvent 
exposed for capture by streptavidin-coated beads. Indeed, UNC2399 displayed 
high in vitro potency (IC50 = 17 ± 2 nM; n = 3) in the EZH2 radioactive 
biochemical assay (Figure 2.6 B), which provides further evidence for our in silico 
binding hypothesis of UNC1999. 
To perform EZH2 chemiprecipitation, we first conjugated UNC2399 to 
streptavidin-coated beads. The compound-conjugated beads were used to 
capture EZH2 protein from HEK293T (human embryonic kidney 293T) cell 
lysates. We were pleased to find that UNC2399 – streptavidin conjugated beads 
(Figure 2.6 C, well 3) enriched EZH2 from cell lysates as compared to 
unconjugated streptavidin beads (DMSO control, Figure 2.6 C, well 2). To control 
for non-specific interactions, we pretreated the cell lysates with a soluble 
competitor, UNC1999 or UNC2400, before pull-down. As expected, pretreatment 
of lysate with UNC1999 (100 µM) antagonized the enrichment of EZH2 by 
UNC2399 – streptavidin beads (Figure 2.6 C, well 4 versus well 3). On the other 
hand, pretreatment with UNC2400 (100 µM) resulted in EZH2 levels nearly 
identical to the untreated lysates (Figure 2.6 C, well 5 versus well 3). It is 
important to note that a direct conjugation of biotin to the free piperazine of 
UNC1999, yielding UNC2398 (Figure 2.6 D), was as potent as UNC2399 in the in 
vitro scintillation proximity assay (Figure 2.6 E), but was unable to 
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chemiprecipitate EZH2 (Figure 2.6 F), so a linker is imperative for efficient 
chemiprecipitation of EZH2. 
Next, we synthesized UNC2239 (Figure 2.7 A) by utilizing click chemistry 
between a UNC1999 analog containing a terminal alkyne (compound 2.9) and a 
membrane permeable merocyanine dye with an azide side chain (Scheme 2.3). 
As expected, UNC2239 displayed high in vitro potency (IC50 = 21 ± 1 nM; n = 3) 
in the EZH2 radioactive biochemical assay, despite the addition of the 
fluorophore (Figure 2.7 B). Mouse embryonic fibroblast (MEF) cells stably 
expressing yellow fluorescent protein (YFP) were treated with the fluorescent 
EZH2 probe UNC2239 or with only the dye component of the probe as a control 
(Figure 2.7 C). The dye is known to distribute uniformly in MEF cells without 
evidence of any compartmental or organelle specific interactions. YFP serves as 
a uniformly distributed volume control fluorophore. When examining the 
localization of the probe, the ratio of dye intensity to YFP intensity was 
normalized for effects arising from varying cell thickness and uneven illumination 
intensity. Because the concentration of the probe and YFP varied from cell-to-
cell, ratio images were normalized by setting the lowest 5% of pixels within each 
cell equal to 1. Cells treated with UNC2239 showed significantly higher 
fluorescence intensity in the nucleus relative to the cytoplasm than cells treated 
with the dye alone (Figure 2.7 C, p < 0.05, n = 6). Perinuclear localization of the 
probe was also observed, potentially due to autophagocytic uptake of the probe. 
The observed localization of UNC2239 is consistent with the nuclear localization 
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of GFP – tagged EZH2 as seen in transfected HEK 293 cells (Figure 2.7 D), 
suggesting that UNC2239 co-localizes with EZH2. 
 
UNC1999 Is Orally Bioavailable in Mice 
We next evaluated the in vivo PK properties of UNC1999. A single 
intraperitoneal (IP) injection of UNC1999 at 15, 50, or 150 mg/kg achieved high 
Cmax (9,700 – 11,800 nM) and exhibited dose linearity in male Swiss albino 
mice (Figure 2.8 A). Both the 150 and 50 mg/kg IP doses resulted in plasma 
concentrations of UNC1999 above its cellular IC50 over the entire 24 h period, 
and the 15 mg/kg IP dose led to the plasma concentrations of UNC1999 above 
its cellular IC50 for approximately 12 h. We next examined whether UNC1999 is 
orally bioavailable and were pleased to find that a single 50 mg/kg oral dose of 
UNC1999 achieved high Cmax (4,700 nM) and good exposure levels in male 
Swiss albino mice (Figure 2.8 B). The plasma concentrations of UNC1999 were 
maintained above its cellular IC50 for approximately 20 h following this single 
oral dose. It is worth noting that all doses including the 150 mg/kg IP dose were 
well tolerated by all test mice, and no adverse effects were observed. 
  
Discussion 
 
The use of homology modeling helped to establish a putative binding 
hypothesis for pyridone containing inhibitors of EZH2. We then tested this 
hypothesis by synthesizing various compounds, and in the process, discovered 
several key compounds, which are of current and future use to the biological 
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community as a set of chemical tools that will help accelerate our understanding 
of PRC2 function, and how this function becomes dysregulated in cancers and 
developmental diseases. 
In addition to our chemical probe UNC1999, we discovered UNC2400, a 
structurally similar analog that is almost completely inactive in both in vitro and 
cellular assays. The use of this compound provided evidence for the presence of 
our hypothesized hydrogen bonding network between the pyridone and acyclic 
amides of UNC1999, and N688 and H689 of EZH2. Further, the fact that 
UNC2400 and UNC1999 display low, yet nearly equal, cytotoxicity in cell viability 
assays, demonstrates that potential toxicity of pyridone containing compounds is 
most likely not due to inhibition of EZH2. This data is exciting, as it provides a 
positive prognosis for the development of EZH2 inhibitors as therapeutics going 
forward. 
Our UNC1999 binding hypothesis also predicted the N-terminal piperazine 
to be solvent exposed, which provided a useful handle to functionalize this site. 
First, PEG-biotinylation led to the discovery of UNC2399. UNC2399 selectively 
chemiprecipitates EZH2 from cell lysates, which is especially useful for 
complexes like PRC2. While the core components of PRC2 (EZH2 or EZH1, 
SUZ12 and EED) are always present, many other proteins (DNMT1, JARID2A, 
etc) which possess strictly different functions are present in a cell- and 
developmental-specific context. So, a small molecule capable of 
chemiprecipitating the complex will be extremely useful for determining the 
composition of complexes in malignant cells versus benign cells going forward. 
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The chemoproteomics applications of UNC2399 are very promising, and will 
surely play a role in the understanding of PRC2 function in malignant 
transformation. We also developed UNC2239, which contains a cell penetrant 
dye conjugated to the piperazine of UNC1999. This compound will have many 
applications going forward, one of which is to provide an alternative to traditional 
immunofluorescence (IF). A cell permeable compound which engages and 
identifies the target is more advantageous than traditional antibody-based 
immunofluorescence for intracellular targets, which involves permeation of the 
membrane. 
UNC1999 is also the most active inhibitor of EZH1 to date, which may 
have potential benefit in treating specific cancers [16]. The exact reasoning for 
this selectivity switch between the scaffolds is unfounded, as the key interactions 
between UNC1999 and EPZ005687 and EZH1/EZH2 appear identical in 
homology models that were constructed. It is possible that this change in 
selectivity may be due to issues beyond direct ligand – protein interactions; 
UNC1999 may affect how EZH1/EZH2 interacts with other PRC2 components, 
but this is purely speculation. The dual inhibition of EZH2 and EZH1 by UNC1999 
might result in higher efficacy in cell-based and animal models where the 
methylation of H3K27 by PRC2-EZH2 is compensated by PRC2-EZH1, but in the 
very least provides another avenue for exploration in the nascent field of PRC2 
small molecule drug discovery. 
Compared with existing EZH2 inhibitors such as EPZ005687 and El1, 
which were reported to not have sufficient in vivo PK properties [34, 44] and 
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GSK126, which was only used via IP injection [32], UNC1999 displayed a more 
attractive cLogP, and is the first orally bioavailable inhibitor of EZH2 and EZH1. 
An orally bioavailable inhibitor makes chronic animal studies more practical and 
convenient, because the compound can easily be administered in the food or 
water of test mice. Contrarily, chronic daily IP injections to test mice could lead to 
infections, which might complicate long-term animal studies. Therefore, the 
intrinsic oral bioavailability of UNC1999 is a valuable attribute for the biomedical 
research community to assess long-term therapeutic benefit(s) and potential 
toxicity resulting from pharmacological inhibition of EZH2 and EZH1 in mouse 
models. 
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Tables 
 
 
Table 2.1: in vitro activity of EZH2 inhibitors. 
a IC50 determination experiments were performed in triplicate. 
b The IC
50
 limit of 
the EZH2 radioactive biochemical assay is 10 nM because the concentration of 
EZH2 used in this assay is 20 nM. GSK126 and EPZ005687 values were taken 
from [32] and [44], respectively. 
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Kinase 
10 µM UNC1999  
Kinase 
10 µM UNC1999  
(% inhibition) (% inhibition) 
ABL -4 CHK1 -2 
CSK -4 CK1ε -4 
EGFR -3 DAPK1 -4 
EPHA2 -6 DYRK1B -4 
EPHB4 -6 Erk2 3 
FGFR1 -9 GSK3β -13 
FLT3 16 HGK -2 
IGF1R -7 IKKβ -3 
ITK -2 IRAK4 -7 
JAK3 -8 JNK2 5 
KDR -2 MAPKAPK2 4 
LCK 0 MST1 -5 
MET -3 NEK2 -4 
PDGFRα -5 p38α 0 
PYK2 -5 p70S6K 6 
SRC -1 PAK2 4 
SYK -6 PBK -10 
TIE2 -6 PDK1 -6 
TRKA 7 PIM1 1 
TYRO3 -1 PKACα -12 
AKT1 -6 PKCα -4 
AMPKα1/β1/γ1 -3 PKD2 5 
AurA -4 ROCK1 5 
CaMK4 20 SGK -3 
CDK2/CycA2 -3 TSSK1 5 
 
Table 2.2: Selectivity of UNC1999 versus representative kinase panel. 
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GPCR 
10 µM UNC1999 
 
GPCR 
10 µM UNC1999 
(% inhibition)  (% inhibition) 
5-HT1A 11 D2 9 
5-HT1B 44 D3 28 
5-HT1D 50 D4 2 
5-HT1e 2 D5 20 
5-HT2A 39 DAT 36 
5-HT2B -9 DOR 21 
5-HT2C 22 GABAA -17 
5-HT3 12 H1 16 
5-HT5a 10 H2 30 
5-HT6 11 H3 95 
5-HT7 -4 KOR 34 
Alpha1A 3 M1 18 
Alpha1B 6 M2 41 
Alpha1D 14 M3 10 
Alpha2A 14 M4 21 
Alpha2B 48 M5 9 
Alpha2C 47 MOR 13 
Beta1 -15 NET 83 
Beta2 14 PBR 31 
Beta3 10 SERT 6 
BZP -6 Sigma 1 57 
D1 13 Sigma 2 93 
 
Table 2.3: Selectivity of UNC1999 versus NIMH PDSP panel. 
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Target Binding Affinity (K
i
, nM) Functional Activity 
H3 300 0 
NET 1500 NT 
Sigma 1 4700 NT 
Sigma 2 65 NA 
 
Table 2.4:  UNC1999 binding affinity and potency. 
(0 = no agonist or antagonist activity at concentrations up to 1 µM, NT = not 
tested, NA = not available).  
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Figures 
 
 
Figure 2.1: EZH2 homology model: UNC1999 and EPZ005687 have similar 
modes of binding. 
A homology model of EZH2 was constructed using GLP as a template (PDB: 
2RFI). (A) EPZ005687 was docked into the SET domain; the ligand (green) 
orients such that the morpholine group is solvent exposed and does not interact 
with EZH2 (purple). Additionally, there are three key hydrogen bonds that appear 
to be requisite for activity (dotted red lines). (B) Proposed ligand interactions of 
EPZ005687 display a hydrogen bond between the middle amide and N688, and 
two hydrogen bonds between the pyridone and H689. (C) A docking model of 
UNC1999 shows a similar hydrogen bonding network as it binds to EZH2 similar 
to EPZ005687 and its N-isopropyl piperazine is solvent exposed. (D) Proposed 
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ligand interactions of UNC1999 display the same key hydrogen bonds and 
hydrophobic interactions as EPZ005687. 
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Figure 2.2: Characterization of UNC1999 and UNC2400 in biochemical 
assays. 
(A) Structures of UNC1999 and negative control UNC2400.  (B) UNC2400 
displayed > 1000-fold decrease in IC
50
 as compared to UNC1999 in the in vitro 
EZH2 radioactive assay. (C) – (D) Lineweaver-Burk plots demonstrated that 
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UNC1999 is non-competitive with the histone H3 substrate (C), and competitive 
with the co-factor SAM (D). (E) – (F) Further evidence demonstrating that 
UNC1999 is SAM competitive; increasing concentration of H3 has no effect on 
UNC1999 IC50 (E), but increasing concentration of SAM leads to a higher IC50 
(F).  
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Figure 2.3: Characterization of UNC1999 versus EZH2 mutants, EZH1, and 
other methyltransferases. 
(A) UNC1999 was less than 5-fold more potent for WT EZH2 versus Y641N 
EZH2 and Y641F EZH2. (B) UNC1999 displayed high potency (IC
50
 = 45 ± 3 nM) 
for EZH1. (C) UNC1999 was selective for EZH2 and EZH1 over 15 other lysine, 
arginine, and DNA methyltransferases assayed. 
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Figure 2.4: UNC1999 potently reduces H3K27me3 levels in cells and shows 
low cell toxicity. 
(A) UNC1999 reduced H3K27me3 levels in MCF10A cells (IC
50
 = 124 ± 11 nM; n 
= 3) as determined by the ICW assay (blue), and displayed low cell toxicity (EC
50
 
= 19,200 ± 1,200 nM; n = 3) in the resazurin assay (grey). (B) UNC2400 
displayed negligible inhibition of H3K27me3 levels (red) in MCF10A cells while 
displaying similar toxicity as UNC1999 (EC50 = 27,500 ± 1,300 nM; n = 3) in the 
resazurin assay (grey). (C) Immunofluorescence staining showed that treatment 
with UNC1999 (5 µM, 72 h) effectively reduced the H3K27me3 mark but did not 
affect EZH2 levels in MCF7 cells. Scale bar represents 10 µm. 
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Figure 2.5: UNC1999 selectively kills DB cells, a DLBCL cell line with the 
EZH2 Y641N mutation. 
(A) UNC1999 displayed a concentration- and time-dependent inhibition of DB cell 
proliferation (EC
50
 = 633 ± 101 nM; n =3). (B) UNC2400 (3,000 nM, 8 days) did 
not significantly inhibit DB cell proliferation in contrast to UNC1999. (C) Western 
blotting of EZH2, H3K27me3, and total H3 following the treatment of DB cells 
with UNC1999 or UNC2400 at 3,000 nM for 3 days. UNC1999 decreased 
H3K27me3, but not EZH2 levels, while UNC2400 did not significantly reduce 
H3K27me3 or EZH2 levels in DB cells. 
  
59 
 
Figure 2.6: Biotinylated UNC1999 (UNC2399) enriches EZH2 from HEK 293T 
cell lysates. 
(A) Structure of UNC2399, a biotinylated UNC1999 analog. (B) UNC2399 
displayed high in vitro potency (IC
50
 = 17 ± 2 nM) for EZH2. (C) In UNC2399 pull-
down experiments, EZH2 levels were markedly enriched (well 3) as compared to 
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the DMSO control (well 2). The ability to pull-down EZH2 out of cell lysates was 
abolished by the pretreatment with 100 µM UNC1999 (well 4), but was not 
affected by the pretreatment with 100 µM UNC2400 (well 5). This blot is 
representative of three biological replicates. (D) Structure of UNC2398. (E) 
UNC2398 retains high in vitro potency for EZH2. (F) UNC2398 pull-down (well 5) 
does not effectively enrich for EZH2 versus DMSO treated beads (well 3). 
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Figure 2.7: Live cell imaging with UNC1999-dye conjugate (UNC2239). 
(A) Structure of UNC2239, a fluorescent dye conjugate of UNC1999. (B) 
UNC2239 displayed high in vitro potency (IC
50
 = 21 ± 1 nM) for EZH2. (C) HEK 
293T cells transfected with EZH2-GFP and stained with nuclear marker Hoechst 
33342 showed nuclear localization of EZH2-GFP.  (D) Ratio images showing 
localization of the EZH2 probe in MEF cells. The ratio of dye fluorescence 
intensity over YFP volume control fluorophore intensity was determined.  Cells 
were normalized by setting the lowest 5% of cytoplasmic ratio values = 1.  
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Figure 2.8: Pharmacokinetic profiles of UNC1999 in male swiss albino mice. 
(A) Plasma concentrations of UNC1999 following a single IP injection (15, 50, or 
150 mg/kg) over the 24 h period. (B) Plasma concentrations of UNC1999 
following a single oral dose (50 mg/kg) over the 24 h period. The dashed black 
line indicates the cellular IC50 of UNC1999. 
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CHAPTER III: DUAL INHIBITION OF EZH2 AND EZH1 IS A VIABLE 
THERAPEUTIC OPTION FOR MLL-REARRANGED LEUKEMIA 
 
Introduction 
 
PRC2 complexes containing either EZH2 or EZH1 play an integral role in 
hematopoietic gene silencing at various stages of hematopoiesis [20, 21]. As 
such, there is extensive evidence demonstrating that deregulation of PRC2 
function plays a role in malignant hematopoiesis [53, 54]. This includes, but is not 
limited to, recurrent gain-of-function EZH2 mutations observed in germinal center 
B-cell lymphoma patients [50, 55], and constitutive expression of wild-type or 
mutant EZH2 in lymphomagenesis [56] and myeloproliferative diseases in murine 
models [57]. Interestingly, in myeloid neoplasms, EZH1 has been shown to 
compensate for the functions of EZH2, and contributes to malignant growth [19, 
21]. To date, small molecule inhibitor development has mostly focused on 
selective inhibition of EZH2 for treating lymphomas bearing EZH2 gain-of-
function mutants [32, 34, 37, 44]. However, dual inhibition of EZH2 and EZH1 
may be a viable therapeutic intervention for malignancies dependent upon both 
isoforms, like MLL-rearranged leukemia [16, 31].
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MLL is a gene encoding a histone 3 lysine 4 (H3K4) specific 
methyltransferase; methylation of H3K4 at gene promoters is highly correlated 
with regions of active transcription. Genetic products resulting from MLL 
rearrangement inappropriately recruit other epigenetic factors and/or 
transcriptional elongation machinery to abnormal sites, which results in aberrant 
gene expression and potential malignant transformation [25, 58]. 
Rearrangements of the MLL gene are responsible for ~70% of acute myeloid or 
lymphoid leukemia in infants, and ~10% of cases in adults [59]. This genetic 
predisposition leads to poor prognosis and low survival rates, which underscores 
the need for novel viable therapeutics [60]. Recently, studies have demonstrated 
that PRC2 acts in parallel with MLL rearrangements to maintain an oncogenic 
signature essential for sustaining leukemogenecity [61].  
Specifically, EZH2 and EZH1 compensate one another to promote MLL-
AF9 AML. Genetic ablation of EZH2 in MLL-AF9 cells does not lead to complete 
loss of H3K27me3, but genetic ablation of EED leads to a global loss of 
H3K27me3 [16]. Due to the fact that EED is absolutely required for PRC2 
function, the prevailing thought in the field is that PRC2-EZH1 complexes 
maintain H3K27me3 at specific loci in the absence of EZH2. Therefore, 
development of a pan EZH2/EZH1 chemical probe will aid in determining 
whether dual inhibition is a viable option for therapy in specific maladies. 
To date, UNC1999 is the most panactive EZH2/EZH1 chemical probe 
available [62]. Herein, we demonstrate the use of UNC1999 as an anti-leukemic 
agent capable of reducing H3K27me3 levels in MLL-rearranged cells. GSK126, 
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which is more selective for EZH2, is not effective in killing cells displaying this 
MLL-rearrangement. Further, we demonstrate a survival advantage of mice 
treated with UNC1999 in a murine model of MLL-AF9 AML. Lastly, we discuss 
the potential for further development of EZH2/EZH1 panactive chemical probes. 
 
Methods 
 
Synthesis of N-methylated derivatives 
 
Scheme 3.1. Reagents and Conditions: (a) Pd(PPh3)4, K2CO3, H2O:Dioxane, 
µ-wave, 150 0C, 60%; (b) TFA:DCM, rt; (c) Acetone, acetic acid, NaBH3CN, 
MeOH, 0 0C  rt, 58%. 
 
tert-butyl 4-(5-(4-(((1,6-dimethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)carbamoyl)-1-isopropyl-1H-indazol-6-yl)pyridin-2-yl)piperazine-1-
carboxylate (3.1). 6-bromo-N-((1,6-dimethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide was prepared as previously 
reported [62]  (.096 g, .209 mmol) and then dissolved in 2 mL H2O:Dioxane (1:5) 
in a microwave vessel. tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)pyridin-2-yl)piperazine-1-carboxylate, prepared as previously reported [62] (.1 
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g, .256 mmol) was added, and then potassium carbonate (.088 g, .639 mmol), 
and Tetrakis(triphenylphosphine)palladium(0) (.05 eq, ~2 mg) were added. The 
mixture was then placed in a microwave reactor for 20 minutes at 150 0C. The 
crude product was separated using Brine:EA, washing 3x with EA. The organic 
layers were combined, dried with Na2SO4, concentrated in vacuo, and purified 
using HPLC to yield tert-butyl 4-(5-(4-(((1,6-dimethyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)carbamoyl)-1-isopropyl-1H-indazol-6-yl)pyridin-2-
yl)piperazine-1-carboxylate as a white powder (.082 g, .128 mmol, 60.1%). 1H 
NMR (400 MHz, d4-MeOH), δ: 8.46 – 8.30 (m, 1H), 8.09 – 7.98 (m, 1H), 7.84 – 
7.69 (m, 1H), 7.45 – 7.30 (m, 1H), 6.32 – 6.18 (m, 1H), 5.19 – 4.97 (m, 1H), 4.61 
(s, 1H), 3.85 – 3.63 (m, 4H), 3.57 (s, 2H), 2.81 – 2.67 (m, 1H), 2.41 (s, 2H), 1.70 
– 1.54 (m, 4H), 1.51 (s, 4H), 1.02 (t, J = 7.3 Hz, 2H).  
 
N-((1,6-dimethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-
6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide 
(UNC3142 (3.2)). tert-butyl 4-(5-(4-(((1,6-dimethyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)carbamoyl)-1-isopropyl-1H-indazol-6-yl)pyridin-2-
yl)piperazine-1-carboxylate (.040 g, .062 mmol) was dissolved in DCM (0.25 mL) 
and added TFA (0.25 mL). The reaction was stirred for ~2 h until complete. Then, 
the contents were concentrated in vacuo, dissolved in MeOH (0.40 mL), and 
placed in an ice bath. Acetone (.058 mL, 0.79 mmol) and acetic acid (.045 mL, 
0.79 mmol) were then added to the reaction. After cooling to 0 0C, NaBH3CN 
(.025 g, 0.40 mmol) was added and the reaction was stirred for 15 minutes. Then 
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the ice bath was removed and the contents were allowed to warm to rt overnight. 
After completion, the MeOH was removed in vacuo and the crude product was 
isolated by separating with EA:Brine, 3x EA washes. The organic layers were 
combined, dried with Na2SO4, and purified using HPLC to give N-((1,6-dimethyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide as a brown oil 
(.021 g, .036 mmol, 58.1%). 1H NMR (400 MHz, d-CHCl3), δ: 8.49 (d, J = 2.2 Hz, 
1H), 8.39 (s, 1H), 7.80 (td, J = 8.8, 4.2 Hz, 1H), 7.69 (s, 1H), 7.58 (s, 1H), 6.73 
(d, J = 8.8 Hz, 1H), 5.97 (s, 1H), 4.88 (s, 1H), 4.65 (d, J = 5.9 Hz, 1H), 3.68 (s, 
2H), 3.53 (s, 2H), 3.04 – 2.45 (m, 4H), 2.32 (s, 2H), 1.72 – 1.52 (m, 5H), 1.25 (s, 
3H), 1.14 (d, J = 6.0 Hz, 3H), 1.02 (s, 2H). 
 
 
Scheme 3.2. Reagents and Conditions. (a) Di-tert-butyl dicarbonate, THF, rt, 
97%; (b) LAH, THF, reflux, 67%; (c) EDCI, HOBt, TEA, DMF, rt, 44%; (d) 
Pd(dppf)Cl2·DCM, K2CO3, H2O:Dioxane, reflux, 76%; (e) TFA:DCM, reflux; (f) 
Acetone, AcOH, NaBH3CN, MeOH, 0 
0C  rt, 53%. 
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tert-butyl ((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)carbamate (3.3). 3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one 
(1.00 g, 5.60 mmol) was dissolved in THF (20.0 mL) and added di-tert-butyl 
dicarbonate (1.22 g, 5.60 mmol). The mixture was then stirred at rt for 4 h. After 
completion, the contents were separated with EA (3X) and brine. The organic 
layers were combined, dried with Na2SO4, and concentrated in vacuo. The crude 
product was then used for the next step without further characterization (1.50 g, 
97%). 
 
6-methyl-3-((methylamino)methyl)-4-propylpyridin-2(1H)-one (3.4). tert-butyl 
((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)carbamate (0.70 g, 2.50 
mmol) was dissolved in THF (50.0 mL) and a solution of LAH (0.95 mg, 25.0 
mmol) in THF (50.0 mL) was added to the mixture dropwise; the mixture was 
heated to reflux for 4 h. After completion, the contents were cooled to 0 0C, 
added 0.5 N NaOH, and extracted with EA 3x. The organic layers were 
combined, dried with Na2SO4, and combined to give 6-methyl-3-
((methylamino)methyl)-4-propylpyridin-2(1H)-one (.332 g, 67% yield) as a yellow 
oil. 1H NMR (300 MHz, d-CHCl3), δ: 5.891 (s, 1H), 3.659 (s, 2H), 2.520-2.494 (m, 
2H), 2.418 (s, 3H, ), 2.256(s, 3H), 1.565-1.514 (m, 2H), 0.980-0.931 (t, 3H, J=7.2 
Hz). 
 
6-bromo-1-isopropyl-N-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (3.5). 6-methyl-3-
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((methylamino)methyl)-4-propylpyridin-2(1H)-one (.232 g, 1.18 mmol) was 
dissolved in DMF (10.0 mL) and added 6-bromo-1-isopropyl-1H-indazole-4-
carboxylic acid (.330 g, 1.18 mmol), prepared as previously reported, EDCI (.338 
g, 1.77 mmol), HOBt (.239 g, 1.77 mmol) and TEA (0.49 mL). The reaction was 
then stirred at rt overnight. The contents were diluted with H2O, stirred for 1 h, 
and then filtered to collect a yellow solid. The product was then washed with H2O 
and DEE to give 6-bromo-1-isopropyl-N-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (.230 g, 44%) as a white 
solid. 1H NMR (300 MHz, d-CHCl3), δ: 13.137 (m, 1H),  (8.072, 7.945) (s, 1H), 
(7.634, 7.489) (s, 1H), 7.275-7.270 (m, 1H), 5.999(s, 1H), 4.766-4.743 (m, 2H), 
2.905(s, 3H), 2.712-2.661 (t, 2H, J=7.6 Hz), 2.15 (s, 3H), 1.552(m, 8H), 1.042-
0.993 (t, 3H J=7.4 Hz). 
 
tert-butyl 4-(5-(1-isopropyl-4-(methyl((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)carbamoyl)-1H-indazol-6-yl)pyridin-2-
yl)piperazine-1-carboxylate (3.6). 6-bromo-1-isopropyl-N-methyl-N-((6-methyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (.152 
g, 0.33 mmol) was dissolved in a mixture of 5 mL H2O:Dioxane (1:5) and then 
tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-
yl)piperazine-1-carboxylate (.142 g, .364 mmol), prepared as previously 
reported[2], and KOAc (.098 g, 1.00 mmol) were added to the flask. The mixture 
was purged and placed under argon atmosphere and added 1,1'-
Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane 
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complex (.027 g, .033 mmol), and the reaction was heated to reflux for 5 h. After 
completion, the contents were cooled, diluted with EA, washed with H2O, and 
dried over Na2SO4. The crude product was then concentrated and prepared for 
silica chromatography with (DCM/MeOH = 40/1) to give tert-butyl 4-(5-(1-
isopropyl-4-(methyl((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)carbamoyl)-1H-indazol-6-yl)pyridin-2-yl)piperazine-1-carboxylate (.175 
g, 76%) as a white solid. 1H NMR (300 MHz, d-CHCl3), (Rotamers), δ: 8.48 (s, 
1H), (8.106, 7.944) (s, 1H), 7.803-7.775(m, 1H), 7.508-7.389(m, 3H), 6.752-
6.723(d, 1H, J=8.7 Hz), (5.990, 5.819) (s, 1H), 4.907(s, 2H), 3.590-3.582(m, 7H), 
(3.066, 2.935) (s, 3H), 2.712-2.685 (m, 1H), 2.289(s. 4H), 1.601-1.580(m, 8H), 
1.489(s, 9H), 1.042-0.995 (t, 3H J=7.0 Hz). 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-methyl-N-((6-
methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (UNC1756 (3.7)). tert-butyl 4-(5-(1-isopropyl-4-(methyl((6-methyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1H-indazol-6-yl)pyridin-
2-yl)piperazine-1-carboxylate (.173 g, 2.96 mmol) was dissolved in DCM (2.0 mL) 
and added an excess of TFA. The product (.042 g, .010 mmol) was concentrated 
in vacuo, dissolved in MeOH (5.0 mL), and placed in an ice bath. Acetone (1.0 
mL, 13.6 mmol) and acetic acid (.065 mL, 1.10 mmol) were then added to the 
reaction. After cooling to 0 0C, NaBH3CN (.034 g, 0.54 mmol) was added and the 
reaction was stirred for 15 minutes. Then the ice bath was removed and the 
contents were allowed to warm to rt overnight. After completion, the MeOH was 
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removed in vacuo and the crude product was isolated by separating with 
DCM:Brine, 3x DCM washes. The organic layers were combined, dried with 
Na2SO4, and purified using HPLC to give 1-isopropyl-6-(6-(4-isopropylpiperazin-
1-yl)pyridin-3-yl)-N-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)-1H-indazole-4-carboxamide as a brown oil (.023 g, .393 mmol, 53%). 
1H NMR (300 MHz, d-CHCl3), (Rotamers), δ: 8.48 (s, 1H), (8.106, 7.944) (s, 1H), 
7.803-7.775(m, 1H), 7.508-7.389(m, 3H), 6.752-6.723(d, 1H, J=8.7 Hz), (5.990, 
5.819) (s, 1H), 4.907(s, 2H), 3.590-3.582(m, 7H), (3.066, 2.935) (s, 3H), 2.712-
2.685 (m, 1H), 2.289(s. 4H), 1.601-1.580(m, 8H), 1.489(s, 9H), 1.042-0.995 (t, 
3H J=7.0 Hz). 
 
Synthesis of compounds for EZH1/EZH2 selectivity  
 
Scheme 3.3. Reagents and Conditions. (a) Acetone, Morpholinium-TFA, reflux, 
o/n; (b) cyanoacetamide, t-BuOK, DMSO, 4-62%; (c) H2, Raney-Ni, MeOH; (d) (6-
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(4-isopropylpiperazin-1-yl)pyridin-3-yl)boronic acid, Pd(dppf)Cl2·DCM, AcOK, 
H2O:Dioxane, reflux, 85%; (e) NaOH, rt, o/n, 95%; (f) TBTU, DIPEA, DMF, rt, 16-
72%. 
 
 
4-ethyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Propionaldehyde 
(5.0 g, 86.5 mmol) and morpholinium trifluoroacetate (1.5 g, 17.3 mmol) were 
added to acetone (50 mL) and heated to reflux overnight. The reaction was 
monitored via TLC, organic solvents were removed in vacuo and the crude 
product was used for the next step without characterization. Cyanoacetamide 
(1.13 g, 13.5 mmol) and potassium tert-butoxide (1.51 g, 13.5 mmol) were 
dissolved in DMSO (15 mL) and stirred at room temperature under N2 for 15 
minutes before adding crude (E)-hex-3-en-2-one. The contents were kept under 
N2 for 3 h before the addition of more potassium tert-butoxide (4.08 g, 4.08 
mmol) and exposure to air. The contents were then stirred overnight at room 
temperature. The reaction was monitored via TLC, and after completion, diluted 
with H2O, and added HCl to precipitate the desired product in a two-step yield of 
16% (.342 g, 2.11 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 5.61 (s, 1H), 2.52 (q, 
2H), 2.31 (s, 3H), 1.11 (t, 3H). 
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4-isobutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. 
Isovaleraldehyde (2.0 g, 23.2 mmol) and morpholinium trifluoroacetate (.4 g, 4.62 
mmol) were added to acetone (14 mL) and heated to reflux overnight. The 
reaction was monitored via TLC, organic solvents were removed in vacuo and 
the crude product was used for the next step without characterization. 
Cyanoacetamide (.733 g, 8.72 mmol) and potassium tert-butoxide (.889 g, 8.72 
mmol) were dissolved in DMSO (15 mL) and stirred at room temperature under 
N2 for 15 minutes before adding (E)-6-methylhept-3-en-2-one (1.00 g, 7.92 
mmol). The contents were kept under N2 for 3 h before the addition of more 
potassium tert-butoxide (2.64 g, 23.5 mmol) and exposure to air. The contents 
were then stirred overnight at room temperature. The reaction was monitored via 
TLC, and after completion, diluted with H2O, and added HCl to precipitate the 
desired product with a two-step yield of 4% (.158 g, .830 mmol). 1H NMR (400 
MHz, d-CHCl3), δ: 5.61 (s, 1H), 2.44 (d, 2H), 2.31 (s, 3H), 1.89 (m, 1H), 0.98 (d, 
6H). 
 
 
4-cyclopentyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. 
Cyclopentanecarbaldehyde (1.0 g, 10.3 mmol) and morpholinium trifluoroacetate 
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(0.2 g, 2.1 mmol) were added to acetone (6 mL) and heated to reflux overnight. 
The reaction was monitored via TLC, organic solvents were removed in vacuo 
and the crude product was used for the next step without characterization. 
Cyanoacetamide (1.4 g, 16.4 mmol) and potassium tert-butoxide (1.8 g, 16.4 
mmol) were dissolved in DMSO (19 mL) and stirred at room temperature under 
N2 for 15 minutes before adding crude (E)-4-cyclopentylbut-3-en-2-one. The 
contents were kept under N2 for 3 h before the addition of more potassium tert-
butoxide (5.0 g, 44.4 mmol) and exposure to air. The contents were then stirred 
overnight at room temperature. The reaction was monitored via TLC, and after 
completion, diluted with H2O, and added HCl to precipitate the desired product in 
a two-step yield of 8% (.157 g, .776 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 5.61 
(s, 1H), 2.31 (s, 3H), 1.97 (m, 2H), 1.78 (m, 2H), 1.66 (m, 2H), 1.56 (m, 2H). 
 
 
2-oxo-4-propyl-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide (.471 g, 
5.60 mmol) and potassium tert-butoxide (.629 g, 5.60 mmol) were dissolved in 
DMSO (6 mL) and stirred at room temperature under N2 for 15 minutes before 
adding (E)-hex-2-enal (.500 g , 5.09 mmol). The contents were kept under N2 for 
3 h before the addition of more potassium tert-butoxide (1.70 g, 15.1 mmol) and 
exposure to air. The contents were then stirred overnight at room temperature. 
The reaction was monitored via TLC, and after completion, diluted with H2O, and 
added HCl to precipitate the desired product in 50% yield (1.24 g, 7.64 mmol). 1H 
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NMR (400 MHz, d-CHCl3), δ: 7.67 (d, 1H), 6.32 (d, 1H), 2.54 (t, 2H), 1.62 (m, 
2H), 0.92 (t, 3H). 
 
 
4-ethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide (1.65 g, 
19.6 mmol) and potassium tert-butoxide (2.20 g, 19.6 mmol) were dissolved in 
DMSO (22 mL) and stirred at room temperature under N2 for 15 minutes before 
adding (E)-pent-2-enal (1.50 g, 17.8 mmol). The contents were kept under N2 for 
3 h before the addition of more potassium tert-butoxide (5.94 g, 53.0 mmol) and 
exposure to air. The contents were then stirred overnight at room temperature. 
The reaction was monitored via TLC, and after completion, diluted with H2O, and 
added HCl to precipitate the desired product in 21% yield (.545 g, 3.68 mmol). 1H 
NMR (400 MHz, d-CHCl3), δ: 7.47 (d, 1H), 6.28 (d, 1H), 2.52 (q, 2H), 1.11 (t, 3H). 
 
 
4,5-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide (1.65 
g, 19.6 mmol) and potassium tert-butoxide (2.20 g, 19.6 mmol) were dissolved in 
DMSO (22 mL) and stirred at room temperature under N2 for 15 minutes before 
adding (E)-2-methylbut-2-enal (1.50 g, 17.8 mmol). The contents were kept 
under N2 for 3 hours before the addition of more potassium tert-butoxide (5.94 g, 
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53.0 mmol) and exposure to air. The contents were then stirred overnight at room 
temperature. The reaction was monitored via TLC, and after completion, diluted 
with H2O, and added HCl to precipitate the desired product in 4% yield (.093 g, 
.628 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 7.94 (s, 1H), 2.50 (s, 3H), 1.98 (s, 
3H). 
 
 
4-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. 
Cyanoacetamide (1.24 g, 14.7 mmol) and potassium tert-butoxide (1.65 g, 14.7 
mmol) were dissolved in DMSO (17 mL) and stirred at room temperature under 
N2 for 15 minutes before adding (E)-5-methylhex-3-en-2-one (1.50 g, 13.4 mmol). 
The contents were kept under N2 for 3 h before the addition of more potassium 
tert-butoxide (4.46 g, 39.7 mmol) and exposure to air. The contents were then 
stirred overnight at room temperature. The reaction was monitored via TLC, and 
after completion, diluted with H2O, and added HCl to precipitate the desired 
product in 29% yield (.676 g, 3.84 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 6.27 
(s, 1H), 3.02 (m, 1H), 2.25 (s, 3H), 1.17 (d, 6H). 
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4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide (.660 g, 
7.85 mmol) and potassium tert-butoxide (.881 g, 7.85 mmol) were dissolved in 
DMSO (9 mL) and stirred at room temperature under N2 for 15 minutes before 
adding crotonaldehyde (.500 g, 7.13 mmol). The contents were kept under N2 for 
3 h before the addition of more potassium tert-butoxide (2.38 g, 21.2 mmol) and 
exposure to air. The contents were then stirred overnight at room temperature. 
The reaction was monitored via TLC, and after completion, diluted with H2O, and 
added HCl to precipitate the desired product in 62% yield (.592 g, 4.41 mmol). 1H 
NMR (400 MHz, d-CHCl3), δ: 7.64 (d, 1H), 6.3 (d, 1H), 2.35 (s, 3H). 
 
 
4-butyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide (.412 g, 
4.46 mmol) and potassium tert-butoxide (.550 g, 4.90 mmol) were dissolved in 
DMSO (6 mL) and stirred at room temperature under N2 for 15 minutes before 
adding (E)-hept-2-enal (.500 g, 4.46 mmol). The contents were kept under N2 for 
3 hours before the addition of more potassium tert-butoxide (1.49 g, 13.2 mmol) 
and exposure to air. The contents were then stirred overnight at room 
temperature. The reaction was monitored via TLC, and after completion, diluted 
with H2O, and added HCl to precipitate the desired product in 38% yield (.903 g, 
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5.10 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 7.68 (d, 1H), 6.32 (d, 1H), 2.63 (t, 
2H), 1.56 (m, 2H), 1.31 (m, 2H), 0.90 (t, 3H). 
 
 
1-methyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-carbonitrile. 
Cyanoacetamide (.420 g, 4.99 mmol) and potassium tert-butoxide (.560 g, 4.99 
mmol) were dissolved in DMSO (6 mL) and stirred at room temperature under N2 
for 15 minutes before adding 1-(cyclopent-1-en-1-yl)ethan-1-one (.500, 4.54 
mmol). The contents were kept under N2 for 3 hours before the addition of more 
potassium tert-butoxide (1.51 g, 13.5 mmol) and exposure to air. The contents 
were then stirred overnight at room temperature. The reaction was monitored via 
TLC, and after completion, diluted with H2O, and added HCl to precipitate the 
desired product in 44% yield (1.03 g, 5.91 mmol). 1H NMR (400 MHz, d-CHCl3), 
δ: 2.89 (t, 2H), 2.64 (t, 2H), 2.19 (s, 3H), 2.01 (m, 2H). 
 
 
4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide (1.65 
g, 19.6 mmol) and potassium tert-butoxide (2.20 g, 19.6 mmol) were dissolved in 
DMSO (22 mL) and stirred at room temperature under N2 for 15 minutes before 
adding (E)-pent-3-en-2-one (1.50 g, 17.8 mmol). The contents were kept under 
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N2 for 3 hours before the addition of more potassium tert-butoxide (5.94 g, 53.0 
mmol) and exposure to air. The contents were then stirred overnight at room 
temperature. The reaction was monitored via TLC, and after completion, diluted 
with H2O, and added HCl to precipitate the desired product in 45% yield (1.18 g, 
7.96 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 6.16 (s, 1H), 2.30 (s, 3H), 2.22 (s, 
3H). 
 
 
6-methyl-2-oxo-4-pentyl-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide 
(.660 g, 7.84 mmol) and potassium tert-butoxide (.860 g, 7.84 mmol) were 
dissolved in DMSO (9 mL) and stirred at room temperature under N2 for 15 
minutes before adding (E)-non-3-en-2-one (1.00 g , 7.13 mmol). The contents 
were kept under N2 for 3 hours before the addition of more potassium tert-
butoxide (2.36 g, 21.2 mmol) and exposure to air. The contents were then stirred 
overnight at room temperature. The reaction was monitored via TLC, and after 
completion, diluted with H2O, and added HCl to precipitate the desired product in 
55% yield (.803 g, 3.93 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 6.26 (s, 1H), 
2.42 (t, 2H), 2.20 (s, 3H), 1.29 (m, 2H), 1.23 (m, 2H), 1.23 (m, 2H), 1.02 (m, 3H). 
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6-ethyl-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide 
(.942 g, 11.2 mmol) and potassium tert-butoxide (1.26 g, 11.2 mmol) were 
dissolved in DMSO (13 mL) and stirred at room temperature under N2 for 15 
minutes before adding (E)-hex-4-en-3-one (1.00 g, 10.2 mmol). The contents 
were kept under N2 for 3 hours before the addition of more potassium tert-
butoxide (3.40 g, 30.3 mmol) and exposure to air. The contents were then stirred 
overnight at room temperature. The reaction was monitored via TLC, and after 
completion, diluted with H2O, and added HCl to precipitate the desired product in 
32% yield (.525 g, 3.24 mmol). 1H NMR (400 MHz, d6-DMSO), δ: 6.19 (s, 1H), 
2.5 (q, 2H), 2.32 (s, 3H), 1.17 (t, 3H). 
 
 
1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile. 
Cyanoacetamide (.745 g, 8.86 mmol) and potassium tert-butoxide (.994 g, 8.86 
mmol) were dissolved in DMSO (10 mL) and stirred at room temperature under 
N2 for 15 minutes before adding 1-(cyclohex-1-en-1-yl)ethan-1-one (1.00 g, 8.05 
mmol). The contents were kept under N2 for 3 hours before the addition of more 
potassium tert-butoxide (2.68 g, 23.9 mmol) and exposure to air. The contents 
were then stirred overnight at room temperature. The reaction was monitored via 
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TLC, and after completion, diluted with H2O, and added HCl to precipitate the 
desired product in 57% yield (.861 g, 4.57 mmol). 1H NMR (400 MHz, d-CHCl3), 
δ: 2.72 (m, 2H), 2.37 (m, 2H), 2.21 (s, 3H), 1.68 (m, 4H). 
 
 
4,5,6-trimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide 
(.942 g, 11.2 mmol) and potassium tert-butoxide (1.26 g, 11.2 mmol) were 
dissolved in DMSO (13 mL) and stirred at room temperature under N2 for 15 
minutes before adding (E)-hex-3-en-2-one (1.00 g, 10.2 mmol). The contents 
were kept under N2 for 3 hours before the addition of more potassium tert-
butoxide (3.40 g, 30.0 mmol) and exposure to air. The contents were then stirred 
overnight at room temperature. The reaction was monitored via TLC, and after 
completion, diluted with H2O, and added HCl to precipitate the desired product in 
38% yield (.626 g, 3.86 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 2.32 (s, 3H), 2.25 
(s, 3H), 1.93 (s, 3H). 
 
 
5-ethyl-2-oxo-4-propyl-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide 
(.811 g, 9.5 mmol) and potassium tert-butoxide (1.04 g, 16.4 mmol) were 
dissolved in DMSO (20 mL) and stirred at room temperature under N2 for 15 
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minutes before adding 3(E)-2-ethylhex-2-enal (1.0 g, 7.92 mmol). The contents 
were kept under N2 for 3 hours before the addition of more potassium tert-
butoxide (2.90 g, 28.5 mmol) and exposure to air. The contents were then stirred 
overnight at room temperature. The reaction was monitored via TLC, and after 
completion, diluted with H2O, and added HCl to precipitate the desired product in 
a two-step yield of 11% (.166 g, .871 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 
7.50 (s, 1H), 2.55 (q, 2H), 2.46 (t, 2H), 1.44 (m, 2H), 1.10 (t, 3H), 0.96 (t, 3H). 
 
 
6-(sec-butyl)-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. 
Cyanoacetamide (1.5 g, 17.7 mmol) and potassium tert-butoxide (2.0 g, 17.7 
mmol) were dissolved in DMSO (20 mL) and stirred at room temperature under 
N2 for 15 minutes before adding (E)-5-methylhept-2-en-4-one (2.0 g, 16.1 mmol). 
The contents were kept under N2 for 3 hours before the addition of more 
potassium tert-butoxide (5.4 g, 47.7 mmol) and exposure to air. The contents 
were then stirred overnight at room temperature. The reaction was monitored via 
TLC, and after completion, diluted with H2O, and added HCl to precipitate the 
desired product in 38% yield (.590 g, 3.10 mmol). 1H NMR (400 MHz, d-CHCl3), 
δ: 6.22 (s, 1H), 2.56 (m, 1H), 2.33 (s, 3H), 1.60 (m, 1H), 1.52 (m, 1H), 1.16 (d, 
3H), 0.78 (t, 3H). 
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5-ethyl-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide 
(1.3 g, 15.7 mmol) and potassium tert-butoxide (1.8 g, 15.7 mmol) were 
dissolved in DMSO (18 mL) and stirred at room temperature under N2 for 15 
minutes before adding (E)-2-ethylbut-2-enal (2.0 g, 14.3 mmol). The contents 
were kept under N2 for 3 hours before the addition of more potassium tert-
butoxide (1.8 g, 42.5 mmol) and exposure to air. The contents were then stirred 
overnight at room temperature. The reaction was monitored via TLC, and after 
completion, diluted with H2O, and added HCl to precipitate the desired product in 
12% yield (.271 g, 1.67 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 7.55 (s, 1H), 
2.64 (q, 2H), 2.06 (s, 3H), 1.13 (t, 3H). 
 
 
6-butyl-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile. Cyanoacetamide 
(1.5 g, 17.8 mmol) and potassium tert-butoxide (2.0 g, 17.8 mmol) were 
dissolved in DMSO (20 mL) and stirred at room temperature under N2 for 15 
minutes before adding (E)-oct-2-en-4-one (2.0 g, 16.2 mmol). The contents were 
kept under N2 for 3 hours before the addition of more potassium tert-butoxide 
(5.4 g, 48.0 mmol) and exposure to air. The contents were then stirred overnight 
at room temperature. The reaction was monitored via TLC, and after completion, 
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diluted with H2O, and added HCl to precipitate the desired product in 12% yield 
(.180 g, .946 mmol). 1H NMR (400 MHz, d-CHCl3), δ: 6.19 (s, 1H), 2.49 (t, 2H), 
2.31 (s, 3H), 1.54 (m, 2H), 1.28 (m, 2H), 0.87 (t, 3H). 
 
 
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4,6-
dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.625 g, 4.22 mmol) was 
dissolved in MeOH (10 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-
4,6-dimethylpyridin-2(1H)-one (10.5 mg, .054 mmol),TBTU (23.6 mg, .073 mmol), 
and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxylic acid (20.0 mg, .049 mmol)were dissolved in DMF (.33 mL) prior to the 
addition of DIPEA (20 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 16% (4.6 mg, .008 mmol). 1H NMR (400 
MHz, Methanol-d4), δ: 8.58 (dd, J = 2.5, 0.7 Hz, 1H), 8.37 (s, 1H), 8.18 (dd, J = 
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9.0, 2.6 Hz, 1H), 7.97 (t, J = 1.2 Hz, 1H), 7.78 (d, J = 1.3 Hz, 1H), 7.16 (dt, J = 
9.2, 1.7 Hz, 1H), 6.20 (s, 1H), 5.08 (h, J = 6.6 Hz, 2H), 4.58 (s, 2H), 3.62 (hept, J 
= 6.7 Hz, 3H), 2.45 (s, 3H), 2.27 (d, J = 0.8 Hz, 3H), 1.57 (d, J = 6.6 Hz, 6H), 
1.43 (d, J = 6.6 Hz, 6H). 
 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((4-methyl-2-oxo-
1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide. 4-methyl-2-oxo-
1,2-dihydropyridine-3-carbonitrile (.592 g, 4.41 mmol) was dissolved in MeOH (9 
mL) and added a catalytic amount of Raney-Ni. The contents were purged and 
kept under H2 overnight. The reaction was monitored via TLC. After completion, 
the contents were filtered, concentrated in vacuo and used for the next step 
without further characterization. Crude 3-(aminomethyl)-4-methylpyridin-2(1H)-
one (7.4 mg, .054 mmol), TBTU (23.6 mg, .073 mmol), and 1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic acid (20.0 mg, .049 
mmol) were dissolved in DMF (.34 mL) prior to the addition of DIPEA (20 uL). 
The contents were stirred at room temperature overnight, monitored by TLC and 
purified using HPLC. The desired product was obtained with a two-step yield of 
40% (10.4 mg, .020 mmol). 1H NMR (400 MHz, d4-MeOH), δ: 8.58 (t, J = 2.6 Hz, 
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2H), 8.45 (s, 1H), 8.37 (s, 1H), 8.12 (d, J = 1.4 Hz, 1H), 8.07 (s, 1H), 7.96 (s, 1H), 
7.78 (s, 1H), 7.31 (d, J = 6.7 Hz, 1H), 6.34 (d, J = 6.7 Hz, 1H), 5.10 (dt, J = 12.1, 
6.6 Hz, 1H), 4.61 (s, 2H), 3.61 (dt, J = 13.4, 6.6 Hz, 2H), 2.49 (s, 3H), 1.58 (t, J = 
7.1 Hz, 6H), 1.43 (d, J = 6.7 Hz, 6H). 
 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((2-oxo-4-propyl-
1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide. 2-oxo-4-propyl-
1,2-dihydropyridine-3-carbonitrile (.600 g, 3.70 mmol) was dissolved in MeOH 
(14 mL) and added a catalytic amount of Raney-Ni. The contents were purged 
and kept under H2 overnight. The reaction was monitored via TLC. After 
completion, the contents were filtered, concentrated in vacuo and used for the 
next step without further characterization. Crude 3-(aminomethyl)-4-
propylpyridin-2(1H)-one (9.7 mg, .054 mmol), TBTU (23.6 mg, .073 mmol), and 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic 
acid (20.0 mg, .049 mmol) were dissolved in DMF (.33 mL) prior to the addition of 
DIPEA (20 uL). The contents were stirred at room temperature overnight, 
monitored by TLC and purified using HPLC. The desired product was obtained 
with a two-step yield of 41% yield (11.1 mg, .020 mmol). 1H NMR (400 MHz, 
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Methanol-d4), δ: 8.57 (dd, J = 2.5, 0.7 Hz, 1H), 8.36 (s, 1H), 8.20 (m, 2H), 7.96 (t, 
J = 1.1 Hz, 1H), 7.77 (d, J = 1.3 Hz, 1H), 7.34 (d, J = 6.8 Hz, 1H), 7.15 (td, J = 
9.0, 0.8 Hz, 1H), 6.36 (d, J = 6.8 Hz, 1H), 5.09 (dt, J = 13.2, 6.4 Hz, 1H), 4.63 (s, 
2H), 3.56 (m, 2H), 2.76 (m, 2H), 1.61 (m, 2H), 1.57 (d, J = 6.5 Hz, 6H), 1.43 (dd, 
J = 6.7, 1.1 Hz, 6H), 1.03 (t, J = 7.3 Hz, 3H). 
 
 
N-((4-ethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4-ethyl-2-
oxo-1,2-dihydropyridine-3-carbonitrile (.550 g, 3.68 mmol) was dissolved in 
MeOH (8 mL) and added a catalytic amount of Raney-Ni. The contents were 
purged and kept under H2 overnight. The reaction was monitored via TLC. After 
completion, the contents were filtered, concentrated in vacuo and used for the 
next step without further characterization. Crude 3-(aminomethyl)-4-ethylpyridin-
2(1H)-one (8.2 mg, .054 mmol), TBTU (23.6 mg, .073 mmol), and 1-isopropyl-6-
(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic acid (20.0 mg, 
.049 mmol) were dissolved in DMF (.33 mL) prior to the addition of DIPEA (20 
uL). The contents were stirred at room temperature overnight, monitored by 
LC/MS and purified using HPLC. The desired product was obtained with a two-
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step yield of 32% yield (8.5 mg, .016 mmol). 1H NMR (400 MHz, Methanol-d4), δ: 
8.57 (d, J = 2.4 Hz, 1H), 8.36 (s, 1H), 8.16 (dd, J = 9.0, 2.5 Hz, 1H), 7.96 (t, J = 
1.1 Hz, 1H), 7.77 (d, J = 1.2 Hz, 1H), 7.36 (d, J = 6.8 Hz, 1H), 7.14 (d, J = 9.0 Hz, 
1H), 6.38 (d, J = 6.8 Hz, 1H), 5.09 (h, J = 6.6 Hz, 1H), 4.63 (s, 2H), 3.61 (hept, J 
= 6.7 Hz, 4H), 3.42 (s, 1H), 2.86 (q, J = 7.6 Hz, 2H), 1.57 (d, J = 6.6 Hz, 6H), 
1.43 (d, J = 6.6 Hz, 6H), 1.25 (t, J = 7.6 Hz, 3H). 
 
 
1-isopropyl-N-((4-isopropyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-
6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4-
isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.550 g, 3.68 mmol) 
was dissolved in MeOH (8 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. 3-(aminomethyl)-4-
isopropyl-6-methylpyridin-2(1H)-one (16.3 mg, .090 mmol), TBTU (39.5 mg, .073 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (33.5 mg, .082 mmol) were dissolved in DMF (.55 mL) prior to 
the addition of DIPEA (30 uL). The contents were stirred at room temperature 
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overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 55% yield (28.5 mg, .050 mmol). 1H NMR 
(400 MHz, Chloroform-d), δ: 12.60 (s, 1H), 8.48 (d, J = 2.5 Hz, 1H), 7.89 (t, J = 
5.8 Hz, 1H), 7.76 (dd, J = 8.8, 2.6 Hz, 1H), 7.70 (d, J = 1.4 Hz, 1H), 7.57 (t, J = 
1.1 Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H), 6.06 ? 6.01 (m, 1H), 4.86 (hept, J = 6.7 Hz, 
1H), 4.71 (d, J = 5.8 Hz, 2H), 3.59 (t, J = 5.1 Hz, 4H), 3.52 (q, J = 6.8 Hz, 1H), 
2.80 (broad, 4H) 2.59 (m, 5H), 2.19 (s, 3H), 1.58 (d, J = 6.7 Hz, 6H), 1.21 (d, J = 
6.8 Hz, 6H), 1.08 (d, J = 6.5 Hz, 6H). 
 
 
N-((4-butyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4-butyl-2-
oxo-1,2-dihydropyridine-3-carbonitrile (.550 g, 3.68 mmol) was dissolved in 
MeOH (8 mL) and added a catalytic amount of Raney-Ni. The contents were 
purged and kept under H2 overnight. The reaction was monitored via TLC. After 
completion, the contents were filtered, concentrated in vacuo and used for the 
next step without further characterization. 3-(aminomethyl)-4-butylpyridin-2(1H)-
one (10.5 mg, .054 mmol), TBTU (23.6 mg, .073 mmol), and 1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic acid (20.0 mg, .049 
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mmol) were dissolved in DMF (.33 mL) prior to the addition of DIPEA (20 uL). 
The contents were stirred at room temperature overnight, monitored by LC/MS 
and purified using HPLC. The desired product was obtained with a two-step yield 
of 32% yield (5.1 mg, .010 mmol). 1H NMR (400 MHz, Methanol-d4), δ: 8.58 (dd, 
J = 2.5, 0.7 Hz, 1H), 8.36 (s, 1H), 8.13 (dd, J = 9.0, 2.5 Hz, 1H), 7.95 (t, J = 1.1 
Hz, 1H), 7.77 (d, J = 1.3 Hz, 1H), 7.33 (d, J = 6.8 Hz, 1H), 7.10 (dd, J = 9.0, 0.8 
Hz, 1H), 6.35 (d, J = 6.7 Hz, 1H), 5.08 (hept, J = 6.5 Hz, 1H), 4.63 (s, 2H), 3.61 
(hept, J = 6.6 Hz, 4H), 2.86 (broad, 4H), 2.77 (m, 2H), 1.54 (m, 6H), 1.38 (m, 6H), 
0.93 (t, J = 7.3 Hz, 3H). 
 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((1-methyl-3-oxo-
3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridin-4-yl)methyl)-1H-indazole-4-
carboxamide. 1-methyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-
carbonitrile (.550 g, 3.68 mmol) was dissolved in MeOH (8 mL) and added a 
catalytic amount of Raney-Ni. The contents were purged and kept under H2 
overnight. The reaction was monitored via TLC. After completion, the contents 
were filtered, concentrated in vacuo and used for the next step without further 
characterization. Crude 4-(aminomethyl)-1-methyl-2,5,6,7-tetrahydro-3H-
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cyclopenta[c]pyridin-3-one (9.6 mg, .054 mmol), TBTU (23.6 mg, .073 mmol), 
and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxylic acid (20.0 mg, .049 mmol) were dissolved in DMF (.33 mL) prior to the 
addition of DIPEA (20 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 42% yield (11.8 mg, .021 mmol). 1H NMR 
(400 MHz, Methanol-d4), δ: 8.54 (m, 1H), 8.38 (s, 1H), 8.17 (dd, J = 9.0, 2.5 Hz, 
1H), 7.98 (t, J = 1.1 Hz, 1H), 7.81 (d, J = 1.3 Hz, 1H), 7.19 ? 7.11 (m, 1H), 5.09 
(hept, J = 6.2 Hz, 1H), 4.54 (s, 2H), 3.62 (hept, J = 6.7 Hz, 2H), 3.13 (t, J = 7.6 
Hz, 2H), 2.77 (t, J = 7.3 Hz, 2H), 2.27 (s, 3H), 2.13 (q, J = 7.5 Hz, 2H), 1.57 (d, J 
= 6.6 Hz, 6H), 1.43 (d, J = 6.7 Hz, 6H). 
 
 
N-((4,5-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4,5-
dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.093 g, .630 mmol) was 
dissolved in MeOH (10 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
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used for the next step without further characterization. Crude 3-(aminomethyl)-
4,5-dimethylpyridin-2(1H)-one (7.4 mg, .054 mmol), TBTU (23.6 mg, .073 mmol), 
and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxylic acid (20.0 mg, .049 mmol) were dissolved in DMF (.33 mL) prior to the 
addition of DIPEA (20 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 20% yield (5.1 mg, .010 mmol). 1H NMR 
(400 MHz, Methanol-d4), δ: 8.59 (dd, J = 2.5, 0.7 Hz, 1H), 8.39 (s, 1H), 8.19 (dd, 
J = 9.0, 2.5 Hz, 1H), 7.99 (t, J = 1.1 Hz, 1H), 7.84 (d, J = 1.3 Hz, 1H), 7.51 (s, 
1H), 7.12 (m, 1H), 5.09 (hept, J = 6.7 Hz, 2H), 4.48 (s, 2H), 3.62 (hept, J = 6.7 
Hz, 3H), 2.26 (s, 3H), 2.08 (s, 3H), 1.58 (d, J = 6.6 Hz, 6H), 1.43 (d, J = 6.6 Hz, 
6H). 
 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((4,5,6-trimethyl-
2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide. 4,5,6-
trimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.500 g,3.08 mmol) was 
dissolved in MeOH (6 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
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via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization.  3-(aminomethyl)-4,5,6-
trimethylpyridin-2(1H)-one (10.0 mg, .060 mmol), TBTU (29.0 mg, .090 mmol), 
and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxylic acid (27.0 mg, .066 mmol) were dissolved in DMF (.60 mL) prior to the 
addition of DIPEA (30 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 56% (18.7 mg, .034 mmol). 1H NMR (400 
MHz, Chloroform-d), δ: 8.47 (d, J = 2.4 Hz, 1H), 8.35 (s, 1H), 7.97 (dd, J = 8.9, 
2.3 Hz, 1H), 7.62 (s, 1H), 7.57 (s, 1H), 7.42 (s, 1H), 6.87 (d, J = 8.9 Hz, 1H), 4.88 
(hept, J = 6.7 Hz, 3H), 4.72 (d, J = 5.4 Hz, 2H), 3.56 (h, J = 6.7 Hz, 2H), 2.60 (s, 
3H), 2.45 (s, 3H), 2.15 (s, 3H), 1.59 (s, 6H), 1.38 (d, J = 6.6 Hz, 6H). 
 
 
N-((6-ethyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 6-ethyl-
4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.530 g, 3.24 mmol) was 
dissolved in MeOH (7 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
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via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-6-
ethyl-4-methylpyridin-2(1H)-one (10.0 mg, .060 mmol), TBTU (29.0 mg, .090 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (27.0 mg, .066 mmol) were dissolved in DMF (.60 mL) prior to 
the addition of DIPEA (30 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 61% (20.3 mg, .037 mmol). 1H NMR (400 
MHz, Chloroform-d), δ: 8.49 (d, J = 2.4 Hz, 1H), 7.89 (dd, J = 8.8, 2.3 Hz, 1H), 
7.61 (s, 1H), 7.59 (s, 1H), 7.37 (s, 1H), 6.80 (d, J = 8.8 Hz, 1H), 6.45 (s, 1H), 4.89 
(p, J = 6.7 Hz, 1H), 4.68 (broad, 4H), 4.62 (m, 2H), 4.40 (s, 1H), 3.56 (p, J = 6.7 
Hz, 3H), 3.25 (s, 4H), 2.69 (q, J = 7.6 Hz, 3H), 2.63 (s, 3H), 1.60 (d, J = 6.6 Hz, 
7H), 1.38 (d, J = 6.6 Hz, 6H), 1.29 (t, J = 7.6 Hz, 3H). 
 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((1-methyl-3-oxo-
2,3,5,6,7,8-hexahydroisoquinolin-4-yl)methyl)-1H-indazole-4-carboxamide. 
1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile (.500 g, 2.66 
mmol) was dissolved in MeOH (5 mL) and added a catalytic amount of Raney-Ni. 
95 
The contents were purged and kept under H2 overnight. The reaction was 
monitored via TLC. After completion, the contents were filtered, concentrated in 
vacuo and used for the next step without further characterization. Crude 4-
(aminomethyl)-1-methyl-5,6,7,8-tetrahydroisoquinolin-3(2H)-one (10.0 mg, .052 
mmol), TBTU (25.0 mg mg, .078 mmol), and 1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic acid (23.3 mg, .057 
mmol) were dissolved in DMF (.52 mL) prior to the addition of DIPEA (30 uL). 
The contents were stirred at room temperature overnight, monitored by LC/MS 
and purified using HPLC. The desired product was obtained with a two-step yield 
of 42% (12.8 mg, .022 mmol). 1H NMR (400 MHz, Chloroform-d), δ: 8.48 (s, 1H), 
8.36 (s, 1H), 8.04 ? 7.97 (m, 1H), 7.63 (s, 1H), 7.56 (s, 1H), 7.41 (s, 1H), 6.90 (d, 
J = 8.9 Hz, 1H), 4.89 (p, J = 6.6 Hz, 3H), 4.68 (d, J = 5.4 Hz, 3H), 3.56 (p, J = 6.7 
Hz, 2H), 3.19 (t, J = 6.1 Hz, 3H), 2.56 (t, J = 6.1 Hz, 2H), 2.40 (s, 2H), 1.81 (d, J 
= 11.8 Hz, 4H), 1.59 (d, J = 6.6 Hz, 6H), 1.38 (d, J = 6.6 Hz, 6H). 
 
 
1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-
4-pentyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide. 6-
methyl-2-oxo-4-pentyl-1,2-dihydropyridine-3-carbonitrile (.500 g, 2.46 mmol) was 
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dissolved in MeOH (5 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-6-
methyl-4-pentylpyridin-2(1H)-one (10.0 mg, .048 mmol), TBTU (23.1 mg, .072 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (21.5 mg, .053 mmol) were dissolved in DMF (.48 mL) prior to 
the addition of DIPEA (25 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 46% (13.2 mg, .022 mmol). 1H NMR (400 
MHz, Chloroform-d), δ: 8.49 (s, 1H), 8.35 (s, 1H), 7.93 (dd, J = 8.7, 2.3 Hz, 1H), 
7.62 (s, 1H), 7.58 (s, 1H), 7.39 (s, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.47 (s, 1H), 4.88 
(q, J = 6.6 Hz, 2H), 4.70 (broad, 4H), 4.63 (m, 2H), 3.56 (p, J = 6.7 Hz, 8H), 2.88 
(m, 3H), 2.43 (s, 3H), 1.54 (m, 12H), 1.39 (dd, J = 6.7, 2.2 Hz, 12H), 0.81 (m, 
3H). 
 
 
N-((4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4-ethyl-
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6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.340 g, 2.11 mmol) was 
dissolved in MeOH (5 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-4-
ethyl-6-methylpyridin-2(1H)-one (13.0 mg, .078 mmol), TBTU (34.2 mg, .107 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (29.0 mg, .071 mmol) were dissolved in DMF (.71 mL) prior to 
the addition of DIPEA (40 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 22% yield (9.4 mg, .017 mmol). 1H NMR 
(600 MHz, Chloroform-d), δ: 8.47 (d, J = 2.5 Hz, 1H), 8.39 (s, 1H), 7.83 (t, J = 5.8 
Hz, 1H), 7.76 (dd, J = 8.6, 2.5 Hz, 1H), 7.68 (s, 1H), 7.57 (s, 1H), 6.67 (d, J = 8.7 
Hz, 1H), 5.91 (s, 1H), 4.87 (hept, J = 6.7 Hz, 1H), 4.64 (d, J = 5.9 Hz, 2H), 3.66 
(s, 4H), 2.71 (s, 4H), 2.43 (s, 4H), 1.58 (d, J = 6.6 Hz, 8H), 1.47 (dp, J = 14.1, 7.2 
Hz, 1H), 1.14 (d, J = 6.7 Hz, 6H), 0.72 (t, J = 7.3 Hz, 3H). 
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N-((4-isobutyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-
(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 4-
isobutyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.020 g, .120 mmol) 
was dissolved in MeOH (.5 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. 3-(aminomethyl)-4-
isobutyl-6-methylpyridin-2(1H)-one (16.4 mg, .084 mmol), TBTU (37.0 mg, .115 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (31.3 mg, .077 mmol) were dissolved in DMF (.77 mL) prior to 
the addition of DIPEA (40 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 62% yield (30.4 mg, .052 mmol). 1H NMR 
(600 MHz, Chloroform-d), δ: 8.48 (s, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 7.76 (d, J = 
8.6 Hz, 1H), 7.72 (s, 1H), 7.57 (s, 1H), 6.67 (d, J = 8.8 Hz, 1H), 5.90 (s, 1H), 4.92 
– 4.80 (m, 1H), 4.66 (d, J = 5.3 Hz, 2H), 3.59 (s, 4H), 2.78 – 2.68 (m, 1H), 2.64 
(s, 4H), 2.61 (d, J = 7.2 Hz, 2H), 2.14 (s, 3H), 1.94 – 1.81 (m, 1H), 1.57 (d, J = 
6.5 Hz, 6H), 1.08 (d, J = 6.4 Hz, 6H), 0.97 (d, J = 6.5 Hz, 6H). 
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N-((6-(sec-butyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-
isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxamide. 6-(sec-butyl)-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
(.100 g, .526 mmol) was dissolved in MeOH (5 mL) and added a catalytic amount 
of Raney-Ni. The contents were purged and kept under H2 overnight. The 
reaction was monitored via TLC. After completion, the contents were filtered, 
concentrated in vacuo and used for the next step without further characterization. 
Crude 3-(aminomethyl)-6-(sec-butyl)-4-methylpyridin-2(1H)-one (13.0 mg, .067 
mmol), TBTU (29.3 mg, .091 mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-
1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic acid (24.8 mg, .061 mmol) were 
dissolved in DMF (.61 mL) prior to the addition of DIPEA (30 uL). The contents 
were stirred at room temperature overnight, monitored by LC/MS and purified 
using HPLC. The desired product was obtained with a two-step yield of 63% 
(24.5 mg, .042 mmol). 1H NMR (600 MHz, Chloroform-d), δ: 8.39 (s, 1H), 7.83 (t, 
J = 5.8 Hz, 1H), 7.76 (dd, J = 8.6, 2.5 Hz, 1H), 7.68 (s, 1H), 7.57 (s, 1H), 6.67 (d, 
J = 8.7 Hz, 1H), 5.91 (s, 1H), 4.87 (hept, J = 6.7 Hz, 1H), 4.64 (d, J = 5.9 Hz, 2H), 
3.66 (s, 4H), 3.48 (s, 2H), 2.71 (s, 4H), 2.43 (s, 4H), 1.58 (d, J = 6.6 Hz, 8H), 1.47 
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(dp, J = 14.1, 7.2 Hz, 1H), 1.34 – 1.18 (m, 2H), 1.14 (d, J = 6.7 Hz, 6H), 0.72 (t, J 
= 7.3 Hz, 3H). 
 
 
N-((5-ethyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 5-ethyl-
4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.100 g, .617 mmol) was 
dissolved in MeOH (13 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-5-
ethyl-4-methylpyridin-2(1H)-one (13.6 mg, .082 mmol), TBTU (35.8 mg, .112 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (30.3 mg, .074 mmol) were dissolved in DMF (.74 mL) prior to 
the addition of DIPEA (40 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 72% (32.9 mg, .059 mmol). 1H NMR (600 
MHz, Methanol-d4), δ: 8.61 (d, J = 2.4 Hz, 1H), 8.40 (s, 1H), 8.19 (dd, J = 9.2, 2.4 
Hz, 1H), 8.00 (s, 1H), 7.81 (s, 1H), 7.27 (s, 1H), 7.17 (d, J = 8.8 Hz, 1H), 5.12 (p, 
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J = 6.6 Hz, 1H), 4.69 (s, 2H), 4.61 (broad, 2H), 3.64 (hept, J = 6.9 Hz, 1H), 3.60 
(broad, 2H), 2.93 (q, J = 7.7 Hz, 2H), 2.18 (s, 3H), 1.60 (d, J = 6.4 Hz, 8H), 1.45 
(d, J = 6.5 Hz, 8H), 1.24 (t, J = 7.6 Hz, 3H). 
 
 
N-((4-cyclopentyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-
isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxamide. 4-cyclopentyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
(.157 g, .776 mmol) was dissolved in MeOH (16 mL) and added a catalytic 
amount of Raney-Ni. The contents were purged and kept under H2 overnight. 
The reaction was monitored via TLC. After completion, the contents were filtered, 
concentrated in vacuo and used for the next step without further characterization. 
Crude 3-(aminomethyl)-4-cyclopentyl-6-methylpyridin-2(1H)-one (16.0 mg, .078 
mmol), TBTU (34.0 mg, .106 mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-
1-yl)pyridin-3-yl)-1H-indazole-4-carboxylic acid (28.7 mg, .071 mmol) were 
dissolved in DMF (.71 mL) prior to the addition of DIPEA (40 uL). The contents 
were stirred at room temperature overnight, monitored by LC/MS and purified 
using HPLC. The desired product was obtained with a two-step yield of 56% 
(26.0 mg, .043 mmol). 1H NMR (600 MHz, Chloroform-d), δ: 8.42 (s, 1H), 8.39 (s, 
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1H), 8.00 (s, 1H), 7.73 (d, J = 7.4 Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 6.56 (d, J = 
8.7 Hz, 1H), 6.04 (s, 1H), 4.92 – 4.80 (m, 1H), 4.69 (d, 2H), 3.87 (broad, J = 91.1, 
63.2 Hz, 2H), 3.54 (m, 1H), 3.38 (d, J = 40.8 Hz, 2H), 3.06 (broad, 4H), 2.20 (s, 
3H), 2.04 (m, 2H), 1.78 (m, J = 18.9 Hz, 4H), 1.57 (d, J = 6.6 Hz, 6H), 1.52 (m, 
2H), 1.32 (d, J = 6.4 Hz, 6H). 
 
 
N-((6-butyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 6-butyl-
4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (.181 g, .951 mmol) was 
dissolved in MeOH (19 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-6-
butyl-4-methylpyridin-2(1H)-one (17.5 , .090 mmol), TBTU (39.4 mg, .123 mmol), 
and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-
carboxylic acid (33.4 mg, .082 mmol) were dissolved in DMF (.82 mL) prior to the 
addition of DIPEA (40 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
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was obtained with a two-step yield of 66% (34.7 mg, .059 mmol). 1H NMR (600 
MHz, Methanol-d4), δ: 8.56 (d, J = 2.4 Hz, 1H), 8.39 (s, 1H), 8.07 (dd, J = 8.8, 2.5 
Hz, 1H), 7.95 (d, J = 5.5 Hz, 1H), 7.78 (s, 1H), 7.03 (d, J = 8.9 Hz, 1H), 6.17 (s, 
1H), 5.10 (p, J = 6.6 Hz, 1H), 4.60 (s, 2H), 3.65 – 3.59 (m, 5H), 3.33 (m, J = 3.2, 
1.6 Hz, 1H), 3.30 (broad, 4H), 2.55 – 2.51 (m, 1H), 2.46 (s, 3H), 2.17 (m, 2H), 
1.64 – 1.57 (d, 6H), 1.45 (d, J = 6.6, 3.8 Hz, 6H), 1.31 (d, 4H), 0.94 (t, J = 7.4 Hz, 
3H). 
 
 
N-((5-ethyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-4-carboxamide. 5-ethyl-
2-oxo-4-propyl-1,2-dihydropyridine-3-carbonitrile (.166 g, .871 mmol) was 
dissolved in MeOH (20 mL) and added a catalytic amount of Raney-Ni. The 
contents were purged and kept under H2 overnight. The reaction was monitored 
via TLC. After completion, the contents were filtered, concentrated in vacuo and 
used for the next step without further characterization. Crude 3-(aminomethyl)-5-
ethyl-4-propylpyridin-2(1H)-one (9.0 mg, .046 mmol), TBTU (23.1 mg, .072 
mmol), and 1-isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-
4-carboxylic acid (21.5 mg, .053 mmol) were dissolved in DMF (.46 mL) prior to 
104 
the addition of DIPEA (25 uL). The contents were stirred at room temperature 
overnight, monitored by LC/MS and purified using HPLC. The desired product 
was obtained with a two-step yield of 18% (4.7 mg, .008 mmol). 1H NMR (400 
MHz, Chloroform-d), δ: 8.49 (s, 1H), 8.36 (s, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.61 
(s, 1H), 7.47 (s, 1H), 7.32 (s, 1H), 6.77 (d, J = 8.7 Hz, 1H), 4.89 (p, J = 6.7 Hz, 
1H), 4.73 (d, J = 5.4 Hz, 2H), 4.41 (s, 2H), 3.56 (p, J = 6.6 Hz, 4H), 2.99 (s, 2H), 
2.59 (q, J = 7.5 Hz, 4H), 1.59 (d, J = 6.7 Hz, 8H), 1.38 (d, J = 6.6 Hz, 7H), 1.22 (t, 
J = 7.4 Hz, 4H), 1.12 (t, J = 7.3 Hz, 3H). 
 
In vitro activity of N-methylated UNC1999 derivatives 
EZH2 and IC50’s were calculated as described in Chapter 2 Methods. 
 
Mass spectrometry–based quantification 
Total histones were prepared and subject to mass spectrometry analysis as 
previously described. [63] 
 
Antibodies  
Antibodies used in immunoblotting include those against H3K27me3 (Millipore 
07-449 and Abcam 6002, 1:5,000), H3K27me2 (Millipore 07-452, 1:5,000), 
H3K27me1 (Active Motif 39377, 1:5000), H3K27ac (Abcam 4729, 1:2,000), 
H3K4me3 (Abcam 8580 and Active Motif 39159, 1:5,000), H3K36me3 (Abcam 
9095, 1:5,000), H3K36me1 (ab9048, 1:1,000); H3K36me2 (Active Motif 39255, 
1:1,000), general H3 (Abcam 1791, 1:10,000), EZH2 (BD Biosciences 612666, 
105 
1:1,000), SUZ12 (Abcam 12073, 1:1,000), and Tubulin (Sigma, 1:10,000). The 
antibodies used for ChIP-Seq are H3K27me3 (Millipore 07-449), H3K27ac 
(Abcam 4729) and SUZ12 (Abcam 12073). 
 
Assays of Cell Proliferation, Wright-Giemsa Staining and Apoptosis. All 
human cell lines were purchased from the ATCC or DSMZ Cell Bank and 
cultured as recommended. Approximately 20,000 cells were plated in triplet in 
the presence of various concentrations of compounds at day 1, and the numbers 
of viable cells were counted using a TC20 automated cell counter (BioRad) every 
3-4 days. Medium containing the compounds was refreshed every 2-3 days, and 
the cell concentration was kept under 1-2 million per mL as recommended. 
Wright-Giemsa staining was performed as previously described [64]. Cell 
apoptotic assays were performed using the Annexin V-FITC Early Apoptosis 
Detection Kit (Cell Signaling). Images of cell staining were captured with an 
EVOS-XL Cell Imaging System (Life Technologies). 
 
Colony Formation Unit (CFU) Assay. Approximately 200-500 leukemia 
progenitor cells were initially plated in replicates in the methylcellulose medium 
(MethoCult™ GF M3434; StemCell Technologies) with either DMSO or 
compound present. For serial replating, approximately 5,000-10,000 cells 
isolated from colonies in the previous plating were seeded again in the same 
semi-solid medium. CFUs were scored by direct quantification every 7-9 days 
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post seeding. Identity of each colony was defined by morphology according to 
manufacturer’s specification. 
 
Cell Cycle Profiling. Exponentially dividing cells were seeded in the medium 
containing either DMSO or compounds. 10^6 of mock-treated versus compound-
treated cells were washed with ice-cold PBS and fixed in pre-chilled methanol 
(80%), followed by staining with PBS added with 20 μg/ml propidium iodide 
(Sigma), 0.1% Triton-X100, and 200 μg/ml RNase A (Roche). DNA contents of 
cells were then detected with a CyAn ADP flow cytometer (Beckman-Coulter), 
and then analyzed by ModFit Software (Verity Software House). 
 
Gene Knockdown. miR30-based shRNAs targeting EED (clone 1820) and 
Renilla (control) were kindly provided by Dr. Chris Vakoc [31] and then sub-
cloned into sites of XhoI and EcoRI of an inducible shRNA expression system, 
TRMVP-IR [65] (pSIN-TREdsRed-miR30-PGK-Venus-IRES-rtTA3, Addgene 
27994). Cells were infected with TRMPVIR virus and sorted based on Venus+ 
signals, followed by treatment with doxycycline (Sigma-Aldrich) at a final 
concentration of 2 μg/ml to induce shRNA expression. Gene knockdown 
efficiency was determined by real-time PCR. 
 
Real-Time PCR. Reverse transcription was performed with random primers and 
the cDNA Reverse Transcription kit according to the manufacturers protocols 
(Invitrogen and Biorad). PCR amplicons (usually 80–150 bp) were designed to 
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span over introns, and quantitative PCR was performed in triplicate using the 
SYBR Green master mix reagent on an ABI 7900 qPCR system (Applied 
Biosystems). The real-time PCR signals are typically examined in triplicates and 
normalized to those of the β-Actin or Gapdh gene. 
 
In vivo Leukemia Assay and Compound Treatment Studies. The murine 
model of MLL-rearranged leukemia was generated by retroviral delivery of MLL-
AF9-IRES-GFP into lineage-negative bone marrow stem/progenitor cells, 
followed by bone marrow transplantation as previously described [66, 67]. To 
generate the secondary leukemia, 2x10^6 leukemia cells isolated from bone 
marrow were suspended in 200 μl of sterile PBS and intravenously introduced to 
the sub-lethally irradiated (300 Rads) syngeneic Balb/c mice (12-week-old) by 
tail-vein injection. Leukemic development was assessed by complete blood 
counting (CBC) of peripheral blood (HemaVet ® 950 LV CBC, Drew Scientific 
Group) and treatment with UNC1999 was commenced on the day when the 
counts in white blood cells (WBC) were found significantly elevated. The powder 
of UNC1999 (verified by HPLC and mass spectrometry) was slowly dissolved 
and incorporated into vehicle (0.5% of sodium carboxymethylcellulose [NaCMC] 
and 0.1% of Tween-80 in sterile water) with continuous trituration by a pestle and 
mortar. After transfer to a conical tube, the UNC1999-vehicle mixture was subject 
to vigorous vortex and brief sonication to achieve a homogenous suspension at a 
formulation concentration of 20 mg/mL. UNC1999 or vehicle control was 
administered orally twice daily [BID] at a dose of 50 mg/kg. Mice were inspected 
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daily, and complete blood counts measured twice per week; mice exhibiting a 
terminal leukemia phenotype (lethargy, splenomegaly and limb paralysis) were 
sacrificed, and cells isolated from leukemic tissues were subjected to further 
pathological analysis as described before [66, 67]. All procedures pertaining to 
animal handling, care, and treatment were performed according to guidelines 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of North Carolina at Chapel Hill. 
 
Results 
 
UNC1999 Reduces H3K27me2 and H3K27me3 Levels in MLL-rearranged 
Leukemia 
Previously, UNC1999 and UNC2400 were characterized as a positive and 
negative control of EZH2 inhibition [62]. In addition to UNC2400, we created two 
monomethyl compounds to observe the effects of only a single methylation on 
EZH2 activity, which resulted in UNC1756 and UNC3142 (Table 3.1). Both 
monomethyl compounds retained a significant amount of activity for EZH2 (IC50 
~100 nM), which demonstrated that methylation of both amides is requisite to 
abolish the potency of UNC1999. We next sought to observe the effects of 
UNC1999 and UNC2400 on the methylation state of histones in cells treated with 
both compounds.  
 Specifically, MLL-ENL cells were treated with UNC1999 or UNC2400, and 
then subjected to mass spectrometry to identify modified histone peptides. 55 
unique histone peptides bearing a single or combinatorial modification were 
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detected, and only those covering the H3 residues 27-40 were altered > 2-fold 
upon UNC1999 treatment (Figure 3.1 A). As expected, the greatest decrease 
was observed in peptides containing either H3K27me3 or H3K27me2. Peptides 
bearing both H3K27me3 and H3K36me2 also displayed a significant decrease in 
H3K27me3 levels when treated with UNC1999. Interestingly, the relative 
abundance of peptides containing the H3K36me1/2 mark was increased in cells 
treated with UNC1999. This phenomenon is due to the “demethylation” effect of 
UNC1999 treatment, and has previously been observed in cells lacking Suz12 
[68]. Overall, H3K27me3 was reduced from 8.5% to 1.3% of total H3 in mock 
versus UNC1999 treated cells, and H3K27me2 was reduced from 30.9% to 7.1% 
of total H3 in mock versus UNC1999 treated cells (Figure 3.1 B). Importantly, 
UNC2400 displayed no significant changes versus mock treated cells, and 
consistent with the antagonistic relationship between H3K27me3 and H3K27ac, 
we observed a large increase in H3K27ac after UNC1999 treatment (Figure 3.1 
C). The effects of UNC1999 did not alter PRC2 levels, the assembly of the PRC2 
complex (Figure 3.1 D), or the amount of chromatin bound EZH2 and EZH1 
(Figure 3.1 E). Taken together, these results demonstrate cell permeability, 
PRC2 engagement, and direct inhibition of the methyltransferase subunit of 
PRC2 in MLL-rearranged leukemia cells. 
 
EZH2 and EZH1 dual inhibition is required for MLL-AF9 cell death 
Based on recent findings that both EZH1 and EZH2 are required for MLL-
rearranged leukemic growth [16], we hypothesized that a more panactive 
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inhibitor of EZH2 and EZH1 would be advantageous over an EZH2-specific 
inhibitor. So we compared the results of UNC1999 treatment (5-fold selective for 
EZH2) with that of GSK126 (150-fold selective for EZH2) in two distinct cellular 
scenarios: DB Cells, a form of diffuse large B cell lymphoma where EZH1 plays a 
minimal role, and MLL-AF9, an MLL-rearranged leukemia, where EZH1 is 
believed to play a larger role in disease progression [16]. In DB Cells, both 
UNC1999 and GSK126 potently reduce the H3K27me3 mark (Figure 3.2 A), and 
halt cellular proliferation (Figure 3.2 B). However, when treating MLL-AF9 cells 
with the same compounds, a different phenomenon is observed. UNC1999 is 
much more efficient at both reducing the H3K27me3 mark (Figure 3.2 A), and 
inhibiting cell proliferation, compared to that of GSK126 (Figure 3.2 C). 
Importantly, we confirmed that MLL-AF9 cells do co-express EZH2 and EZH1 
(data not shown). These results indicate that the additional EZH1 inhibition of 
UNC1999 is an advantage over other more EZH2-selective chemical probes in 
this context. 
 We next applied UNC1999 treatment to various other leukemic cell lines, 
10 of which bear MLL-rearrangements. All of the 10 MLL-rearranged leukemia 
cell lines responded to UNC1999 treatment with EC50 ranging from 102 nM to 
1.96 µM, and several cell lines demonstrated comparable sensitivity as DB Cell 
(Figure 3.3). LOUCY cells, a T-cell acute lymphoblastic leukemia cell line that 
does not possess EZH2 nor display the H3K27me3 hypertrimethylation 
phenotype, were not affected by UNC1999 treatment, which indicated that the 
previous results were not due to off-target cytotoxicity. Further, K562 cells, a Bcr-
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Abl-bearing myeloid leukemia cell line, did not respond to UNC1999. This data 
demonstrates the robust effect of UNC1999 treatment in MLL-rearranged 
leukemia. 
 
UNC1999 Treatment Reactivates CDKN2a 
To identify the mechanism of leukemic death upon UNC1999 treatment, 
microarray analysis in cells bearing the MLL-AF9 translocation was performed. 
This analysis revealed that expression of several hundred transcripts are altered 
after UNC1999 treatment, and consistent with PRC2 function, the majority of 
transcripts that elicited a change were upregulated as opposed to 
downregulated; UNC2400 had no effect (Figure 3.4 A). As expected, RNA 
silencing of EED (shEED) had a different effect on the number and type of 
upregulated and downregulated genes (Figure 3.4 A & B). One gene of specific 
interest that was upregulated in the presence of UNC1999 treatment was 
Cdkn2a. 
 Cdkn2a is a gene that encodes two crucial cell cycle regulators, p16Ink4a 
and p19Arf. UNC1999 treatment induced reactivation of these two proteins in a 
dose- and time-dependent manner; after seven days of treatment >150-fold and 
>60-fold upregulation of p16Ink4a and p19Arf were observed, respectively 
(Figure 3.4 C). This increase in expression of the Cdkn2a gene products resulted 
in time-dependent cell cycle arrest at the G1-to-S transition (Figure 3.4 D). Cells 
treated with UNC2400 demonstrated no concomitant increase in Cdkn2a gene 
products, or cell cycle arrest when compared to DMSO-treated cells.  
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 To examine whether the UNC1999-induced phenotypes were dependent 
on Cdkn2a expression, we generated p16Ink4a and p19Arf double knockout cells 
and compared their response to UNC1999 treatment with that of their wild-type 
counterparts. Unlike wild-type cells, p16Ink4a-/-/p19Arf-/- cells elicited no response 
to UNC1999 treatment; there was no detectable change in proliferation (Figure 
3.4 E), or apoptosis (Figure 3.4 F). These studies demonstrate that inhibition of 
MLL-AF9 cell growth is in part due to derepression of key cell cycle regulating 
genes (p16Ink4a & p19ARF), and confirm that the Cdkn2a products are key 
downstream mediators of UNC1999-induced inhibition. 
 
UNC1999 Provides a Survival Advantage in a MLL-AF9 Murine Model 
To determine if UNC1999 provides an advantage at the organismal level, 
we generated a murine model of MLL-AF9 by transplanting primary bone marrow 
tumors to syngenic recipients, which developed aggressive leukemia with a 
consistent latency of 20 to 35 days. Mice were treated with vehicle or 50 mg/kg 
UNC1999 via oral gavage 7 days post-transplantation. Leukemic progression 
was then monitored via periodic assessment of peripheral blood. Although there 
was steady accumulation of white blood cells (WBCs) in both the UNC1999 and 
vehicle-treated cohorts, UNC1999-treated mice displayed significantly less 
accumulation of WBC, which is consistent with delayed leukemic progression 
(Figure 3.5 A). UNC1999 did not alter red blood cell or platelet counts (Figure 3.5 
B & C). Further, UNC1999-treated mice exhibited a significant increase in 
survival (36.6 ± 11.7 days) when compared with vehicle treated mice (24 ± 6.7 
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days) (Figure 3.5 D). Analysis of cells isolated from bone marrow and spleens of 
moribund mice demonstrated that UNC1999-treatment significantly reduced 
H3K27me3 levels (Figure 3.5 E), elevated p16ink4a and p19arf expression 
(Figure 3.5 F), and reduced the size of lymph nodes (Figure 3.5 G) when 
compared to vehicle-treated mice; splenomagely was observed in both cohorts. 
In summary, oral administration of UNC1999 delays the onset of MLL-AF9 
leukemia in mice, and EZH2/EZH1 dual inhibition provides a new therapeutic 
option for MLL-rearranged leukemia. 
 
Analogs of UNC1999 Demonstrate Capability for Panactive EZH2/EZH1 
Inhibitors 
While UNC1999 is the most panactive EZH2/EZH1 inhibitor to date, we 
aimed to explore the potential for increased EZH1 activity in order to discover a 
more panactive inhibitor, which we presume would provide a greater survival 
advantage in mice afflicted with MLL-AF9. Previously, GSK released a 
publication which detailed the change in EZH2/EZH1 selectivity among a class of 
inhibitors very similar in structure to UNC1999 [47]. Specifically, modulation of 
the 4-position on the pyridone ring appeared to affect this selectivity; substituting 
the methyl group for an n-propyl group led to a 5-fold increase in EZH2 affinity 
and a 25-fold increase in affinity for EZH1 (Table 3.3). Further, simply changing 
the substitution of the pyridine ring from the indazole core affected the activity of 
EZH1, albeit reducing it compared to the prior substitution (Table 3.3). To date, 
these three compounds are the only published structure activity relationship 
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(SAR) for pyridone containing compounds against both EZH1 and EZH2. 
Therefore, we aimed to explore the tolerability of modifications to the pyridone 
ring of UNC1999 (Figure 3.6) with the goal of increasing EZH1 inhibition. 
 Initially, we aimed to install various substituents at the C4 position of the 
pyridone (Figure 3.6, R1), which resulted in the compounds displayed in Table 
3.4. This set of nine compounds led to two main conclusions. First, the methyl 
group at the C6 position of the pyridone (R3 in Figure 3.6) is imperative for potent 
inhibition of both EZH2 and EZH1; compare UNC3855 vs UNC3860, UNC3857 
vs kdk7-058, and UNC3856 vs UNC1999 (Table 3.4). Second, like what was 
observed in the set of compounds from GSK, larger hydrophobic substituents at 
the C4 position of the pyridone (Figure 3.6, R1) appear to increase the affinity of 
the compounds for both EZH2 and EZH1; compare UNC3855 vs UNC3857 vs 
UNC3856 vs UNC3859 and UNC3860 vs kdk7-058 vs UNC1999 vs UNC3862 vs 
kdk215-059. This trend does appear to have a ceiling, as kdk215-146 was less 
potent for both EZH2 and EZH1 than UNC3862, UNC1999 and kdk215-059 
(Table 3.4). 
 Next, we aimed to determine if any substituents were tolerated at the C5 
position of the pyridone (Figure 3.6, R2); no EZH2 or EZH1 inhibition data of 
compounds with substitutions here are available in the public domain. This 
resulted in the compounds pictured in Table 3.3. While substituents at C5 were 
largely tolerated for inhibition of EZH2, essentially any substituent at the C5 
position resulted in next-to-no inhibition of EZH1 activity. This is most easily 
demonstrated by comparing UNC3861 with kdk215-060. UNC3861 contains a 
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cyclopentyl group attached to the pyridone ring at C4 and C5, and is still 
relatively potent for EZH2 (IC50 = 80 nM), but is essentially inactive against 
EZH1 (IC50 = 5000 nM). However, if that cyclopentyl ring is pulled off of C5, such 
that there is a cyclopentyl substituent at the C4 position and a hydrogen atom at 
C5, a large amount of EZH1 activity is restored (IC50 = 126 nM). This data 
demonstrates that no hydrophobic substituents are tolerated at C5 for EZH1 
inhibition.  
 As the last part of our initial exploration into substituted pyridones, we 
explored additional groups at the C6 position (Figure 3.6, R3). Like the C5 
position, there is a lack of compounds reported in the literature containing 
anything other than a methyl group at the C6 position. Our initial efforts resulted 
in the compounds contained in Table 3.4. It appears that inhibition of EZH2 
tolerates substitutions at the C6 position much more than EZH1 inhibition; 
addition of just a single carbon onto the C6 methyl group of UNC1999 results in a 
compound that is ineffective at inhibiting EZH1 catalytic activity (kdk215-143, 
Table 3.6). We also experimented with two larger groups at C6, an isobutyl group 
(kdk7-057) and an n-butyl group (kdk215-061), but both of these compounds also 
lost all EZH1 inhibition displayed by UNC1999. This small set of compounds 
suggests that inhibition of EZH1 catalytic activity is antagonized by the addition of 
substituents at the C6 position of the pyridone. 
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Discussion 
 
This study represents the first oral delivery of a dual EZH1/EZH2-specific 
compound as a means to inhibit MLL-rearranged leukemia. This is especially 
relevant because MLL-rearranged leukemia demonstrate a poor prognosis, so 
extremely toxic therapies (daunorubicin and cytarabine) are implemented in an 
attempt to eradicate the disease. Prior to our study, 3-deazaneplanocin (DZNep) 
was claimed to be an inhibitor of EZH2, and demonstrated tumor suppressive 
roles in MLL-rearranged leukemia [69], but DZNep operates through non-specific 
mechanisms; it is a SAH-hydrolase inhibitor, and depletes the global pool of SAH 
[70, 71]. Contrarily, inhibition of EZH2 activity in MLL-AF9 AML cells was 
demonstrated via use of a stapled peptide that inhibited EED-EZH2 binding, and 
led to PRC2 degradation [72]. While this research was integral in demonstrating 
a proof of concept for EZH2 inhibition, one could argue that this method is as 
effective as shEED or shEZH2, and will have serious issues being translated into 
patients bearing MLL-rearranged leukemia. Removal of a protein from a 
biological system is not equal to catalytic inhibition of said protein. This is 
especially true in the case of EZH2, because it is a single component of a much 
larger complex that recruits other silencing factors. For example, our data 
demonstrated that silencing of EED (shEED) had a differing effect on the number 
and types of upregulated and downregulated genes than catalytic inhibition of 
EZH2 with UNC1999. Small molecules that inhibit the catalytic activity of EZH2 
will present far fewer issues when translating into the clinic. 
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Our data demonstrate that UNC1999 treatment effectively reduces 
H3K27me3 levels in cells, and at the organismal level. Mechanistically, UNC1999 
treatment leads to concurrent increases in expression of Cdkn2a gene products 
(p16ink4a and p19ARF), and accordingly, UNC1999 is ineffective at inhibiting the 
proliferation of cells bearing p16Ink4a and p19ARF double knockouts. While 
UNC1999 does prolong the survival of mice afflicted with MLL-AF9 AML, the 
effects are much more modest than those seen at the cellular level. A similar 
effect has been seen with the development of Brd4 [73] and DOT1L [74] 
inhibitors. In short, much more effort needs to be done to optimize the potency, 
selectivity, and pharmacokinetic properties of these compounds in an in vivo 
setting. In the case of MLL-AF9 AML, additional EZH1 activity may be an avenue 
that will provide additional benefits.  
To date, there is a dearth of information in the literature surrounding the 
EZH2/EZH1 selectivity of the current classes of EZH2 inhibitors. We aimed to 
increase the activity of UNC1999 analogs against EZH1 in order to create a more 
panactive chemical probe of both EZH1 and EZH2; such a compound may be of 
use in treating MLL-rearranged leukemia. While we have been unsuccessful in 
creating such a probe to date, we did learn that additional hydrophobicity at the 
C4 position of the pyridone increases the activity for EZH1 and EZH2. However, 
all alkyl substituents appended to either the C5 or C6 position of the pyridone 
resulted in nearly complete loss of EZH1 inhibition. Going forward, we plan to 
continue to explore the potential for substituents at the C4 position.  
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EZH1 and EZH2 have high sequence similarity (96%) in their SET 
domain, but one residue that differs in a sequence alignment of EZH1 and EZH2 
is M743, which is a threonine in EZH1 (T744). A recent computational study 
observed the ligand-residue contacts of various pyridone-containing EZH2 
inhibitors. This group created a larger EZH2 complex using the apo SET domain 
crystal structure as a foundation, and added additional residues in an attempt to 
create a closer to full-length structure. Docking of compounds, followed by 
simulations and alanine-scanning for important residues determined that M743 
makes significant contacts with the pyridone of bound ligands during the course 
of an MD simulation [75]. We are curious if we can take advantage of T744 of 
EZH1, by introducing moieties that may engage in hydrogen bonds with the 
threonine of EZH1 (i.e., alcohols, carbonyls, etc.). This may lead to greater 
affinity for EZH1, and hopefully maintain the EZH2 activity. Nonetheless, it 
remains to be seen if increased in vitro EZH1 activity translates to increased 
efficacy at the cellular and/or organismal level.  
119 
Tables 
 
 
 
Compound R1 R2 
EZH2 IC50 
(nM) 
 
UNC1999 H H <10 
 
UNC1756 Me H 72 
 
UNC3142 H Me 103 
 
UNC2400 Me Me >13000 
 
Table 3.1: N-methylated derivatives of UNC1999. 
H = hydrogen, Me = methyl. 
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Cell Line EC50 Genetic Mutation 
 
DB Cell .227 EZH2Y641N 
 
EOL-1 .102 MLL-PTD; FIP1L1-PDGFRA 
 
K562 >250 BCR-ABL 
 
LOUCY >200 EZH2 deletion 
 
m-MLL-AF9 .404 – .621 MLL-AF9 
 
m-MLL-ENL .547 – .636 MLL-ENL 
 
MV4;11 .523 MLL-AF4 
 
OCI-AML2 1.50 MLL-AF9 
 
RS4;11 1.96 MLL-AF4 
 
Table 3.2: UNC1999 activity in leukemic cell lines of differing genetic 
backgrounds.  
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Compound R1 R2 
EZH2 IC50 
(nM) 
EZH1 IC50 
(nM) 
Fold 
Selectivity 
GSK926 Me 
 
20 2500 125 
4 n-Pr 
 
4 100 25 
GSK343 n-Pr 
 
4 240 60 
UNC1999 n-Pr 
 
<10 45 ≥5 
 
Table 3.3: EZH2/EZH1 selectivity of GSK reported compounds [47] and 
UNC1999. 
Me = methyl, n-Pr = n-propyl. 
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Compound R1 R2 
EZH2 IC50 
(nM) 
EZH1 IC50 
(nM) 
Fold 
Selectivity 
 
UNC3855 Me H 790 NI N/A 
 
UNC3857 Et H 560 5000 9 
 
UNC3856 n-Pr H 150 3500 23 
 
UNC3859 n-Bu H 35 2000 57 
 
UNC3860 Me Me 50 2500 50 
 
kdk7-58 Et Me 17 1160 68 
 
UNC3862 i-Pr Me <10 320 ≥32 
 
kdk215-59 i-Bu Me <10 141 ≥14 
 
kdk215-146 n-heptyl Me 18 488 27 
 
UNC1999 n-Pr Me <10 45 ≥5 
 
Table 3.4: EZH2/EZH1 selectivity of UNC1999 analogs: exploration of C4 
(R1) and C6 (R2) of pyridone. 
H = hydrogen, Me = methyl, Et = ethyl, n-Pr = propyl, i-Pr = isopropyl, i-Bu = 
isobutyl, n-heptyl = heptane. NI = no inhibition, N/A = not applicable. 
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Compound R1 R2 R3 n 
EZH2 IC50 
(nM) 
EZH1 
IC50 (nM) 
Fold 
Selectivity 
 
kdk215-142 Me Me Me 0 325 >5000 ≤15 
 
UNC3858 Me Me H 0 5000 5000 1 
 
kdk7-56 Et Me H 0 1156 >5000 ≥4 
 
kdk215-60 c-pentyl H Me 0 <10 126 ≥13 
 
UNC3861 Me Me Me 1 80 5000 40 
 
kdk215-144 Me Me Me 2 >2500 >5000 2 
 
kdk215-147 n-Pr Et H 0 152 >5000 ≤33 
 
UNC1999 n-Pr H Me 0 <10 45 ≥5 
 
Table 3.5: EZH2/EZH1 selectivity of UNC1999 analogs: exploration of C5 
(R2) of pyridone. 
H = hydrogen, Me = methyl, Et = ethyl, n-Pr = propyl, c-Pen = cyclopentane. 
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Compound R1 R2 
EZH2 IC50 
(nM) 
EZH1 IC50 
(nM) 
Fold 
Selectivity 
 
kdk215-143 Me Et 107 >5000 ≤47 
 
kdk7-57 Me i-bu 47 >2500 ≤53 
 
kdk215-61 Me n-bu 493 >5000 ≤10 
 
UNC1999 n-Pr Me <10 45 ≥10 
 
Table 3.6: EZH2/EZH1 selectivity of UNC1999 analogs: exploration of C6 
(R2) of pyridone. 
Me = methyl, Et = ethyl, n-Pr = propyl, i-Pr = isopropyl, i-Bu = isobutyl. 
  
125 
Figures 
 
 
 
Figure 3.1: Activity of UNC1999 and UNC2400 in MLL-rearranged cells. 
(A) Quantitative mass spectrometry analysis of H3 peptides covering histone H3 
(a.a. 27-40) after treatment with 3 µM UNC1999 (blue) or UNC2400 (red) for 4 
days. (B) Overall percentages of unmodified, monomethylated, dimethylated, or 
trimethylated H3K27 (H3K27me1/2/3) following DMSO, UNC2400, or UNC1999 
treatment. (C) Immunoblot of the indicated histone modifications in MLL-AF9–
transformed leukemia progenitor cells after treatment with DMSO, UNC2400 or 
UNC1999 (3 µM). (D) Co-IP of PRC2 components following Flag IP with extracts 
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of a Flag-PHF1 stable expression cell line [76] in the presence of DMSO, 
UNC2400, or UNC1999 (2 µM). (E) Immunoblots detecting the chromatin-bound 
and nucleoplasmic fraction of EZH2 or EZH1 after treatment with DMSO, 
UNC2400, or UNC1999 (2 µM) for 5 days. ac = acetylation, co-IP = 
coimmunoprecipitation, Ig = immunoglobulin, IP = immunoprecipitation, me1/2/3 
= mono/di/trimethylation. 
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Figure 3.2: UNC1999 is more effective than GSK126 at suppressing 
H3K27me3 and inhibiting MLL-rearranged leukemic cell growth. 
(A) Immunoblots of global H3K27me3 level after treatment of DB lymphoma cells 
(top) or MLL-AF9–transformed murine leukemia progenitors (bottom) with 
DMSO, GSK126, UNC1999 or UNC2400 (2 µM) for 5 days. Total H3 serves as 
control. (B) Relative proliferation of DB cells treated with a range of 
concentrations of GSK126 (top) or UNC1999 (bottom) for the indicated duration. 
(C) Relative proliferation of MLL-AF9–transformed leukemia progenitors treated 
with a range of concentrations of GSK126 (top) or UNC1999 (bottom) for the 
indicated duration. 
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Figure 3.3: UNC1999 activity in leukemic cell lines. 
Dose-response curves of various MLL-rearranged leukemic cell lines (EOL-1, m-
MLL-AF9, m-MLL-ENL, MV4;11, RS4;11), Diffuse large B-cell lymphoma cells 
(DB), T-cell lymphoma (LOUCY), and Bcr-Abl CML (K562) in the presence of 
UNC1999 after 16 days. 
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Figure 3.4: UNC1999 derepresses PRC2 gene targets. 
(A) upregulated (blue) and downregulated (red) transcripts in 2 independent 
MLL-AF9–transformed leukemia lines after a 5-day treatment with 3 µM of 
compounds or after knockdown of EED vs Renilla, as identified by microarray 
analysis. (B) RT-qPCR detects relative expression levels of the indicated genes 
in MLL-AF9–transformed leukemia cells following treatment with 3 µM of 
compounds or EED knockdown (shEED) for 5 days; normalized to GAPDH. (C) 
RT-qPCR shows time-dependent derepression of p16Ink4a and p19Arf by 
UNC1999 in a leukemia line derived from MLL-AF9–induced primary tumors. *P 
< .05; **P < .01; ***P < .001. (D) Summary of cell-cycle status of MLL-AF9–
transformed murine leukemia progenitors following 2-day or 7-day treatment with 
DMSO, UNC2400 or UNC1999 (3 µM). (E) Relative proliferation of MLL-AF9–
transformed murine leukemia cells, either wild-type (red) or p16Ink4a-/-/p19Arf-/- 
(purple), after treatment with various concentrations of UNC1999 for 12 days. (F) 
Summary of apoptotic induction in MLL-AF9–transformed murine leukemia 
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progenitors, either wild-type (WT) or p16Ink4a-/-/p19Arf-/-, following a 6-day 
treatment with 3 µM of compounds as assayed by propidium iodide staining. 
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Figure 3.5: UNC1999 treatment prolongs survival of mice with MLL-AF9. 
(A-C) Summary of counts of the WBCs (A), neutrophils (B), and RBCs (C) in the 
peripheral blood of vehicle- (white) or UNC1999-treated (black) leukemic mice at 
the indicated date post transplantation. *P < .05; **P < .01; ***P < .001. (D) 
Kaplan-Meier curve showing leukemia kinetics after transplantation of MLL-AF9–
induced primary murine leukemia into syngeneic mice. Starting from day 7 post 
transplantation, mice received oral administration of either vehicle (blue) or 50 
mg/kg UNC1999 (red) twice per day. Black lines (top) represent non-transplanted 
normal mice treated with vehicle or UNC1999. Cohort size = 6 to 7 mice. (E) 
Summary of H3K27me3 levels in cells isolated from bone marrow or spleen of 
vehicle- (LV) and UNC1999-treated (LT) leukemic mice as quantified by flow 
cytometry. *P < .05; **P < .01. (F) Fold-change in p16Ink4a and p19Arf gene 
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expression in cells isolated from bone marrow or spleen of the UNC1999-treated 
(black) leukemic mice in comparison with vehicle-treated (white). *P < .05; **P < 
.01. (G) Comparison of sizes of lymph nodes isolated from the MLL-AF9–induced 
leukemic mice after treatment with either vehicle or 50 mg/kg UNC1999. WBC = 
white blood cell; BM = bone marrow; GFP = green fluorescent protein; RBC = red 
blood cell; SP = spleen. 
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Figure 3.6: Location of pyridone substitutions of EZH1/EZH2 selectivity. 
C4 carbon = R1, C5 carbon = R2, and C6 carbon = R3. 
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CHAPTER IV: IRREVERSIBLE INHIBITORS AS PUTATIVE EZH2-SPECIFIC 
CHEMICAL PROBES 
 
Introduction 
  
While both EZH2 and EZH1 activity contribute to the progression of MLL-
rearranged leukemia, EZH2 is most often the main antagonist in the progression 
of solid tumors. In ovarian cancer, overexpression of EZH2 leads to poor 
prognosis and is associated with drug resistance [77, 78]. Specifically, following 
cisplatin treatment, resistant stem cell-like side populations persist and have 
been shown to overexpress EZH2 [79, 80]. EZH2 has also been shown to 
promote proliferation and invasiveness of prostate cancer cells by repressing the 
expression of TIMP2 and TIMP3, which allows for dysregulated matrix 
metalloproteinase activity [14, 80]. In these instances, it would be advantageous 
to maintain basal EZH1 activity, due to its imperative endogenous role in 
hematopoietic stem cell maintenance [20]. To date, the most selective chemical 
probe for EZH2 is GSK126, which is reported to be 150-fold more potent for 
EZH2 over EZH1 [32]. This is remarkable considering the high overall identity 
(76%) and SET domain identity (96%) between the two proteins, and it is 
uncertain if current scaffolds can attain more selectivity. We plan to develop the 
first irreversible inhibitor for EZH2 which will provide: 1) the most potent EZH2
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inhibitor to date, 2) the most selective EZH2 inhibitor to date, and 3) direct 
confirmation of our binding hypothesis. 
One issue hampering further design of small molecules to inhibit EZH2 is 
the lack of an EZH2-inhibitor co-crystal structure. To date, the only solved PRC2-
related crystal structures are EED in complex with a small peptide from the EZH2 
binding interface [81], and the apo structure of the EZH2 SET domain [82, 83]. 
The EED-EZH2 crystal structure proved useful, because it was instrumental in 
the development of an EZH2 stapled peptide, which inhibits PRC2 activity by 
triggering EZH2 degradation [72]. The utility of the previously published EZH2 
apo crystal structures remains to be seen, and considering the high degree of 
complexity of PRC2 (i.e. multiple subunits present in tissue-specific contexts) one 
would expect that a crystallized conformation of the apo SET domain of EZH2 
may not reflect the true architecture of a functional SET domain contained within 
the entire complex. Nonetheless, in an attempt to demonstrate the utility of this 
crystal structure, we aim to design and synthesize irreversible inhibitors of EZH2. 
Our goal is to exploit a cysteine residue that is hypothesized to be in close 
proximity to our predicted UNC1999 binding site. 
 
Methods 
 
In vitro activity of irreversible inhibitors 
EZH2 and EZH1 IC50’s were calculated as described in Chapter 2 Methods. 
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Synthesis of Irreversible Inhibitors 
 
Scheme 4.1. Reagents and Conditions. (a) CuCN, NMP, µ-wave (200 C), 25 
min, 99%; (b) LiOH, MeOH, rt, o/n, 95%; (c) NaH, epichlorohydrin, DMF, rt, o/n, 
98%; (d) 3-(aminomethyl)-4,6-dimethylpyridin-2(1H)-one, HOAt, EDCI, DMSO, 
NMM, rt, 5 h, 17%. 
 
methyl 6-bromo-1H-indole-4-carboxylate. Synthesized according to previously 
published procedures [47].  
 
methyl 6-cyano-1H-indole-4-carboxylate (4.1). methyl 6-bromo-1H-indole-4-
carboxylate (200 mg, .790 mmol) and CuCN (141 mg, 1.57 mmol) were dissolved 
in NMP (3.00 mL) and placed into a microwave reactor for 25 min at 200 0C. The 
contents were then quenched with H2O, extracted with EA, dried over MgSO4, 
filtered, concentrated in vacuo and purified by ISCO (EA:Hexane, 1:10). The 
desired product was obtained at 99.6% yield (158 mg, .789 mmol). 
 
6-cyano-1H-indole-4-carboxylic acid (4.2). methyl 6-cyano-1H-indole-4-
carboxylate (170 mg, .849 mmol) was dissolved in MeOH (5 mL) and then LiOH 
(107 mg, 2.55 mmol) dissolved in H2O (1 mL) was added. The reaction was 
stirred at room temperature overnight. The next morning, TLC showed 
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disappearance of starting material, so the reaction was quenched with 5% HCl, 
and purified by ISCO to obtain the desired product at 94.5% yield (150 mg, .802 
mmol). 
 
6-cyano-1-(oxiran-2-ylmethyl)-1H-indole-4-carboxylic acid (4.3). 6-cyano-1H-
indole-4-carboxylic acid (140 mg, .752 mmol) was dissolved in DMF (10 mL) and 
then NaH (75.0 mg, 1.88 mmol) was slowly added and he resulting mixture was 
stirred at room temperature for 15 minutes. Then epichlorohydrin (.117 mL, 1.504 
mmol) was added and the reaction was stirred at room temperature overnight. 
Product formation was confirmed by LC/MS and then the contents were purified 
by ISCO (Hex:EA; 1:1) in 98% yield (180 mg, .743 mmol). 
 
6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(oxiran-2-
ylmethyl)-1H-indole-4-carboxamide (xy224-020 (4.4)). 6-cyano-1-(oxiran-2-
ylmethyl)-1H-indole-4-carboxylic acid (.185 g, .764 mmol), 3-(aminomethyl)-4,6-
dimethylpyridin-2(1H)-one (.128 g, .840 mmol), and HOAt (.156 g, 1.15 mmol) 
were dissolved in DMSO (5 mL) and stirred at room temperature for 15 minutes 
prior to addition of EDCI (.219 g, 1.15 mmol) and NMM (0.25 mL, 2.29 mmol) for 
5 hours at room temperature. LC/MS demonstrated formation of the desired 
product, the mixture was then purified using ISCO (DCM:MeOH; 1:1) to give the 
title compound in 17% yield (.049 g, .130 mmol). 1H NMR (400 MHz, Methanol-
d4), δ: 8.11 (s, 1H), 7.67 (d, J = 1.3 Hz, 1H), 7.62 (d, J = 3.2 Hz, 1H), 6.97 (dd, J 
= 3.2, 0.9 Hz, 1H), 6.11 (s, 1H), 4.72 (dd, J = 15.4, 2.5 Hz, 1H), 4.54 (s, 2H), 4.23 
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(dd, J = 15.4, 6.1 Hz, 1H), 3.30 (p, J = 1.7 Hz, 8H), 2.80 (dd, J = 4.8, 4.0 Hz, 1H), 
2.47 (dd, J = 4.8, 2.6 Hz, 1H), 2.40 (s, 3H), 2.24 (d, J = 0.9 Hz, 3H). 
 
 
Scheme 4.2. Reagents and Conditions. (a) NaH, 3-bromopropanoate, DMF, rt, 
o/n, 63%; (b) 3-(aminomethyl)-4,6-dimethylpyridin-2(1H)-one, HOAt, EDCI, 
DMSO, NMM, rt, 2 h, 87%; (c) LiOH, THF, rt, o/n, 96%; (d) diphenyl 
phosphorazidate, TEA, toluene, dioxane, rt, o/n, 100%; (e) acrylic acid, HOAt, 
EDCI, DMSO, NMM, rt, 2 h, 88%; (f) 2-fluoroacrylic acid, HOAt, EDCI, DMSO, 
NMM, rt, 2 h, 73%. 
 
6-cyano-1-(3-methoxy-3-oxopropyl)-1H-indole-4-carboxylic acid (4.5). 6-
cyano-1H-indole-4-carboxylic acid (300 mg, 1.61 mmol) was dissolved in DMF 
(10 mL) and NaH (148 mg, 3.71 mmol) was slowly added and stirred at room 
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temperature for 15 minutes before adding methyl 3-bromopropanoate (0.35 mL, 
3.22 mmol). The reaction was stirred at room temperature overnight. The next 
morning, LC/MS showed that the reaction was complete, the contents were then 
quenched with 5% HCl, extracted with EA, dried over MgSO4, filtered, 
concentrated in vacuo and purified via ISCO (Hexane:EA, 100%  40%) to give 
the desired product at 63% yield (370 mg, 1.36 mmol). 
 
methyl 3-(6-cyano-4-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methyl)carbamoyl)-1H-indol-1-yl)propanoate (4.6). 6-cyano-1-(3-methoxy-
3-oxopropyl)-1H-indole-4-carboxylic acid (370 mg, 1.36 mmol), 3-(aminomethyl)-
4,6-dimethylpyridin-2(1H)-one (248 mg, 1.63 mmol), and HOAt (277 mg, 2.04 
mmol) were dissolved in DMSO (5.00 mL) and stirred at room temperature for 15 
minutes prior to addition of EDCI (391 mg, 2.04 mmol) and NMM (0.45 mL, 4.08 
mmol) for 2 hours at room temperature. LC/MS demonstrated formation of 
product, the mixture was then quenched with H2O, and purified using HPLC to 
give the desired product in 87% yield (480 mg, 1.22 mmol). 
 
3-(6-cyano-4-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methyl)carbamoyl)-1H-indol-1-yl)propanoic acid (4.7). methyl 3-(6-cyano-
4-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1H-indol-1-
yl)propanoate (200 mg, .493 mmol) was dissolved in THF (10 mL) prior to 
addition of LiOH (51.0 mg, 1.23 mmol) dissolved in H2O (2 mL). The reaction 
was stirred overnight at room temperature and monitored by TLC the next 
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morning. After completion, the contents were precipitated with addition of HCl, 
the observed precipitate was filtered to give the desired product in 96% yield 
(186 mg, .473 mmol). 
 
1-(2-aminoethyl)-6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-1H-indole-4-carboxamide (4.8). 3-(6-cyano-4-(((4,6-dimethyl-2-oxo-
1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1H-indol-1-yl)propanoic acid (.050 g, 
.127 mmol) was dissolved in toluene (15 mL) and dioxane (15 mL) and added 
diphenyl phosphorazidate (.042 g, .153 mmol) before addition of TEA (.05 mL, 
.382 mmol). The contents were stirred overnight at room temperature, then 
concentrated in vacuo, and THF (10 mL) and LiOH (3 eq) dissolved in H2O were 
added and the contents were stirred overnight at room temperature before 
purification by HPLC to afford the desired product in quantitative yield (46.2 mg, 
.127 mmol).  
 
1-(2-acrylamidoethyl)-6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-1H-indole-4-carboxamide (4.9). 1-(2-aminoethyl)-6-cyano-N-((4,6-
dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide (46.2 
mg, .127 mmol), acrylic acid (11.0 mg, .153 mmol), and HOAt (26.0 mg, .191 
mmol) were dissolved in DMSO (2.00 mL) and stirred for 15 minutes prior to the 
addition of EDCI (37.0 mg, .191 mmol) and NMM (.05 mL, .454 mmol), then the 
contents were stirred at room temperature for 2 hours. The reaction was 
monitored by LC/MS and purified by HPLC after completion to give the title 
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compound in 88% yield (46.8 mg, .112 mmol). 1H NMR (400 MHz, Methanol-d4), 
δ: 8.04 (s, 1H), 7.66 (d, J = 1.3 Hz, 1H), 7.57 (d, J = 3.2 Hz, 1H), 6.92 (m, 1H), 
6.17 (d, J = 2.0 Hz, 1H), 6.11 (m, 2H), 6.06 (dd, J = 17.1, 9.9 Hz, 2H), 5.62 (dd, J 
= 9.9, 2.1 Hz, 2H), 4.54 (s, 2H), 4.44 (t, J = 6.0 Hz, 3H), 3.63 (t, J = 6.0 Hz, 3H), 
2.40 (s, 3H), 2.25 (d, J = 0.8 Hz, 3H). 
 
6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(2-(2-
fluoroacrylamido)ethyl)-1H-indole-4-carboxamide (4.10). 1-(2-aminoethyl)-6-
cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-
carboxamide (15.0 mg, .041 mmol), 2-fluoroacrylic acid (4.50 mg, .042 mmol), 
and HOAt (8.40 mg, .062 mmol) were dissolved in DMSO (3 mL) and stirred for 
15 minutes prior to the addition of EDCI (11.8 mg, .062 mmol) and NMM (.01 mL, 
.124 mmol), then the contents were stirred at room temperature for 2 hours. The 
reaction was monitored by LC/MS and purified by HPLC after completion to give 
the desired product in 73% yield (13.1 mg, .030 mmol). 1H NMR (400 MHz, 
Methanol-d4), δ: 8.58 (s, 1H), 8.07 (s, 1H), 7.66 (d, J = 1.3 Hz, 1H), 7.58 (d, J = 
3.1 Hz, 1H), 6.95 (dd, J = 3.2, 0.9 Hz, 1H), 6.13 (s, 1H), 5.42 (d, J = 3.4 Hz, 1H), 
5.12 (dd, J = 15.3, 3.4 Hz, 1H), 4.54 (s, 2H), 4.45 (t, J = 6.1 Hz, 2H), 3.66 (q, J = 
6.1 Hz, 2H), 2.40 (s, 3H), 2.25 (d, J = 0.8 Hz, 3H). 
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Scheme 4.3. Reagents and Conditions. (a) LiOH, THF, MeOH, NaH, rt, o/n, 
95%;(b) NaH, bromoacetonitrile, DMF, rt, o/n, 97%; (c) 3-(aminomethyl)-4,6-
dimethylpyridin-2(1H)-one, HOAt, EDCI, DMSO, NMM, rt, 2 h, 75%; (d) 6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)boronic acid, Pd(dppf)Cl2·DCM, AcOK, 
H2O:Dioxane, reflux, 3 h, 97%; (e) H2, Raney-Ni, rt, 3 h; (f) acrylic acid, HOAt, 
EDCI, DMSO, NMM, rt, 2 h, 91%; (g) 2-fluoroacrylic acid, HOAt, EDCI, DMSO, 
NMM, rt, 2 h, 89%. 
 
6-bromo-1H-indole-4-carboxylic acid (4.11). methyl 6-bromo-1H-indole-4-
carboxylate (1.00 g, 3.94 mmol) was dissolved in MeOH (20 mL) and THF (5 mL) 
and then LiOH (469 mg, 11.2 mmol) dissolved in H2O (5 mL) was added. The 
contents were stirred overnight at room temperature. The next morning, TLC 
showed the reaction was complete, the organic solvents were removed in vacuo, 
and then HCl was added. Precipitate was observed, filtered, and collected to 
afford the desired product at 95% yield (900 mg, 3.75 mmol). 
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6-bromo-1-(cyanomethyl)-1H-indole-4-carboxylic acid (4.12). 6-bromo-1H-
indole-4-carboxylic acid (400 mg, 1.67 mmol) was dissolved in DMF (10 mL) and 
NaH (167 mg, 4.17 mmol) was slowly added and stirred at room temperature for 
15 minutes before adding bromoacetonitrile (238 mg mL, 2.00 mmol). The 
reaction was stirred at room temperature overnight. The next morning, LC/MS 
showed that the reaction was complete, the contents were then quenched with 
H2O, extracted with EA, washed with NaCl, dried over MgSO4, filtered, 
concentrated in vacuo and purified via ISCO (Hexane:EA, 100%  70%) to give 
the desired product at 97% yield (260 mg, .932 mmol). 
 
6-bromo-1-(cyanomethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-1H-indole-4-carboxamide (4.13). 6-bromo-1-(cyanomethyl)-1H-
indole-4-carboxylic acid (.260 g, .932 mmol), 3-(aminomethyl)-4,6-
dimethylpyridin-2(1H)-one (.170 g, 1.12 mmol), and HOAt (.190 g, 1.40 mmol) 
were dissolved in DMSO (10 mL) and stirred at room temperature for 15 minutes 
prior to addition of EDCI (.268 g, 1.40 mmol) and NMM (0.31 mL, 2.80 mmol) for 
2 hours at room temperature. LC/MS demonstrated formation of product, the 
mixture was then quenched with H2O, which precipitated the desired product, 
which was obtained after filtering in 75% yield (.290 g, .703 mmol). 
 
1-(cyanomethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-
(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide (4.14). 
6-bromo-1-(cyanomethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-
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1H-indole-4-carboxamide (.290 g, .701 mmol), (6-(4-isopropylpiperazin-1-
yl)pyridin-3-yl)boronic acid (.192 g, .772 mmol), potassium acetate (.206 g, 2.11 
mmol), and 1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (.029 g, 
.035 mmol) were dissolved in dioxane (30 mL) and H2O (6 mL). The mixture was 
heated to reflux for 3 hours, and monitored by LC/MS for product formation. The 
contents were then extracted using EA and purified using ISCO (DCM:MeOH; 
5:1) to give the desired product in 97% yield (.369 g, .680 mmol). 
 
1-(2-aminoethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-
(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide (4.15). 
1-(cyanomethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide (.025 g, .046 
mmol) was dissolved in MeOH (10 mL) and Raney-Ni (~5 mg) was added to the 
solution. The solution was stirred for 3 hours under H2 and monitored via LC/MS 
for product formation. The contents were filtered, concentrated in vacuo and 
used for the next step without any further characterization.  
 
1-(2-acrylamidoethyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-
carboxamide (xy203-042 (4.16)). 1-(2-aminoethyl)-N-((4,6-dimethyl-2-oxo-1,2-
dihydropyridin-3-yl)methyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indole-
4-carboxamide (.032 g, .059 mmol), acrylic acid (.005 g, .071 mmol), and HOAt 
(.012 g, .089 mmol) were dissolved in DMSO (2 mL) and stirred for 15 minutes 
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prior to the addition of EDCI (.017 g, .089 mmol) and NMM (.02 mL, .177 mmol), 
then the contents were stirred at room temperature for 2 hours. The reaction was 
monitored by LC/MS and purified by HPLC after completion to give the title 
compound in 91% yield (32.0 mg, .054 mmol). 1H NMR (400 MHz, Methanol-d4), 
δ: 8.47 (d, J = 2.4 Hz, 1H), 7.93 (dd, J = 8.8, 2.5 Hz, 1H), 7.75 (t, J = 1.1 Hz, 1H), 
7.61 (d, J = 1.4 Hz, 1H), 7.30 (d, J = 3.2 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 6.80 
(d, J = 3.2 Hz, 1H), 6.00 (m, 4H), 5.54 (dd, J = 8.4, 3.5 Hz, 1H), 4.91 (s, 1H), 4.54 
(s, 2H), 4.38 (t, J = 6.2 Hz, 3H), 3.48 (m, 5H), 3.20 (s, 1H), 2.37 (s, 3H), 2.20 (s, 
3H), 1.38 (d, J = 6.7 Hz, 6H). 
 
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(2-(2-
fluoroacrylamido)ethyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-1H-
indole-4-carboxamide (xy203-156 (4.17)). 1-(2-aminoethyl)-N-((4,6-dimethyl-2-
oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-
1H-indole-4-carboxamide (20.0 mg, .037 mmol), 2-fluoroacrylic acid (4.00 mg, 
.071 mmol), and HOAt (7.50 mg, .055 mmol) were dissolved in DMSO (2 mL) 
and stirred for 15 minutes prior to the addition of EDCI (10.5 mg, .055 mmol) and 
NMM (.015 mL, .111 mmol), then the contents were stirred at room temperature 
for 2 hours. The reaction was monitored by LC/MS and purified by HPLC after 
completion to give the title compound in 89% yield (7.07 mg, .033 mmol). 1H 
NMR (400 MHz, Methanol-d4), δ: 8.44 (m, 1H), 7.95 (dd, J = 8.9, 2.6 Hz, 1H), 
7.78 (d, J = 1.2 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 7.31 (d, J = 3.3 Hz, 1H), 6.88 
(m, 2H), 6.79 (m, 1H), 6.09 (s, 1H), 5.10 (d, J = 3.4 Hz, 1H), 5.06 (d, J = 3.4 Hz, 
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1H), 4.90 (m, 75H), 4.62 (s, 2H), 4.43 (t, J = 6.2 Hz, 2H), 3.67 (t, J = 6.2 Hz, 2H), 
3.55 (m, 4H), 2.63 (m, 6H), 2.33 (s, 3H), 2.20 (s, 3H), 1.13 (d, J = 6.5 Hz, 6H). 
 
 
Scheme 4.4. Reagents and Conditions. (a) NaH, 2-bromopropane, DMF, rt, 
o/n, 25%; (b) 3-(aminomethyl)-4,6-dimethylpyridin-2(1H)-one, HOAt, EDCI, 
DMSO, NMM, rt, 2 h, 96%; (C) 6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)boronic 
acid, Pd(dppf)Cl2·DCM, AcOK, H2O:Dioxane, reflux, 3 h, 84%. 
 
6-bromo-1-isopropyl-1H-indole-4-carboxylic acid (4.18). 6-bromo-1H-indole-
4-carboxylic acid (.500 g, 2.08 mmol) was dissolved in DMF (10 mL) and NaH 
(.208 g, 5.20 mmol) was slowly added to the mixture, and stirred at room 
temperature for 15 minutes prior to the addition of 2-bromopropane (.312 mL, 
3.12 mmol). The contents were then stirred overnight at room temperature. The 
reaction was monitored via TLC. After completion, the reaction was quenched 
with H2O, extracted with DCM, washed with NaCl, the solvent was removed in 
vacuo and purified by ISCO (Hex:EA; 5:3) to afford the desired product in 25% 
yield (.147 g, .521 mmol). 
 
147 
6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-
1H-indole-4-carboxamide (4.19). 6-bromo-1-isopropyl-1H-indole-4-carboxylic 
acid (.147 g, .521 mmol), 3-(aminomethyl)-4,6-dimethylpyridin-2(1H)-one (.095 g, 
.625 mmol), and HOAt (.106 g, .782 mmol) were dissolved in DMSO (10 mL) and 
stirred at room temperature for 15 minutes prior to addition of EDCI (.150 g, .782 
mmol) and NMM (0.17 mL, 1.56 mmol) for 2 hours at room temperature. LC/MS 
demonstrated formation of product, the mixture was then quenched with H2O, 
which precipitated the desired product, which was obtained after filtering in 96% 
yield (.210 g, .504 mmol). 
 
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide (xy224-065 
(4.20)). 6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-
isopropyl-1H-indole-4-carboxamide (.210 g, .504 mmol), (6-(4-isopropylpiperazin-
1-yl)pyridin-3-yl)boronic acid (.150 g, .605 mmol), potassium acetate (.148 g, 
1.51 mmol), and 1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (~20 
mg) were dissolved in dioxane (50 mL) and H2O (10 mL). The mixture was 
heated to reflux for 3 hours, and monitored by LC/MS for product formation. The 
contents were then extracted using EA and purified using ISCO (DCM:MeOH, 
5:1) to give the title compound in 84% yield (.229 g, .423 mmol). 1H NMR (400 
MHz, Methanol-d4), δ: 8.43 (m, 1H), 7.93 (dd, J = 8.9, 2.5 Hz, 2H), 7.74 (s, 2H), 
7.62 (d, J = 1.5 Hz, 1H), 7.48 (d, J = 3.3 Hz, 1H), 6.91 (d, J = 8.9 Hz, 2H), 6.80 
(m, 1H), 6.10 (s, 2H), 4.55 (d, J = 5.0 Hz, 6H), 3.58 (t, J = 5.1 Hz, 5H), 2.70 (s, 
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4H), 2.41 (s, 3H), 2.23 (d, J = 0.8 Hz, 3H), 1.53 (d, J = 6.6 Hz, 6H), 1.12 (d, J = 
6.5 Hz, 6H). 
 
 
Scheme 4.5. Reagents and Conditions. (a) LiOH, THF, MeOH, NaH, rt, o/n, 
92%;(b) NaH, bromoacetonitrile, DMF, rt, o/n, 48%; (c) 3-(aminomethyl)-6-
methyl-4-propylpyridin-2(1H)-one, HOAt, EDCI, DMSO, NMM, rt, 2 h, 20%; (d) 6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)boronic acid, Pd(dppf)Cl2·DCM, AcOK, 
H2O:Dioxane, reflux, 3 h, 74%; (e) H2, Raney-Ni, rt, 3 h; (f) acrylic acid, HOAt, 
EDCI, DMSO, NMM, rt, 2 h, 85%; (g) 2-fluoroacrylic acid, HOAt, EDCI, DMSO, 
NMM, rt, 2 h, 83%. 
 
6-bromo-1H-indazole-4-carboxylic acid (4.21). methyl 6-bromo-1H-indazole-4-
carboxylate (1.00 g, 3.92 mmol) was dissolved in THF (50 mL) and LiOH (.313 g, 
7.84 mmol) dissolved in H2O (10 mL) was added. The contents were stirred at 
room temperature overnight and the reaction was monitored by TLC to observe 
the disappearance of starting material. After completion, the organic solvents 
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were removed in vacuo, and HCl was added to precipitate the desired product in 
92% yield (.870 g, 3.61 mmol). 
 
6-bromo-1-(cyanomethyl)-1H-indazole-4-carboxylic acid (4.22). 6-bromo-1H-
indazole-4-carboxylic acid (.870 g, 3.61 mmol) was dissolved in DMF (30 mL) 
and NaH (.360 g, 9.02 mmol) was slowly added. The mixture was then stirred at 
room temperature for 15 minutes. Then bromoacetonitrile (.325 mL, 4.69 mmol) 
was added to the mixture and the contents were stirred overnight at room 
temperature. The reaction was monitored by LC/MS, and after completion the 
contents were quenched with H2O, separated with EA and purified by ISCO 
(Hex:EA; 3:1) to afford the desired product in 48% yield (.560 g, 1.90 mmol). 
 
6-bromo-1-(cyanomethyl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-
yl)methyl)-1H-indazole-4-carboxamide (4.23). 6-bromo-1-(cyanomethyl)-1H-
indazole-4-carboxylic acid (.100 g, .357 mmol), 3-(aminomethyl)-6-methyl-4-
propylpyridin-2(1H)-one (.077 g, .428 mmol), and HOAt (.073 mg, .536 mmol) 
were dissolved in DMSO (10 mL) and stirred at room temperature for 15 minutes 
prior to addition of EDCI (.103 g, .536 mmol) and NMM (0.078 mL, .714 mmol) 
for 2 hours at room temperature. LC/MS demonstrated formation of product, the 
mixture was then purified using ISCO (DCM:MeOH; 10:1) to give the desired 
product in 20% yield (.032 g, .072 mmol). 
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1-(cyanomethyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-
oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(4.24). 6-bromo-1-(cyanomethyl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-
3-yl)methyl)-1H-indazole-4-carboxamide (.032 g, .072 mmol), (6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)boronic acid (.022 g, .087 mmol), potassium 
acetate (.021 g, .217 mmol), and 1,1′-Bis(diphenylphosphino)ferrocene] 
dichloropalladium(II) (~10 mg) were dissolved in dioxane (20 mL) and H2O (4 
mL). The mixture was heated to reflux for 3 hours, and monitored by LC/MS for 
product formation. The contents were then extracted using EA and purified using 
ISCO (DCM:MeOH, 10:1) to give the desired product in 74% yield (.030 g, .053 
mmol).  
 
1-(2-aminoethyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-
oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(4.25). 1-(cyanomethyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (.030 
g, .053 mmol) was dissolved in MeOH (50 mL) and Raney-Ni (~50 mg) was 
added to the solution. The solution was stirred overnight at room temperature 
and monitored via LC/MS for product formation. The contents were filtered, 
concentrated in vacuo and used for the next step without any further 
characterization. 
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1-(2-acrylamidoethyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-
methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (xy3-083 (4.26)). 1-(2-aminoethyl)-6-(6-(4-isopropylpiperazin-1-
yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-
indazole-4-carboxamide (.015 g, .026 mmol), acrylic acid (.009 g, .040 mmol), 
and HOAt (.014 g, .053 mmol) were dissolved in DMSO (5 mL) and stirred for 15 
minutes prior to the addition of EDCI (.020 g, .053 mmol) and NMM (.1 mL, .454 
mmol), then the contents were stirred at room temperature for 2 hours. The 
reaction was monitored by LC/MS and purified by HPLC after completion to give 
the title compound in 85% yield (.014 g, .022 mmol). 1H NMR (600 MHz, 
Methanol-d4), δ: 8.50 (d, J = 2.5 Hz, 1H), 8.37 (s, 1H), 7.96 (dd, J = 8.9, 2.6 Hz, 
1H), 7.82 (d, J = 1.4 Hz, 1H), 7.76 (d, J = 1.4 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H), 
6.15 (s, 1H), 6.10 (dd, J = 17.2, 1.7 Hz, 2H), 5.46 (m, 4H), 4.63 (m, 3H), 4.59 (s, 
3H), 3.72 (t, J = 5.8 Hz, 3H), 3.62 (s, 4H), 3.57 (s, 2H), 3.34 (d, J = 2.8 Hz, 3H), 
2.69 (m, 10H), 2.30 (d, J = 15.3 Hz, 1H), 2.26 (s, 3H), 1.58 (m, 4H), 1.29 (s, 5H), 
1.14 (dd, J = 6.5, 3.8 Hz, 10H), 1.02 (t, J = 7.4 Hz, 4H), 0.85 (m, 4H). 
 
1-(2-(2-fluoroacrylamido)ethyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-
N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (xy3-096 (4.27)). 1-(2-aminoethyl)-6-(6-(4-isopropylpiperazin-1-
yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-
indazole-4-carboxamide (.065 g, .114 mmol), 2-fluoroacrylic acid (.015 g, .171 
mmol), and HOAt (.031 g, .228 mmol) were dissolved in DMSO (5 mL) and 
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stirred for 15 minutes prior to the addition of EDCI (.044 g, .228 mmol) and NMM 
(.1 mL, .454 mmol), then the contents were stirred at room temperature for 2 
hours. The reaction was monitored by LC/MS and purified by HPLC after 
completion to give the title compound in 83% yield (.061 g, .095 mmol). 1H NMR 
(600 MHz, Methanol-d4), δ: 8.50 (d, J = 2.5 Hz, 1H), 8.36 (d, J = 0.8 Hz, 1H), 
7.96 (dd, J = 8.9, 2.6 Hz, 1H), 7.86 (t, J = 1.2 Hz, 1H), 7.73 (m, 1H), 6.87 (m, 
2H), 6.14 (s, 1H), 5.44 (m, 1H), 5.39 (d, J = 3.5 Hz, 1H), 5.05 (dd, J = 15.3, 3.4 
Hz, 1H), 4.67 (t, J = 5.9 Hz, 3H), 4.59 (s, 3H), 3.74 (t, J = 5.9 Hz, 3H), 3.54 (m, 
6H), 3.43 (m, 1H), 3.31 (m, 1H), 2.66 (m, 11H), 2.26 (s, 4H), 1.57 (m, 3H), 1.28 
(s, 1H), 1.05 (m, 10H), 1.01 (t, J = 7.3 Hz, 4H). 
 
 
Scheme 4.6. Reagents and Conditions. (a) NaH, 1-chloro-5-iodopentane, 
DMF, rt, o/n;  (b) NaOH, MeOH, rt, o/n, 47%; (c) 3-(aminomethyl)-6-methyl-4-
propylpyridin-2(1H)-one, HOAt, EDCI, DMSO, NMM, rt, 2 h, 72%; (d) 6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)boronic acid, Pd(dppf)Cl2·DCM, AcOK, 
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H2O:Dioxane, reflux, 3 h, 97%; (e) NaN3, DMF, 80 C, 2 h; (f) MeOH, Pd/C, H2, rt, 
2 h; (g) acrylic acid, HOAt, EDCI, DMSO, NMM, rt, 2 h, 76%; (h) 2-fluoroacrylic 
acid, HOAt, EDCI, DMSO, NMM, rt, 2 h, 82%. 
 
6-bromo-1-(5-chloropentyl)-1H-indazole-4-carboxylic acid (4.28). methyl 6-
bromo-1H-indazole-4-carboxylate (.500 g, 1.96 mmol) was dissolved in DMF (20 
mL) and NaH (.117 g, 2.94 mmol) was slowly added, the mixture was stirred at 
room temperature for 15 minutes prior to the addition of 1-chloro-5-iodopentane 
(.683 g, 2.94 mmol). The contents were then stirred at room temperature 
overnight. The reaction was monitored by LC/MS and concentrated in vacuo after 
completion. Then the contents were dissolved in MeOH (5 mL) and NaOH (.024 
g, 5.88 mmol) dissolved in H2O (5 mL) was added; the contents were stirred at 
room temperature overnight. The reaction was monitored via TLC, and after 
disappearance of the starting material, the organic solvents were removed in 
vacuo, the contents were extracted with EA and purified by ISCO (Hexane:EA; 
4:1) to afford the desired product in 47% yield over 2 steps (.320 g, .926 mmol). 
 
6-bromo-1-(5-chloropentyl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-
3-yl)methyl)-1H-indazole-4-carboxamide (4.29). 6-bromo-1-(5-chloropentyl)-
1H-indazole-4-carboxylic acid (330 mg, .926 mmol), 3-(aminomethyl)-4,6-
dimethylpyridin-2(1H)-one (183 mg, 1.02 mmol), and HOAt (189 mg, 1.39 mmol) 
were dissolved in DMSO (15 mL) and stirred at room temperature for 15 minutes 
prior to addition of EDCI (266 mg, 1.39 mmol) and NMM (0.31 mL, 2.77 mmol) 
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for 2 hours at room temperature. LC/MS demonstrated formation of product, the 
mixture was then quenched with H2O, separated with EA, and purified using 
ISCO (Hexane:EA; 5:1) to give the desired product in 72% yield (340 mg, .669 
mmol). 
 
1-(5-chloropentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(4.30). 6-bromo-1-(5-chloropentyl)-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (.340 g, .669 mmol), (6-
(4-isopropylpiperazin-1-yl)pyridin-3-yl)boronic acid (.167 g, .669 mmol), 
potassium acetate (206 mg, 2.11 mmol), and 1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (~5 mg) were dissolved in 
dioxane (10 mL) and H2O (2 mL). The mixture was heated to reflux for 3 hours, 
and monitored by LC/MS for product formation. The contents were then extracted 
using EA and purified using ISCO (DCM:MeOH; 5:1) to give the desired product 
in 97% yield (.286 g, .452 mmol). 
 
1-(5-azidopentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(4.31). 1-(5-chloropentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-
methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (.090 g, .142 mmol) and sodium azide (.046 g, .711 mmol) were 
dissolved in DMF (5 mL), the reaction was heated to 80 0C for 2 hours. The 
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reaction was monitored via LC/MS, quenched with H2O after completion and 
extracted with DCM. The crude product was used for the next step without further 
characterization. 
 
1-(5-aminopentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-
2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide 
(4.32). 1-(5-azidopentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-
methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (.030 g, .047 mmol) was dissolved in MeOH (4 mL) and afforded a 
catalytic amount of Pd/C and placed under Hydrogen at room temperature for 2 
hours. The reaction was monitored by LC/MS, concentrated in vacuo, and used 
for the next step without further characterization.  
 
1-(5-acrylamidopentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-
methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-
carboxamide (xy3-104 (4.33)). 1-(5-aminopentyl)-6-(6-(4-isopropylpiperazin-1-
yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-
indazole-4-carboxamide (.030 g, .049 mmol), acrylic acid (.007 g, .073 mmol), 
and HOAt (.014 g, .098 mmol) were dissolved in DMSO (5 mL) and stirred for 15 
minutes prior to the addition of EDCI (.020 g, .098 mmol) and NMM (.1 mL, .454 
mmol), then the contents were stirred at room temperature for 2 hours. The 
reaction was monitored by LC/MS and purified by HPLC after completion to give 
the title compound in 76% yield (.025 g, .037 mmol). 1H NMR (600 MHz, 
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Methanol-d4), δ: 8.52 (d, J = 2.5 Hz, 1H), 8.34 (d, J = 0.8 Hz, 1H), 7.99 (dd, J = 
8.9, 2.7 Hz, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.77 (d, J = 1.3 Hz, 1H), 6.92 (d, J = 
8.9 Hz, 1H), 6.10 (m, 2H), 5.58 (dd, J = 7.8, 4.2 Hz, 1H), 4.59 (s, 2H), 4.50 (t, J = 
6.9 Hz, 2H), 3.61 (t, J = 5.2 Hz, 4H), 3.19 (t, J = 7.0 Hz, 2H), 2.71 (m, 3H), 2.69 
(t, J = 5.2 Hz, 4H), 2.26 (s, 3H), 1.95 (p, J = 7.0 Hz, 2H), 1.59 (m, 2H), 1.55 (p, J 
= 7.2 Hz, 2H), 1.27 (m, 3H), 1.08 (m, 6H), 1.01 (t, J = 7.4 Hz, 3H). 
 
1-(5-(2-fluoroacrylamido)pentyl)-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-
yl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-
4-carboxamide (xy3-103 (4.34)). 1-(5-acrylamidopentyl)-6-(6-(4-
isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2-
dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide (.012 g, .020 mmol), 2-
fluoroacrylic acid (.005 g, .070 mmol), and HOAt (.013 g, .094 mmol) were 
dissolved in DMSO (5 mL) and stirred for 15 minutes prior to the addition of EDCI 
(.018 g, .094 mmol) and NMM (.1 mL, .454 mmol), then the contents were stirred 
at room temperature for 2 hours. The reaction was monitored by LC/MS and 
purified by HPLC after completion to give the desired product in 82% yield (.011 
g, .016 mmol). 1H NMR (600 MHz, Methanol-d4), δ: 8.52 (d, J = 2.5 Hz, 1H), 8.34 
(d, J = 0.9 Hz, 1H), 7.99 (dd, J = 8.9, 2.6 Hz, 1H), 7.90 (s, 1H), 7.77 (d, J = 1.3 
Hz, 1H), 6.92 (d, J = 8.9 Hz, 1H), 6.14 (s, 1H), 5.11 (dd, J = 15.3, 3.3 Hz, 1H), 
4.84 (m, 4H), 4.59 (s, 2H), 4.50 (t, J = 6.9 Hz, 2H), 3.61 (t, J = 5.2 Hz, 4H), 3.29 
(d, J = 3.9 Hz, 6H), 3.22 (t, J = 7.1 Hz, 2H), 2.67 (m, 7H), 2.25 (d, J = 2.8 Hz, 
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3H), 1.96 (p, J = 7.1 Hz, 2H), 1.63 (m, 2H), 1.52 (m, 3H), 1.30 (m, 2H), 1.27 (m, 
1H), 1.13 (d, J = 6.5 Hz, 7H), 1.01 (t, J = 7.4 Hz, 3H). 
 
Results 
 
Homology Modeling and EZH2 SET Domain Crystal Structure Guide EZH2 
Irreversible Design 
Prior to the release of the EZH2 apo crystal structure (PDB: 4MI0 and 
PDB: 4MI5) [82, 83] we built a homology model of EZH2 using the GLP crystal 
structure (PDB: 3RFI) as a template [62]. Our initial binding hypothesis was 
generated using this model, so we were eager to see if the predicted mode of 
binding generated with our homology model was recapitulated in the crystal 
structure. Indeed, our homology model superimposes well onto the crystal 
structure (blue vs purple in figure 4.1 A) yielding an RMSD of 2.2 Å. Further, 
docking of UNC1999 into the crystal structure results in a very similar pose as 
the homology model. Our binding hypothesis predicts that cysteine 663 (C663) 
resides approximately 5.2 Å away from the isopropyl substituent of the indazole 
core of UNC1999 (Figure 4.1 A). This is especially advantageous as the indazole 
nitrogen can easily be modified to install reactive moieties capable of irreversible 
inhibition. Further, this cysteine residue is a serine residue in EZH1 (Figure 4.1 
B), so we believe that we can take advantage of the more nucleophilic properties 
of cysteine to develop a selective, irreversible inhibitor of EZH2, which will give 
direct confirmation of our proposed UNC1999 binding hypothesis. 
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In vitro Activity of First Generation UNC1999 Irreversible Analogs 
 Our goal in designing the first EZH2 irreversible inhibitors was to tease out 
nearly all EZH1 inhibition, thereby creating an EZH2-specific chemical probe. As 
such, we decided to adopt the indole core of GSK126 instead of the indazole 
core of UNC1999, and the dimethyl pyridone of GSK126, EPZ005687 and El1. 
We believed these features would negate a significant amount of the reversible 
binding to EZH1, while maintaining it for EZH2; after initial reversible binding the 
cysteine would be able to attack the reactive moiety. We also varied the 
substituent at the 6 position of the indole, and decided to synthesize compounds 
bearing the smaller nitrile in addition to the piperazine substituted pyridine. While 
the piperazine substituted pyridine is believed to contribute to the potency of the 
inhibitors, we felt that the nitrile would allow for additional movement of the 
compound that may be needed to allow for C663 to engage the irreversible 
moieties. We began with an epoxide, acrylamide, and α-fluoroacrylamide as 
reactive moieties, installing them on the indole nitrogen. Our binding hypothesis 
predicted that these moieties would be tolerated in the active site. 
 The synthesis of the aforementioned compounds can be found in Scheme 
4.1, and the corresponding structures with in vitro activities are displayed in 
Table 4.1. Unexpectedly, almost all of the compounds synthesized with this 
design in mind were inactive against both EZH1 and EZH2. All of the nitrile 
derivatives displayed >5 µM IC50s against both enzymes (Table 4.1, xy203-020, 
xy203-117, and xy203-157). Of the compounds bearing the piperazine-
substituted pyridine, only xy224-014 displayed an IC50 < 2 µM against EZH2. 
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Due to the change in scaffold from our previous EZH2 inhibitors, we synthesized 
xy224-065 as a positive control. Xy224-065 displayed potent inhibition of EZH2 
(IC50 = 24 nM), and as hoped with this scaffold, was significantly less potent for 
EZH1 (IC50 = 1.95 µM). 
   
In vitro Activity of Second Generation UNC1999 Irreversible Analogs 
 The results from the set of compounds in Table 4.1 made it clear that the 
switch to the indole and dimethylpyridone led to a significant loss in reversible 
binding. Further, maintaining the piperazine-substituted pyridine may be essential 
for potency, so we revisited our initial UNC1999 scaffold, and decided to append 
the same irreversible moieties to the indazole. Prior to synthesizing the set of 
compounds in Table 4.2, we studied the binding of UNC1999 derivatives bearing 
irreversible moieties in silico. Indeed, our UNC1999 binding hypothesis is 
recapitulated when appending an acrylamide to the indazole nitrogen (Figure 
4.2), so we moved forward with acrylamides, and α-fluoroacrylamides. We also 
decided to increase the linker length from the indazole to the reactive group. 
 The set of compounds pictured in Table 4.2 yielded much more positive 
results than those of Table 4.1; all had IC50s in the nanomolar range for EZH2. 
However, we did pick up additional EZH1 activity in switching back to the 4-
methyl-6-propyl pyridone indazole scaffold; xy3-103 and xy3-104 demonstrated 
fairly potent inhibition of EZH1. While none of these compounds were as effective 
as UNC1999, we hoped that we may be able to observe an EZH2-inhibitor 
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adduct via MS, but unfortunately, none of the compounds produced said adduct, 
and were therefore determined not to be irreversible inhibitors. 
 
Discussion 
 
 Irreversible inhibitors have proved to be very useful tools in the study of 
protein function, which is demonstrated in the success of activity-based protein 
profiling [84]. Not only do these probes lend themselves as tools to aid in the 
discovery of additional inhibitors, but they also serve to help characterize enzyme 
active sites [85, 86]. One issue hampering further discovery and understanding of 
EZH2 inhibitors is the lack of direct evidence for a mode of binding, which in part, 
is due to the lack of an EZH2-ligand co-crystal structure. An irreversible inhibitor 
of EZH2 may facilitate said structure.  
Homology modeling of the EZH2 SET domain led to the hypothesis that a 
cysteine residue resides near the presumed binding site of UNC1999. After 
release of the EZH2 SET domain apo structure, we were delighted to discover 
that our homology model superimposed well onto the crystal structure, and that 
the cysteine of interest (C663) was also present in the same vicinity as C663 in 
the homology model. Additionally, this cysteine is a serine in EZH1 (S664), so we 
aimed to create an EZH2-selective, irreversible inhibitor by exploiting the 
increased nucleophilicity of the cysteine versus the serine. However, our efforts 
were initially thwarted as none of the 4,6-dimethyl pyridone indole compounds 
displayed promising results in vitro. Yet, switching back to the 4-propyl-6-methyl 
pyridone indazole scaffold did provide compounds that were nanomolar potent, 
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which demonstrated that substituents are tolerated at this position. The exact 
reasoning for this change in tolerability of the reactive moieties with the indazole 
versus the indole is unfounded. Further, the longer linker (n=2 vs n=5) resulted in 
more potent compounds, but none of the designed irreversible inhibitors were 
able to create an EZH2-ligand adduct, as detected by MS.  
It is very possible that the full-length EZH2 architecture does not mimic the 
EZH2 SET domain apo structure. This could mean that C663 is buried deep 
within the complex, and is not available for attack of the reactive moiety. It is also 
possible, that if the cysteine is solvent exposed, as our truncated model 
suggests, that the local environment is influencing the pKa of C663, making it 
less reactive [87]. Acrylamides are fairly slow reacting irreversible motifs, which is 
beneficial, because there is less potential for off-target effects. However, going 
forward, we plan to install more reactive irreversible moieties (such as α-fluoro- 
and α-chloroketones) in order to try and engage C663 as a proof of concept for 
EZH2 irreversible inhibition.  
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Tables 
 
 
 
Compound R1 R2 
EZH2 IC50 
(nM) 
EZH1 IC50 
(nM) 
 
xy203-020 
 
-CN 
 
>5000 >5000 
 
xy203-117 
 
-CN 
 
>5000 >5000 
 
xy203-157 
 
-CN 
 
>5000 >5000 
 
xy203-042 
 
 
 
>2500 >5000 
 
xy224-014 
 
 
 
1254 >5000 
 
xy224-065 
 
 
i-Pr 24 1945 
 
Table 4.1: First generation of EZH2 irreversible inhibitors. 
i-Pr = isopropyl. CN = cyano. 
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Compound R n 
EZH2 IC50 
(nM) 
EZH1 IC50 
(nM) 
xy3-083 
 
2 613 >5000 
xy3-096 
 
2 336 >2500 
xy3-104 
 
5 84 592 
xy3-103 
 
5 118 1348 
xy3-116 
 
6 92 1272 
 
UNC1999 i-Pr 0 <10 45 
 
Table 4.2: Second generation of EZH2 irreversible inhibitors. 
i-Pr = isopropyl. 
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Figures 
 
 
Figure 4.1: Rationale for EZH2 irreversible inhibitor design. 
(A) Superimposition of EZH2 homology model (blue) and apo X-ray co-crystal 
structure of the EZH2 SET domain (purple). UNC1999 (green) is hypothesized to 
occupy the SET domain with a pose that orients the isopropyl substituent of the 
indazole towards a nearby (5.2 Å) cysteine residue (C663). (B) C663 in EZH2 is 
a serine residue (S664) in EZH1. 
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Figure 4.2: xy3-083 binding hypothesis. 
Docking of xy3-083 (green) into the EZH2 apo crystal structure (purple) predicts 
that the compound binds in a way that orients the reactive moiety (acrylamide 
pictured here) towards C663. 
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CHAPTER V: CHEMICAL PROBE FUNCTIONALIZATION PROVIDES A 
NOVEL METHOD FOR DETECTION OF GENETIC OCCUPANCY 
 
 
Introduction 
 
Chemical probes that demonstrate sufficient cellular potency and target 
selectivity can greatly accelerate understanding of protein function [43, 45]. This 
is especially important in relatively nascent fields like epigenetic drug discovery; 
chemical probes allow for extensive target validation, and can be functionalized 
to create chemical tools from the parent chemical probe [62, 88, 89]. G9a and 
EZH2 are two very interesting potential drug targets, and several highly potent 
small molecule inhibitors are widely available for both. So, we focused our efforts 
on functionalizing the small molecule inhibitor of G9a, as we previously did with 
EZH2 (Chapter 1 & [62]), into a tool that will allow the research community to 
further advance the understanding of these two interesting targets. 
 Like EZH2, G9a is a lysine methyltransferase, but differs in substrate 
specificity; G9a catalyzes the mono- and dimethylation of histone H3 lysine 9 
(H3K9) [90-95].  G9a activity has an effect on multiple biological pathways and 
human diseases including cancer (reviewed in [96]), and is overexpressed in a
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number of tumors [97]; specifically, it is associated with increased metastasis and 
invasion of tumor cells in lung cancer [98].  Surprisingly, loss of G9a-dependent 
histone 3 lysine 9 dimethylation (H3K9me2) has also been observed in various 
cancer cell lines [99]. In parallel with EZH2, the discrepancy of G9a activity in 
different cancer types underscores the importance of further research into the 
biological role of G9a, and chemical tools will provide an immeasurable amount 
of assistance in teasing out these observed discrepancies. 
Herein, we describe the discovery of UNC0965, a biotinylated tool of the 
G9a chemical probe UNC0638 [100]. UNC0965 displays low nanomolar in vitro 
potency, reduces the H3K9me2 mark in cellular assays, and selectively 
chemiprecipitates G9a from whole cell lysates. UNC2399 is a biotinylated analog 
of UNC1999 [62] that displays low nanomolar in vitro potency, and selectively 
chemiprecipitates EZH2 from whole cell lysates. We also show that UNC0965 is 
a useful tool for exploring the localization of G9a on chromatin both in vitro, and 
in vivo, and provide rationale for the development of the same application for 
UNC2399.
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Methods 
 
UNC0965 Synthesis 
 
 
Scheme 5.1. Reagents and Conditions: (a) 1-Chloro-3-iodopropane, K2CO3, 
CH3CN, reflux; (b) HNO3, Ac2O, 0 °C to RT, 75% over two steps; (c) pyrrolidine, 
K2CO3, NaI, cat. tetrabutylammonium iodide, CH3CN, reflux, 81%; (d) Fe dust, 
NH4OAc, EA-H2O, reflux, 63%; (e) 4N HCl, dioxane, cyclohexanecarbonitrile; (f) 
N,N-diethylaniline, POCl3, reflux, 47% over two steps; (g) hex-5-yn-1-yl 4-
methylbenzenesulfonate, K2CO3, DMF, 60 °C, 88%; (h) TFA, DCM, rt, 99%; (i) 1-
(hex-5-yn-1-yl)piperidin-4-amine·2TFA (5.8), K2CO3, DMF, 60 °C, 81%; (j) biotin-
PEG3-azide, cat. Cu(CH3CN)4PF6, DCM, rt, 92%. 
 
2-Cyclohexyl-N-(1-(hex-5-yn-1-yl)piperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-
1-yl)propoxy)quinazolin-4-amine (5.9). Compound 5.6 was prepared from the 
commercially available starting material (5.1) according to the synthetic route 
developed previously [100-103]. Compound 5.8 was synthesized from 
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commercially available tert-butyl piperidin-4-ylcarbamate (5.7) in two 
straightforward steps. A mixture of tert-butyl piperidin-4-ylcarbamate (5.7) (0.735 
g, 3.67 mmol), hex-5-yn-1-yl 4-methylbenzenesulfonate (0.926 g, 3.67 mmol) and 
K2CO3 (0.760 g, 5.50 mmol) in DMF (5.5 mL) was stirred overnight at 60°C. The 
resulting mixture was cooled to rt, added H2O (11 mL) and then extracted with 
CH2Cl2 (20 mL × 3). The combined organic phases were dried over Na2SO4, 
concentrated and purified by flash column chromatography on silica gel (0 – 6% 
MeOH / CH2Cl2) to afford the intermediate tert-butyl (1-(hex-5-yn-1-yl)piperidin-4-
yl)carbamate (0.906 g, 88%).  Trifluoroacetic acid (2.0 mL) was added to a 
solution of this intermediate (0.906 g, 3.22 mmol) in CH2Cl2 (10 mL) for 6 h at rt. 
The mixture was concentrated to afford 1-(hex-5-yn-1-yl)piperidin-4-amine·TFA 
(5.8) as a slurry oil. MS (ESI): 181 [M + H]+. Compound 5.6 (0.210 g, 0.52 mmol) 
(prepared according to the previously reported methods [104]) was added to a 
suspension of compound 5.8 (~ 1.1 mmol) and K2CO3 (1.1 g, 8 mmol) in DMF 
(4.0 mL). The resulting mixture was stirred overnight at 60 °C, cooled to rt, added 
H2O (10 mL), and extracted with CH2Cl2 (3 x 20 mL). The combined organic 
layers were dried over Na2SO4, concentrated, and purified by flash column 
chromatography on silica gel (0 – 10% MeOH / CH2Cl2) to afford the title 
compound 5.9 as a yellowish solid (0.231 g, 81% yield). 1H NMR (400 MHz, 
CDCl3), δ: 7.13 (s, 1H), 6.86 (s, 1H), 5.32 (d, J = 7.2 Hz, 1H), 4.27–4.15 (m, 1H), 
4.12 (t, J = 6.7 Hz, 2H), 3.86 (s, 3H), 2.97–2.85 (m, 2H), 2.68 (tt, J = 11.7, 3.4 
Hz, 1H), 2.61–2.52 (m, 2H), 2.52–2.41 (m, 4H), 2.40–2.31 (m, 2H), 2.24–2.10 (m, 
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6H), 2.10–2.00 (m, 2H), 1.99–1.89 (m, 3H), 1.86–1.47 (m, 15H), 1.44–1.21 (m, 
3H). MS (ESI): 548 [M + H]+. HPLC: 97%, RT: 2.81 min. 
 
N-(2-(2-(2-(2-(4-(4-(4-((2-Cyclohexyl-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-yl)amino)piperidin-1-yl)butyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (5.10). Cu(CH3CN)4PF6 (2.1 mg, 
0.0054 mmol) was added to a solution of compound 5.9 (17 mg, 0.0312 mmol) 
and biotin-PEG3-azide (14 mg, 0.0312mmol) in DCM (3.0 mL). The resulting 
mixture was stirred overnight at rt, concentrated and purified by preparative 
HPLC to give the title compound 5.10 as a white solid (28 mg, 92%). 1H NMR 
(400 MHz, CDCl3), δ: 7.45 (s, 1H), 7.15 (s, 1H), 6.98 (s, 1H), 6.69 (t, J = 5.6 Hz, 
1H), 6.35 (s, 1H), 5.55 (d, J = 7.2 Hz, 1H), 5.43 (s, 1H), 4.49 (t, J = 5.2 Hz, 2H), 
4.36-4.43 (m, 1H), 4.28–4.21 (m, 2H), 4.17 (t, J = 6.8 Hz, 2H), 3.92 (s, 3H), 3.86 
(t, J = 5.2 Hz, 2H), 3.62–3.56 (m, 8H), 3.53 (t, J = 5.2 Hz, 2H), 3.43–3.39 (m, 
2H), 3.12–3.07 (m, 1H), 2.94–2.91 (m, 2H), 2.85 (AB, JAB =12.8 5.2 Hz, 1H), 
2.75–2.66 (m, 4H), 2.62.61 (t,J = 7.2 Hz, 2H), 2.52–2.47 (m, 5H), 2.40 (t, J = 7.6 
Hz, 2H), 2.23–2.12 (m, 6H), 2.09 (t, J =7.2 Hz, 2H), 1.98–1.95 (m, 2H), 1.84–1.54 
(m, 18H), 1.45–1.23 (m, 5H). MS (ESI): 992 [M + H]+. HPLC: 99%, RT: 3.19 min. 
HRMS (ESI) calcd for C51H82N11O7S [M + H]
+: 992.6119. Found:992.6143. 
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Cell Lines 
 HEK 293T cells were grown at 37°C/5% CO2 on 15 cm plates in 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum.  
MDA-MB-231 cells were grown as described in [100]. 
 
Western Blotting 
 Western blotting was performed as described previously [62], except that 
blotting was performed with rabbit anti-G9a (Cell Signalling #3306), and goat 
anti-rabbit IgG(H+L) IR Dye 800 CW (LI-COR #926-32211).  Imaging was 
performed on the LI-COR Odyssey. 
 
Antibody ChIP 
 HEK 293T cells were grown to 90% confluency on four 15 cm plates.  
Each ChIP contained chromatin from approximately 1x107 cells.  Chromatin 
preparation and ChIP assay were performed using the Active Motif ChIP-IT® 
High Sensitivity kit #53040 according to manufacturer’s guidelines.  Antibodies 
used included: G9a, Abcam #ab40542, and rabbit IgG whole molecule, Jackson 
Immunoresearch #011-000-003. 
 
In vitro chem-ChIP 
 Chromatin was prepared from HEK 293T cells as described for the 
antibody ChIP.  Each ChIP contained chromatin from approximately 8x106 cells.  
Streptavidin-conjugated magnetic beads (Dynabeads® M-280 streptavidin, Life 
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Technologies #11205D, 250 µg per chemiprecipitation) were washed 3 times 
with 500 µL TBST (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20), 
diluted in 100 µL TBST, and 4 µL of 10 mM UNC0965 was added, followed by 
rotation on an end-over-end rotator for 1 hour at room temperature to saturate 
the beads. After binding, the beads were washed with TBST (500 µL x 3) to 
remove excess unbound compound. Chromatin was then added to the beads 
and the mixture was placed on an end-over-end rotator at 4°C overnight. The 
next morning, tubes were removed from the rotator, and supernatant was 
aspirated from the beads. The beads were washed (500 µL x 3) with ChIP wash 
buffer (0.1% SDS, 1% TritonX-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris, 
pH=8.0) followed by one wash with 500 µL of ChIP final wash buffer (1% SDS, 
1% TritonX-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl, pH 8.0).  During 
each wash, the sample was rotated at room temperature for 3 minutes.  The 
washed beads were resuspended in 200 µL TE (10 mM Tris-HCl, pH 8.0, 1 mM 
EDTA, pH 8.0) with 20 µg proteinase K, and the contents were transferred into a 
PCR tube.  The mixture was incubated at 55°C, for 30 minutes followed by 2 
hours at 80°C to reverse the crosslinks.  The DNA in the collected supernatant 
was then purified as described in Active Motif ChIP-IT® High Sensitivity kit 
#53040. 
 
In vivo chem-ChIP 
 HEK 293T cells were grown to 80% confluency on 15 cm plates as 
described.  Cells were treated with 5 µM UNC0965 for 15 minutes prior to 
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formaldehyde crosslinking.  Chromatin was prepared as described for the 
antibody ChIP.  Each chem-ChIP represented approximately 8x106 cells.  
Streptavidin-conjugated magnetic beads (Dynabeads® M-280 streptavidin, Life 
Technologies #11205D, 500 µg per chemiprecipitation) were washed 3 times 
with 500 µL TBST (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20).  
Chromatin was then added to the beads and the mixture was placed on a rotator 
at 4°C overnight. Wash and DNA purification steps were performed as described 
in the method for in vitro chem-ChIP, above. 
 
Quantitative PCR 
 Antibody ChIP and in vivo chem-ChIP DNA was prepared by diluting input 
samples 1:1000 and ChIP/chem-ChIP samples 1:10 in water.  In vitro chem-ChIP 
DNA was prepared by diluting input samples 1:1000 and ChIP/chem-ChIP 
samples 1:3 in water.  Two microliters of each diluted sample was subjected to 
relative quantification qPCR in duplicate on the ABI 7900HT using FastStart 
SYBR Green Master Mix ROX (Roche) in a 10 uL final volume. Percent input 
was determined using the ΔCt method [105] followed by normalization to a 
genomic region near the GAPDH gene that is not occupied by G9a. 
 
In-cell Western and Cell Toxicity assays  
 In-cell western and cell toxicity assays were performed in MDA-MB-231 
cells as previously reported [104]. 
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Results  
 
Discovery of UNC0965 
Previously, our lab reported the discovery of UNC0638 (Figure 5.1 A) 
[100] and UNC1152 (Figure 5.1 B) [106] the first chemical probe, and a 
structurally similar negative control of G9a, respectively. The discovery of 
UNC0638 also led to an X-ray co-crystal structure of the G9a-UNC0638-SAH 
complex [100]. In this structure, UNC0638 adopted a conformation that buried 
the 7-(3-pyrrolidin-1-yl-)propoxy side chain in the lysine binding channel, and the 
isopropyl group of the 4-(N-isopropylpiperidin-4-ylamino) moiety was solvent 
exposed. We took advantage of this solvent exposed chemical handle, and 
biotinylated the piperidine of UNC0638 yielding UNC0965; a functionalized 
chemical tool for biological applications (Figure 5.1 C). We hypothesized that a 
relatively long linker (~20 atoms from the piperidine nitrogen to the biotin 
carbonyl) would ensure that the biotin was at a sufficient distance from the 
surface of G9a to permit binding to streptavidin-conjugated magnetic beads while 
keeping the G9a warhead available for binding to G9a. This hypothesis was 
supported by docking studies using the G9a X-ray structure. As expected, 
UNC0965 docked in a nearly identical orientation to UNC0638 (Figure 5.2); with 
the 7-(3-pyrrolidin-1-yl)propoxy side chain embedded in the lysine binding 
channel, and the biotin solvent exposed, well away from the surface of the 
protein. 
We next confirmed that UNC0965 binds G9a and inhibits its catalytic 
activity. As with EZH2, we used a scintillation proximity assay [104] to determine 
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the in vitro IC50 of UNC0965 (Figure 5.3 A).  This assay is a direct measurement 
of the G9a catalyzed transfer of a tritiated methyl group from 3H-SAM to the 
histone peptide substrate.  UNC0965 showed potent inhibition, with an IC50 
value of < 2.5 nM. This strong inhibition of G9a catalytic activity implied that 
UNC0965 would bind the protein tightly enough to efficiently chemiprecipitate 
G9a from cell lysates. 
 
UNC0965 Selectively Chemiprecipitates G9a 
 UNC0965 was coupled to streptavidin-conjugated magnetic beads in order 
to chemiprecipitate G9a from HEK 293T whole cell extracts (Figure 5.3 B).  
Beads pre-treated with DMSO (1%) did not pull down G9a (Figure 5.3 B, lane 2).  
UNC0965-coated streptavidin-conjugated beads effectively pulled down G9a, 
while pre-incubation of the lysate with UNC0638 blocked this interaction (Figure 
5.3 B, lanes 3 and 4).  Additionally, pre-treatment of lysates with UNC1152, a 
negative control of UNC0638 that does not significantly inhibit G9a catalytic 
activity (compound 26a in [104]), was unable to block the ability of UNC0965-
coated beads to chemiprecipitate G9a (Figure 5.3 B, lanes 4 and 5). UNC0965 is 
capable of chemiprecipitating G9a from cell lysates, which further confirms that 
the biotin moiety of UNC0965 does not interfere with compound binding to G9a.   
 
UNC0965 Chemiprecipitates G9a Crosslinked to Chromatin in vitro 
Using traditional antibody ChIP, we identified four chromosomal regions in 
HEK 293T cells (Table 5.1) that showed a significant fold change in G9a 
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occupancy over background when compared to a negative control region near 
the GAPDH gene (Figure 5.4 A). We performed in vitro chem-ChIP using the 
same protocol used for antibody ChIP.  Instead of the G9a antibody and IgG 
control, we used streptavidin-conjugated magnetic beads pre-incubated with 
UNC0965 and DMSO, respectively.  We then examined the identified G9a 
occupied chromosomal regions by qPCR (Figure 5.4 B).  The UNC0965 in vitro 
chem-ChIP showed a greater than 5-fold increase over DMSO at each 
chromosomal region.  The difference between the G9a antibody ChIP signal and 
the IgG signal was less significant (p<0.5 to p<0.01) (Figure 5.4 A), than the 
signal for UNC0965 in vitro chem-ChIP compared to DMSO (p<0.01 to p<0.001).  
Thus, UNC0965 effectively captures G9a in an in vitro ChIP assay (termed in 
vitro chem-ChIP), and in this case with a better signal over background with G9a 
than the traditional antibody ChIP. 
 
UNC0965 is Cell Permeable and Engages Chromatin Bound G9a in Cells 
Unlike antibodies, small-molecule tools capable of permeating the cell 
membrane can be used to engage the target in cells prior to crosslinking.  We 
assessed the cellular activity of UNC0965 using an in-cell western assay as 
reported previously [13].  Treatment of cells for 48 hours with increasing 
concentrations of UNC0965 resulted in a decrease in H3K9me2 (IC50 = 3.3 ± 1.2 
µM), with low cell toxicity (EC50 > 50 µM), indicating that UNC0965 is indeed cell 
permeable (Figure 5.5 A).  
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For the in vivo chem-ChIP assay, we aimed to minimize any effects of 
G9a inhibition on its chromatin localization by quickly treating the cells with 
compound, rather than treating for several days. Therefore, we grew HEK 293T 
cells to 80% confluency, and then exposed the cells to 5 µM UNC0965 or 0.05% 
(volume equivalent) DMSO for 15 minutes prior to formaldehyde crosslinking.  
We then performed the standard antibody ChIP protocol, but used streptavidin-
conjugated magnetic beads for the precipitation step. Cells treated with 
UNC0965 showed a significant average change in G9a occupancy over DMSO-
treated cells (p<0.01) (Figure 5.5 B), which was very comparable to the in vitro 
chem-ChIP results (Figure 5.4 B). These data demonstrate that even with 
compound pre-treatment of the cells, the biotin moiety of UNC0965 remains 
solvent exposed after formaldehyde crosslinking, confirming that UNC0965 is a 
useful chemical tool for what we call “in vivo chem-ChIP” and could be used in 
additional cellular applications. 
 
Putative Applications of UNC2399 
 The success of UNC0965 with G9a in both the in vitro and in vivo chem-
ChIP assays inspired us to try the same technique with UNC2399 and EZH2. We 
began by conducting a traditional EZH2 ChIP assay in PC3 cells (Figure 5.6 A). 
Table 5.2 details the regions tested, and about half of the regions tested 
displayed significant (> 2-fold change) amplification versus IgG control (1, 2, 4, 8, 
and 10, Table 5.1 for details), while the other half were amplified but < 2-fold 
versus IgG control (3, 5, 6, 7, 9, Table 5.1 for details); primer pair 11 is GAPDH 
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and was used as a negative control. We next aimed to recapitulate the results 
from Figure 5.6 A using the in vitro chem-ChIP method, but to our surprise, we 
observed no significant amplification with UNC2399 versus UNC2398 control 
(Figure 5.6 B); DMSO treated beads (not pictured) resulted in a similar profile. 
We believe that the failure of UNC2399 in the in vitro chem-ChIP assay may be 
due to masking of the SET domain after crosslinking of the chromatin. So, in vivo 
chem-ChIP may be the best route for determination of EZH2 genetic occupancy 
using UNC2399.  
Unfortunately, UNC2399 is inactive in the EZH2 ICW, so we aimed to 
create a UNC2399 analog that is capable of both chemiprecipitating EZH2 and 
permeating the cell membrane. It is probable that the 12 PEG linker of UNC2399 
contributes to the low cell permeability, so we first aimed to determine the 
shortest linker possible that maintains the ability to chemiprecipitate EZH2 via 
titration of the linker length with various PEG-biotin groups (Figure 5.6 C). This 
data suggests that kdk215-090 (6 PEG groups) is fully capable of 
chemiprecipitating EZH2, which cuts the PEG12 linker in half. Next, we tested 
kdk215-090 in the ICW assay (Figure 5.6 D), and noticed modest inhibition at 
high concentrations of compound, suggesting a high dose of kdk215-090 may be 
able to engage EZH2 in the cellular environment. We are currently in the process 
of testing this compound in the in vivo chem-ChIP assay. 
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Discussion 
 
Our success with UNC0965 and G9a highlights methods to convert highly 
selective chemical probes into extremely valuable tools that may aid in 
understanding biological questions. Use of a functionalized chemical tool for 
chromatin precipitation has distinct advantages over an antibody. First, such 
chemical tools can be easily synthesized at low cost, and eliminate the batch-to-
batch variability common with antibody reagents. Second, a biotin tag can be 
designed to be solvent exposed for chemical tools that have a well-defined mode 
of binding. This design has a potential added advantage over traditional ChIP; 
crosslinking can prevent access of an antibody to the protein of interest.  Third, 
chemical tools can be cell permeable, which allows cell treatment prior to 
crosslinking.  This in vivo chem-ChIP method would be particularly well suited for 
proteins that are difficult to precipitate after crosslinking due to antibody epitope 
masking. The in vivo chem-ChIP method provides an additional advantage in that 
it allows the user to engage the target of interest prior to crosslinking, cell lysing, 
and fragmentation of the chromatin; potentially providing a more physiologically 
relevant readout. 
While both the in vitro and in vivo chem-ChIP technique proved to be a 
viable alternative method for G9a, the same was not observed for UNC2399 and 
EZH2. Unexpectedly, UNC2399 failed to chemiprecipitate EZH2 crosslinked to 
chromatin in PC3 (Figure 5.6 A), MLL-AF9, and HEK 293T cells (MLL-AF9 & 
HEK 293T data not shown). To date, only the in vitro chem-ChIP method has 
been attempted with EZH2, because UNC2399 is not active in the EZH2 ICW 
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assay. We hypothesize that this is due to a similar masking effect as is 
occasionally seen with antibodies. The in vitro chem-ChIP technique does not 
attempt to chemiprecipitate the target until after crosslinking, lysing, and 
fragmenting the chromatin, and we believe that this process may block access of 
the UNC2399 binding site in the SET domain of EZH2. Further complicating the 
issue is the fact that EZH2 is one subunit of a much larger complex, so this site 
may be more challenging to access than in the case of UNC0965 and G9a. We 
presume that part of the inactivity of UNC2399 in the ICW is due to the very long 
hydrophilic PEG linker, which is four times longer in UNC2399 than UNC0965. 
We determined that we could cut this linker in half (PEG 6 from PEG12) while 
maintaining the ability to chemiprecipitate EZH2; kdk215-090 demonstrated 
modest activity in the ICW. Going forward, we will attempt the in vivo chem-ChIP 
assay with kdk215-090 by exposing cells to a large dose of kdk215-090 (5-10 
µM). We hope this will alleviate any masking of the binding site that may be 
present with formaldehyde crosslinking. Nonetheless, more work needs to be 
done to optimize the cellular activity of UNC2399 derivatives in order to engage 
EZH2 prior to crosslinking.  
Future applications of this chemiprecipitation technique could include 
proteomic analysis of precipitated proteins to identify G9a-binding partners. 
Further, it would be interesting to compare genome-wide occupancy of G9a 
between all three methods (ChIP, in vitro, and in vivo chem-ChIP) to determine 
how well the overall signal for UNC0965 chem-ChIP compares to that of 
traditional ChIP. 
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Tables 
 
Primer Pair Gene Primer Sequence (5’  3’) 
CR1 hg19_chr18:34850198-34850296 
F - GTGCTGACCTGTCCATGGTGCTGAT 
R - GGCAGTCTGTCTAGTACAGACCAGT 
CR2 hg19_ chr7:154861842-154861989 
F - CAGCACCGCGGACAGCACCACATGT 
R - CTACGTAAGCCATCAGCTGATAAGG 
CR3 hg19_ chr9:126872846-126872928 
F - CTTGTCTGCTGTATGCCAGGCACCA 
R - CCTATGTTGCAAATTCATTGGGCAC 
CR4 hg19_ chr3:38847557-38847667 
F - GCTTGGTGAATGATTGATCTGTTTG 
R - CTTGAATTACGCTCTTCTTCCCTTT 
GAPDH hg19_ chr12:6643539-6643704 
F - TACTAGCGGTTTTACGGGCG 
R - TCGAACAGGAGGAGCAGAGAGCGA 
 
Table 5.1: Primer sequences for qPCR of G9a ChIP and chem-ChIP. 
F = forward, R = reverse.  
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Primer Pair Gene Primer Sequence (5’  3’) 
1 MTAP 
F - CACACACACACACCACCTTTTGG 
R - CCATCCACGACCTCTCTCTCTAAAG 
2 MTAP Intron 
F - CCCCCCTCCCTGTATCAAATAG 
R - AGTTTGCAGGGGAGAAACA 
3 hINK4A intron 
F - ATCGCTGAGCGATGAAGGTAG 
R - ATCACAAAAAGGAAAGGCAAG 
4 hINK4A exon 
F - CAAGCTTCCTTTCCGTCATGC 
R - GCCAGAGAGAACAGAATGGTCAGAGCCA 
5 hINK4A exon 
F - GCCAAGGAAGAGGAATGAGGAG 
R - CCTTCAGATCTTCTCAGCATTCG 
6 hINK4A TSS 
F - CGACTTCAGGGGTGCCACATTC 
R - TCTTTCCAGGCAAGGGGACGC 
7 hINK4A TSS 
F - CTCAGTGTAGAGCTATTGCCTC 
R - GGTTCTGATGCGGCATTGTAGGAT 
8 hARF(p14) TSS 
F - GAGAGTGAGGACCTCTCAAACAGAAC 
R - GAGTATTATTCTTTCTTCATAAT 
9 hARF1 TSS 
F - CGCCGTGTCCAGATGTCG 
R - TGAATGTCAGTTTTGAACTAAAAGCCG 
10 hINK4B exon 
F - GTTTGTACCGAGGTCCGGCAGCA 
R - GCACTGGCCGAGCCACCCACTTAAGG 
11 GAPDH 
F - TACTAGCGGTTTTACGGGCG 
R - TCGAACAGGAGGAGCAGAGAGCGA 
 
Table 5.2: Primer sequences used for EZH2 qPCR. 
F = forward, R = reverse. 
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Figures 
 
 
Figure 5.1: G9a chemical toolbox. 
(A) Structure of UNC0638. (B) Structure of UNC1152. (C) Structure of UNC0965. 
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Figure 5.2: Docking model of UNC0965. 
UNC0965 (green) is predicted to bind to G9a (purple) in a nearly identical fashion 
as UNC0638, and the biotin moiety is solvent exposed allowing for capture by 
streptavidin-conjugated magnetic beads. 
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Figure 5.3: in vitro characterization of UNC0965. 
(A) UNC0965 shows potent inhibition (IC50 < 2.5 nM) of G9a catalytic activity in 
an in vitro scintillation proximity assay. Experiments were performed in duplicate. 
(B) Streptavidin-conjugated magnetic beads pre-coated with UNC0965 
selectively chemiprecipitate G9a from HEK 293T cell lysates.  G9a western blot 
indicates that UNC0965-treated beads (lane 3) chemiprecipitate G9a compared 
to DMSO-treated beads (lane 2). This interaction can be blocked or retained, by 
pretreating lysate with UNC0638 (lane 4) or its negative control UNC1152 (lane 
5), respectively. These data are representative of three biological replicates. 
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Figure 5.4: G9a occupancy can be determined using antibody ChIP or in 
vitro chem-ChIP with UNC0965. 
(A) ChIP using G9a antibody or IgG control followed by qPCR.  (B) In vitro chem-
ChIP with UNC0965-coated streptavidin-conjugated magnetic beads followed by 
qPCR.  PCR primer sets correspond to chromosomal regions (CR) occupied by 
G9a as well as a GAPDH control region that shows no G9a occupancy.  
Chromosomal regions assayed include: CR1 (blue), CR2 (purple), CR3 (green), 
and CR4 (red), and GAPDH (grey).  Error bars represent the standard deviation 
of three biological replicates.  Statistical significance between DMSO and 
UNC0965 chem-ChIP for each region was determined by an unpaired t-test and 
indicated by asterisks (* = p<.05, ** = p<.01, *** = p<.001). 
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Figure 5.5: UNC0965 is cell penetrant and can be used for in vivo chem-
ChIP assays. 
(A) In-cell western assay of MDA-MB-231 cells treated with UNC0965 and 
assayed for total cellular H3K9me2 levels.  UNC0965 reduces cellular levels of 
H3K9me2 (blue squares; IC50 = 3.3 ± 1.2 µM) and is not toxic in the compound 
concentration range tested (grey triangles; EC50 > 50 µM). Error bars represent 
the standard deviation of 3 biological replicates. These data confirm that 
UNC0965 is cell penetrant. (B) In vivo chem-ChIP.  HEK 293T cells were treated 
with UNC0965 (5 µM) or DMSO (0.05%) for 15 minutes, crosslinked with 
formaldehyde, and then chromatin was isolated. ChIP was performed using 
streptavidin-conjugated magnetic beads followed by qPCR. PCR primer sets 
correspond to chromosomal regions (CR) occupied by G9a as well as a GAPDH 
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control region that shows no G9a occupancy. Chromosomal regions assayed 
include: CR1 (blue), CR2 (purple), CR3 (green), and CR4 (red), and GAPDH 
(grey). Error bars represent the standard deviation of three biological replicates.  
Statistical significance between DMSO and UNC0965 chem-ChIP for each region 
was determined by an unpaired t-test and indicated by asterisks (** = p<.01, *** = 
p<.001). 
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Figure 5.6: EZH2 ChIP and in vitro chem-ChIP of UNC2399 in PC3 cells. 
(A) ChIP using EZH2 antibody or IgG control in PC3 cells followed by qPCR.  (B) 
In vitro chem-ChIP with UNC2399-coated streptavidin-conjugated magnetic 
beads in PC3 cells followed by qPCR.  PCR primer sets correspond to 
chromosomal regions occupied by EZH2 as well as a GAPDH control region that 
shows no EZH2 occupancy.  Chromosomal regions assayed are detailed in 
Table 5.2. (C) UNC2399 linker titration. Results are representative of three 
biological replicates. (D) In-cell western assay of kdk215-090. The assay was 
performed in triplicate and error bars represent the standard deviation.
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Chapter VI: CONCLUSION 
 
 
Key Findings 
 
 The research conducted throughout the course of this dissertation has 
undoubtedly progressed chemical probe development for EZH1, EZH2, and G9a. 
The discovery of UNC1999 afforded the biological community the first orally 
bioavailable chemical probe of both lysine methyltransferases EZH2 and EZH1 
[62]; prior inhibitors were not active in animal models [34, 44], or required 
administration via IP injection [32]. In addition to UNC1999, we also discovered 
UNC2400, UNC2239, and UNC2399. UNC2400 provides a structurally similar 
UNC1999 analog that is inactive against EZH2, providing the perfect negative 
control for in vitro and cellular assays. UNC2239 is a cell permeable UNC1999-
dye conjugate that can be of use when traditional IF methods do not work. 
UNC2399 is a biotinylated UNC1999 analog that selectively chemiprecipitates 
EZH1/EZH2 from cellular lysates, which is a very desirable attribute for a variety 
of applications. Not only did this set of compounds provide a full chemical 
toolbox, but the compounds also provided evidence for the prevailing binding 
hypothesis for pyridone-containing EZH2 inhibitors.
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Previous EZH2 inhibitors were also 50-150-fold selective for EZH2 when 
compared with EZH1, but UNC1999 is < 5-fold selective for EZH2 versus EZH1, 
which makes it the most panactive EZH1/EZH2 chemical probe to date. This is a 
potential advantage for UNC1999 as there are certain maladies where EZH1 has 
demonstrated compensation of EZH2 functions, like MLL-rearranged leukemia 
[16]. Indeed, UNC1999 displayed potent inhibition of an MLL-rearranged 
leukemic cell-line, MLL-AF9, but GSK126 (150-fold selective for EZH2) did not 
[39]. Further, UNC1999 displayed a survival advantage in mice bearing MLL-AF9 
AML, which represents the first oral delivery of a dual EZH1/EZH2-specific 
compound as a means to inhibit MLL-rearranged leukemia. An additional aim of 
this research was to increase the activity of UNC1999 for EZH1, effectively 
making a more panactive EZH1/EZH2 inhibitor. While this objective was not 
achieved, it was determined that modifications to the C5 or C6 carbon of the 
pyridone abolished all EZH1 activity, and that bulkier hydrophobic substituents at 
the C4 of the pyridone may lead to a more potent EZH1 inhibitor. 
 In contrast to dual EZH1/EZH2 inhibition as a potential therapy, many 
solid tumors appear to rely solely on EZH2, so an EZH2-specific chemical probe 
would be more advantageous in this scenario. We attempted to take advantage 
of a cysteine residue near the hypothesized binding site of UNC1999, but 
unfortunately, none of the compounds synthesized were able to covalently 
modify the cysteine residue of interest. However, we did determine that the 
indazole nitrogen bearing the isopropyl group of UNC1999 can be modified with 
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reactive functionalities and still retain a greater level of potency for EZH2 versus 
EZH1. 
 Prior to the start of this research, UNC0638, the first chemical probe for 
G9a [100] had been discovered. To functionalize this compound into a useful 
chemical tool, we appended a biotin tag to UNC0638 and discovered UNC0965. 
This compound retained in vitro activity for G9a, selectively chemiprecipitated 
G9a from cell lysates, and was also able to chemiprecipitate G9a from 
crosslinked chromatin, both in vitro and ex vivo. This proof of concept for what 
we termed the chem-ChIP assay is a significant advancement in the field of 
epigenetic drug discovery, because the method can be applied to a variety of 
targets for which there are probes available. Treating cells with a small molecule 
instead of an chemical antibody lowers costs, allows for target engagement in a 
more physiologically relevant environment, and aids in scenarios where quality 
ChIP-grade antibodies are not available due to epitope masking of crosslinked 
chromatin. To our dismay, UNC2399 was unable to chemiprecipitate EZH2 after 
crosslinking to chromatin. We believe that this may be due to masking of the SET 
domain after crosslinking. Use of the in vivo chem-ChIP assay may alleviate 
these issues, because the target is engaged prior to crosslinking, but UNC2399 
is inactive in cellular assays, likely due to the long hydrophilic PEG12 linker, so 
we cannot perform the in vivo chem-ChIP method in the cellular environment. 
However, we did determine that only 6 PEG groups (kdk215-090) need to be 
present in order to maintain the ability to chemiprecipitate EZH2, and kdk215-090 
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does display modest inhibition of H3K27me3 in cellular assays, suggesting it may 
be more cell permeable than UNC2399. 
 
Future Directions 
 
 Continued exploration into panactive EZH1/EZH2 probes, as well as 
EZH2-specific irreversible probes is of extreme interest, because both have 
applications. Going forward, derivatives of UNC1999 with larger hydrophobic 
groups at the C4 of the pyridone may increase the activity for EZH1. Additionally, 
introducing substituents with hydrogen bond donors and acceptors at pyridone 
C4 may lead to increased EZH1 potency, because of the hypothesis that M743 of 
EZH2 interacts with the pyridone moiety, and this residue is a threonine (T744) in 
EZH1. In an attempt to discover EZH2-specific, irreversible inhibitors, additional 
reactive functionalities will be installed on UNC1999 derivatives with the goal of 
engaging the cysteine of EZH2 (C663); C663 is a serine in EZH1. 
 Finally, due to the inability of UNC2399 to chemiprecipitate EZH2 
crosslinked to chromatin, we will try to perform the cellular chem-ChIP method 
using kdk215-090, because it displayed notable inhibition in cellular assays. This 
suggests that we can treat cells with kdk215-090, engage the target prior to 
crosslinking, and then chemiprecipitate the crosslinked chromatin-ligand 
complex. In parallel with kdk215-090, we also plan to try to use a UNC1999 
alkyne derivative to enter the cell prior to crosslinking, and then use azide beads 
to perform a click reaction after crosslinking. The advantage here is that the 
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smaller azide group should be more adept at navigating through chromatin in 
order to engage the SET domain of EZH2. 
 
Potential Adverse Effects of PRC2 Inhibition 
 
It is well-received that overexpression of EZH2 plays a role in the 
progression of metastatic prostate cancer [14, 40], and that overactive PRC2 
and/or gain-of-function EZH2 mutants play a role in a variety of hematological 
maladies. However, EZH2 also appears to have a tumor suppressor role. EZH2 
deletion has been observed in the development of myelodysplastic syndrome 
(MDS) [18, 41], and homozygous frame-shift or truncation mutations that disrupt 
EZH2, frequently occur in T-ALL [107-109] and myeloid leukemia such as 
primary myelofibrosis (PMF), myeloproliferative neoplasms (MPN), and chronic 
myelomonocytic leukemia (CMML) [110]. This observation is compounded by the 
fact that both EZH2 and EZH1 are regulators of hematopoietic stem cell function 
[20, 42], and EZH1 activity is crucial for maintaining self-renewal capacity of adult 
HSCs, by protecting cells from senescence [20]. The collective evidence 
suggests that there exists a dichotomous role of PRC2 in different biological 
contexts, which raises concerns over PRC2 and/or EZH2 inhibition in clinical 
treatments. Moreover, PRC2 is important in normal development, so EZH2/EZH1 
inhibitors may also cause toxicity by inhibiting the normal functions of the PRC2. 
These facts further highlight the need for high quality chemical probes, 
and functionalized chemical tools. Far too often, research is performed with a 
non-specific compound that has been stated to be an EZH2 inhibitor; DZNep, for 
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example. UNC1999, UNC2399, UNC0638, and UNC0965 are freely available to 
the research community with no restrictions on their use. We can only hope that 
as a community we continue to study the effects of PRC2 inhibition with the 
correct tools, and hopefully, further validate EZH2 as a therapeutic target.  
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APPENDIX: PERSONAL CONTRIBUTIONS TO DISSERTATION CHAPTERS 
 
 All in vitro scintillation proximity assays, and in-cell western assays to 
assess the potency of synthesized compounds in any chapter were performed by 
collaborators at the Structural Genomics Consortium (SGC). Compounds from 
Chapter 2 were synthesized by the author with additional support from Dr. Anqi 
Ma and Dr. Feng Liu. The cellular studies and synthesis of the dye portion of 
UNC2239 were completed by Dr. Chris MacNevin of Dr. Klaus Hahn’s laboratory. 
All UNC2239 chemiprecipitations were performed by the author, in addition to 
homology modeling, docking studies, and compound design. All biological work 
reported in Chapter 3 was conducted in the laboratory of Dr. Greg Wang. The 
author synthesized UNC1999 N-methylated derivative UNC3142, while 
UNC1756 was synthesized at Changchun Discovery Sciences (CDS). The 
entirety of the final products and intermediates of compounds synthesized to 
assess EZH1/EZH2 selectivity in Chapter 3 were performed by the author. The 
docking and design of irreversible inhibitors of EZH2 from Chapter 4 were 
completed by the author, while all compounds were synthesized by Dr. Xiaobao 
Yang. Synthesis of UNC0965 from Chapter 5 was performed by Dr. Feng Liu. 
The author performed all of the chemiprecipitations of UNC0965, antibody ChIP, 
and chem-ChIP; Dr. Samantha Pattenden was an integral part in preparation of 
chromatin samples. UNC2399 chem-ChIP, EZH2 ChIP, and synthesis of 
compounds for truncated UNC2399 derivatives and linker titration 
chemiprecipitations were performed by the author, and Dr. Samantha Pattenden 
prepared chromatin for the in vitro UNC2399 chem-ChIP.
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